

NOVEL METHODS OF CONSTRUCTING LIBRARIES
COMPRISING DISPLAYED AND/OR EXPRESSED
MEMBERS OF A DIVERSE FAMILY OF PEPTIDES,
POLYPEPTIDES OR PROTEINS AND THE NOVEL LIBRARIES

5 This application is a continuation-in-part of
United States provisional application 06/198,069, filed
April 17, 2000, a continuation-in-part of United States
patent application 09/837,306, filed on April 17, 2001,
and a continuation-in-part of United States application
10 XX/XXX,XXX, filed by Express Mail(EI125454535US) on
October 25, 2001. All of the earlier applications are
specifically incorporated by reference herein.

 The present invention relates to libraries of
genetic packages that display and/or express a member
15 of a diverse family of peptides, polypeptides or
proteins and collectively display and/or express at
least a portion of the diversity of the family. In an
alternative embodiment, the invention relates to
libraries that include a member of a diverse family of
20 peptides, polypeptides or proteins and collectively
comprise at least a portion of the diversity of the
family. In a preferred embodiment, the displayed
and/or expressed polypeptides are human Fabs.

 More specifically, the invention is directed
25 to the methods of cleaving single-stranded nucleic
acids at chosen locations, the cleaved nucleic acids
encoding, at least in part, the peptides, polypeptides

or proteins displayed on the genetic packages of, and/or expressed in, the libraries of the invention. In a preferred embodiment, the genetic packages are filamentous phage or phagemids or yeast.

5 The present invention further relates to vectors for displaying and/or expressing a diverse family of peptides, polypeptides or proteins.

 The present invention further relates to methods of screening the libraries of the invention and
10 to the peptides, polypeptides and proteins identified by such screening.

BACKGROUND OF THE INVENTION

 It is now common practice in the art to prepare libraries of genetic packages that display,
15 express or comprise a member of a diverse family of peptides, polypeptides or proteins and collectively display, express or comprise at least a portion of the diversity of the family. In many common libraries, the peptides, polypeptides or proteins are related to
20 antibodies. Often, they are Fabs or single chain antibodies.

 In general, the DNAs that encode members of the families to be displayed and/or expressed must be amplified before they are cloned and used to display
25 and/or express the desired member. Such amplification typically makes use of forward and backward primers.

 Such primers can be complementary to sequences native to the DNA to be amplified or complementary to oligonucleotides attached at the 5' or
30 3' ends of that DNA. Primers that are complementary to sequences native to the DNA to be amplified are disadvantaged in that they bias the members of the

10045674-102501

families to be displayed. Only those members that contain a sequence in the native DNA that is substantially complementary to the primer will be amplified. Those that do not will be absent from the
5 family. For those members that are amplified, any diversity within the primer region will be suppressed.

For example, in European patent 368,684 B1, the primer that is used is at the 5' end of the V_H region of an antibody gene. It anneals to a sequence
10 region in the native DNA that is said to be "sufficiently well conserved" within a single species. Such primer will bias the members amplified to those having this "conserved" region. Any diversity within this region is extinguished.

15 It is generally accepted that human antibody genes arise through a process that involves a combinatorial selection of V and J or V, D, and J followed by somatic mutations. Although most diversity occurs in the Complementary Determining Regions (CDRs),
20 diversity also occurs in the more conserved Framework Regions (FRs) and at least some of this diversity confers or enhances specific binding to antigens (Ag). As a consequence, libraries should contain as much of the CDR and FR diversity as possible.

25 To clone the amplified DNAs of the peptides, polypeptides or proteins that they encode for display on a genetic package and/or for expression, the DNAs must be cleaved to produce appropriate ends for ligation to a vector. Such cleavage is generally
30 effected using restriction endonuclease recognition sites carried on the primers. When the primers are at the 5' end of DNA produced from reverse transcription of RNA, such restriction leaves deleterious 5' untranslated regions in the amplified DNA. These

regions interfere with expression of the cloned genes and thus the display of the peptides, polypeptides and proteins coded for by them.

SUMMARY OF THE INVENTION

5 It is an object of this invention to provide novel methods for constructing libraries that display, express or comprise a member of a diverse family of peptides, polypeptides or proteins and collectively display, express or comprise at least a portion of the
10 diversity of the family. These methods are not biased toward DNAs that contain native sequences that are complementary to the primers used for amplification. They also enable any sequences that may be deleterious to expression to be removed from the amplified DNA
15 before cloning and displaying and/or expressing.

 It is another object of this invention to provide a method for cleaving single-stranded nucleic acid sequences at a desired location, the method comprising the steps of:

- 20 (i) contacting the nucleic acid with a single-stranded oligonucleotide, the oligonucleotide being functionally complementary to the nucleic acid in the region in which cleavage is desired and
25 including a sequence that with its complement in the nucleic acid forms a restriction endonuclease recognition site that on restriction results in cleavage of the nucleic acid at the desired location; and
30 (ii) cleaving the nucleic acid solely at the recognition site formed by the complementation of the nucleic acid and the oligonucleotide;

the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location, and the cleavage being carried out using a restriction endonuclease that is active at the chosen temperature.

It is a further object of this invention to provide an alternative method for cleaving single-stranded nucleic acid sequences at a desired location, the method comprising the steps of:

(i) contacting the nucleic acid with a partially double-stranded oligonucleotide, the single-stranded region of the oligonucleotide being functionally complementary to the nucleic acid in the region in which cleavage is desired, and the double-stranded region of the oligonucleotide having a restriction endonuclease recognition site; and

(ii) cleaving the nucleic acid solely at the cleavage site formed by the complementation of the nucleic acid and the single-stranded region of the oligonucleotide;

the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur

In an alternative embodiment of this object
5 of the invention, the restriction endonuclease
recognition site is not initially located in the
double-stranded part of the oligonucleotide. Instead,
it is part of an amplification primer, which primer is
complementary to the double-stranded region of the
10 oligonucleotide. On amplification of the DNA-partially
double-stranded combination, the restriction
endonuclease recognition site carried on the primer
becomes part of the DNA. It can then be used to cleave
the DNA.

It is another object of the present invention to provide a method of capturing DNA molecules that comprise a member of a diverse family of DNAs and collectively comprise at least a portion of the diversity of the family. These DNA molecules in single-stranded form have been cleaved by one of the methods of this invention. This method involves ligating the individual single-stranded DNA members of the family to a partially duplex DNA complex. The method comprises the steps of:

(i) contacting a single-stranded nucleic acid sequence that has been cleaved with a restriction endonuclease with a partially double-stranded oligonucleotide, the single-stranded region of the oligonucleotide being functionally complementary to the nucleic

acid in the region that remains after
cleavage, the double-stranded region of the
oligonucleotide including any sequences
necessary to return the sequences that remain
5 after cleavage into proper reading frame for
expression and containing a restriction
endonuclease recognition site 5' of those
sequences; and

(ii) cleaving the partially double-
10 stranded oligonucleotide sequence solely at
the restriction endonuclease cleavage site
contained within the double-stranded region
of the partially double-stranded
oligonucleotide.

15 As before, in this object of the invention,
the restriction endonuclease recognition site need not
be located in the double-stranded portion of the
oligonucleotide. Instead, it can be introduced on
amplification with an amplification primer that is used
20 to amplify the DNA-partially double-stranded
oligonucleotide combination.

It is another object of this invention to
prepare libraries, that display, express or comprise a
diverse family of peptides, polypeptides or proteins
25 and collectively display, express or comprise at least
part of the diversity of the family, using the methods
and DNAs described above.

It is an object of this invention to screen
those libraries to identify useful peptides,
30 polypeptides and proteins and to use those substances
in human therapy.

Additional objects of the invention are
reflected in claims 1-116. Each of these claims is

10045674.100503

specifically incorporated by reference in this specification.

BRIEF DESCRIPTION OF THE DRAWINGS

5 FIG. 1 is a schematic of various methods that may be employed to amplify VH genes without using primers specific for VH sequences.

10 FIG. 2 is a schematic of various methods that may be employed to amplify VL genes without using primers specific for VL sequences.

 FIG. 3 is a schematic of RACE amplification of antibody heavy and light chains.

15 FIG. 4 depicts gel analysis of amplification products obtained after the primary PCR reaction from 4 different patient samples.

 FIG. 5 depicts gel analysis of cleaved kappa DNA from Example 2.

 FIG. 6 depicts gel analysis of extender-cleaved kappa DNA from Example 2.

20 FIG. 7 depicts gel analysis of the PCR product from the extender-kappa amplification from Example 2.

25 FIG. 8 depicts gel analysis of purified PCR product from the extender-kappa amplification from Example 2.

 FIG. 9 depicts gel analysis of cleaved and ligated kappa light chains from Example 2.

 FIG. 10 is a schematic of the design for CDR1 and CDR2 synthetic diversity.

30 FIG. 11 is a schematic of the cloning schedule for construction of the heavy chain repertoire.

 FIG. 12 is a schematic of the cleavage and ligation of the antibody light chain.

10045674-102503

FIG. 13 depicts gel analysis of cleaved and ligated lambda light chains from Example 4.

FIG. 14 is a schematic of the cleavage and ligation of the antibody heavy chain.

5 FIG. 15 depicts gel analysis of cleaved and ligated lambda light chains from Example 5.

FIG. 16 is a schematic of a phage display vector.

FIG. 17 is a schematic of a Fab cassette.

10 FIG. 18 is a schematic of a process for incorporating fixed FR1 residues in an antibody lambda sequence.

FIG. 19 is a schematic of a process for incorporating fixed FR1 residues in an antibody kappa
15 sequence.

FIG. 20 is a schematic of a process for incorporating fixed FR1 residues in an antibody heavy chain sequence.

TERMS

20 In this application, the following terms and abbreviations are used:

Sense strand	The upper strand of ds DNA as usually written. In the sense strand, 5'-ATG-3' codes for Met.
25	
Antisense strand	The lower strand of ds DNA as usually written. In the antisense strand, 3'-TAC-5' would correspond to a Met
30	codon in the sense strand.

Forward primer	A "forward" primer is complementary to a part of the sense strand and primes for synthesis of a new antisense-strand molecule. "Forward primer" and "lower-strand primer" are equivalent.
5	
Backward primer	A "backward" primer is complementary to a part of the antisense strand and primes for synthesis of a new sense-strand molecule. "Backward primer" and "top-strand primer" are equivalent.
10	
15 Bases	Bases are specified either by their position in a vector or gene as their position within a gene by codon and base. For example, "89.1" is the first base of codon 89, 89.2 is the second base of codon 89.
20	
Sv	Streptavidin
Ap	Ampicillin
ap ^R	A gene conferring ampicillin resistance.
25	
RERS	Restriction endonuclease recognition site

10045674 "1005001

RE	Restriction endonuclease - cleaves preferentially at RERS
URE	Universal restriction endonuclease
5 Functionally complementary	Two sequences are sufficiently complementary so as to anneal under the chosen conditions.
AA	Amino acid
10 PCR	Polymerization chain reaction
GLGs	Germline genes
Ab	Antibody: an immunoglobulin. The term also covers any protein having a binding domain which is homologous to an immunoglobulin binding domain. A few examples of antibodies within this definition are, <i>inter alia</i> , immunoglobulin isotypes and the Fab, F(ab ¹) ₂ , scfv, Fv, dAb and Fd fragments.
15	
20	
Fab	Two chain molecule comprising an Ab light chain and part of a heavy-chain.
25	

	scFv	A single-chain Ab comprising either VH::linker::VL or VL::linker::VH
	w.t.	Wild type
5	HC	Heavy chain
	LC	Light chain
	VK	A variable domain of a Kappa light chain.
10	VH	A variable domain of a heavy chain.
	VL	A variable domain of a lambda light chain.

In this application when it is said that nucleic acids are cleaved solely at the cleavage site of a restriction endonuclease, it should be understood that minor cleavage may occur at random, e.g., at non-specific sites other than the specific cleavage site that is characteristic of the restriction endonuclease. The skilled worker will recognize that such non-specific, random cleavage is the usual occurrence. Accordingly, "solely at the cleavage site" of a restriction endonuclease means that cleavage occurs preferentially at the site characteristic of that endonuclease.

As used in this application and claims, the term "cleavage site formed by the complementation of the nucleic acid and the single-stranded region of the

oligonucleotide" includes cleavage sites formed by the single-stranded portion of the partially double-stranded oligonucleotide duplexing with the single-stranded DNA, cleavage sites in the double-stranded
5 portion of the partially double-stranded oligonucleotide, and cleavage sites introduced by the amplification primer used to amplify the single-stranded DNA-partially double-stranded oligonucleotide combination.

10 In the two methods of this invention for preparing single-stranded nucleic acid sequences, the first of those cleavage sites is preferred. In the methods of this invention for capturing diversity and cloning a family of diverse nucleic acid sequences, the
15 latter two cleavage sites are preferred.

In this application, all references referred to are specifically incorporated by reference.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The nucleic acid sequences that are useful in
20 the methods of this invention, i.e., those that encode at least in part the individual peptides, polypeptides and proteins displayed, or expressed in or comprising the libraries of this invention, may be native, synthetic or a combination thereof. They may be mRNA,
25 DNA or cDNA. In the preferred embodiment, the nucleic acids encode antibodies. Most preferably, they encode Fabs.

The nucleic acids useful in this invention may be naturally diverse, synthetic diversity may be
30 introduced into those naturally diverse members, or the diversity may be entirely synthetic. For example, synthetic diversity can be introduced into one or more CDRs of antibody genes. Preferably, it is introduced

10045674-1000001

5 comprise a population of immunoglobulin genes that
comprise synthetic diversity in at least one, and more
preferably both of the CDR1 and CDR2 and diversity in
CDR3 captured from B cells.

Synthetic diversity may be created, for example, through the use of TRIM technology (U.S. 5,869,644). TRIM technology allows control over exactly which amino-acid types are allowed at variegated positions and in what proportions. In TRIM technology, codons to be diversified are synthesized using mixtures of trinucleotides. This allows any set of amino acid types to be included in any proportion.

Another alternative that may be used to generate diversified DNA is mixed oligonucleotide synthesis. With TRIM technology, one could allow Ala and Trp. With mixed oligonucleotide synthesis, a mixture that included Ala and Trp would also necessarily include Ser and Gly. The amino-acid types allowed at the variegated positions are picked with reference to the structure of antibodies, or other peptides, polypeptides or proteins of the family, the observed diversity in germline genes, the observed somatic mutations frequently observed, and the desired areas and types of variegation.

In a preferred embodiment of this invention,
30 the nucleic acid sequences for at least one CDR or
other region of the peptides, polypeptides or proteins
of the family are cDNAs produced by reverse
transcription from mRNA. More preferably, the mRNAs
are obtained from peripheral blood cells, bone marrow

cells, spleen cells or lymph node cells (such as B-lymphocytes or plasma cells) that express members of naturally diverse sets of related genes. More preferable, the mRNAs encode a diverse family of

5 antibodies. Most preferably, the mRNAs are obtained from patients suffering from at least one autoimmune disorder or cancer. Preferably, mRNAs containing a high diversity of autoimmune diseases, such as systemic lupus erythematosus, systemic sclerosis, rheumatoid

10 arthritis, antiphospholipid syndrome and vasculitis are used.

In a preferred embodiment of this invention, the cDNAs are produced from the mRNAs using reverse transcription. In this preferred embodiment, the mRNAs

15 are separated from the cell and degraded using standard methods, such that only the full length (*i.e.*, capped) mRNAs remain. The cap is then removed and reverse transcription used to produce the cDNAs.

The reverse transcription of the first

20 (antisense) strand can be done in any manner with any suitable primer. See, *e.g.*, HJ de Haard et al., Journal of Biological Chemistry, 274(26):18218-30 (1999). In the preferred embodiment of this invention where the mRNAs encode antibodies, primers that are

25 complementary to the constant regions of antibody genes may be used. Those primers are useful because they do not generate bias toward subclasses of antibodies. In another embodiment, poly-dT primers may be used (and may be preferred for the heavy-chain genes).

30 Alternatively, sequences complementary to the primer may be attached to the termini of the antisense strand.

In one preferred embodiment of this invention, the reverse transcriptase primer may be biotinylated, thus allowing the cDNA product to be

immobilized on streptavidin (Sv) beads. Immobilization can also be effected using a primer labeled at the 5' end with one of a) free amine group, b) thiol, c) carboxylic acid, or d) another group not found in DNA that can react to form a strong bond to a known partner on an insoluble medium. If, for example, a free amine (preferably primary amine) is provided at the 5' end of a DNA primer, this amine can be reacted with carboxylic acid groups on a polymer bead using standard amide-forming chemistry. If such preferred immobilization is used during reverse transcription, the top strand RNA is degraded using well-known enzymes, such as a combination of RNaseH and RNaseA, either before or after immobilization.

The nucleic acid sequences useful in the methods of this invention are generally amplified before being used to display and/or express the peptides, polypeptides or proteins that they encode. Prior to amplification, the single-stranded DNAs may be cleaved using either of the methods described before. Alternatively, the single-stranded DNAs may be amplified and then cleaved using one of those methods.

Any of the well known methods for amplifying nucleic acid sequences may be used for such amplification. Methods that maximize, and do not bias, diversity are preferred. In a preferred embodiment of this invention where the nucleic acid sequences are derived from antibody genes, the present invention preferably utilizes primers in the constant regions of the heavy and light chain genes and primers to a synthetic sequence that are attached at the 5' end of the sense strand. Priming at such synthetic sequence avoids the use of sequences within the variable regions of the antibody genes. Those variable region priming

sites generate bias against V genes that are either of rare subclasses or that have been mutated at the priming sites. This bias is partly due to suppression of diversity within the primer region and partly due to
5 lack of priming when many mutations are present in the region complementary to the primer. The methods disclosed in this invention have the advantage of not biasing the population of amplified antibody genes for particular V gene types.

10 The synthetic sequences may be attached to the 5' end of the DNA strand by various methods well known for ligating DNA sequences together. RT CapExtension is one preferred method.

 In RT CapExtension (derived from Smart
15 PCR^(TM)), a short overlap (5'...GGG-3' in the upper-strand primer (USP-GGG) complements 3'-CCC....5' in the lower strand) and reverse transcriptases are used so that the reverse complement of the upper-strand primer is attached to the lower strand.

20 FIGs. 1 and 2 show schematics to amplify VH and VL genes using RT CapExtension. FIG. 1 shows a schematic of the amplification of VH genes. FIG. 1, Panel A shows a primer specific to the poly-dT region of the 3' UTR priming synthesis of the first, lower
25 strand. Primers that bind in the constant region are also suitable. Panel B shows the lower strand extended at its 3' end by three Cs that are not complementary to the mRNA. Panel C shows the result of annealing a synthetic top-strand primer ending in three GGGs that
30 hybridize to the 3' terminal CCCs and extending the reverse transcription extending the lower strand by the reverse complement of the synthetic primer sequence. Panel D shows the result of PCR amplification using a 5' biotinylated synthetic top-strand primer that

100456789101112131415161718192021222324252627282930

replicates the 5' end of the synthetic primer of panel C and a bottom-strand primer complementary to part of the constant domain. Panel E shows immobilized double-stranded (ds) cDNA obtained by using a 5'-biotinylated top-strand primer.

FIG. 2 shows a similar schematic for amplification of VL genes. FIG. 2, Panel A shows a primer specific to the constant region at or near the 3' end priming synthesis of the first, lower strand. Primers that bind in the poly-dT region are also suitable. Panel B shows the lower strand extended at its 3' end by three Cs that are not complementary to the mRNA. Panel C shows the result of annealing a synthetic top-strand primer ending in three GGGs that hybridize to the 3' terminal CCCs and extending the reverse transcription extending the lower strand by the reverse complement of the synthetic primer sequence. Panel D shows the result of PCR amplification using a 5' biotinylated synthetic top-strand primer that replicates the 5' end of the synthetic primer of panel C and a bottom-strand primer complementary to part of the constant domain. The bottom-strand primer also contains a useful restriction endonuclease site, such as AscI. Panel E shows immobilized ds cDNA obtained by using a 5'-biotinylated top-strand primer.

In FIGs. 1 and 2, each V gene consists of a 5' untranslated region (UTR) and a secretion signal, followed by the variable region, followed by a constant region, followed by a 3' untranslated region (which typically ends in poly-A). An initial primer for reverse transcription may be complementary to the constant region or to the poly A segment of the 3'-UTR. For human heavy-chain genes, a primer of 15 T is preferred. Reverse transcriptases attach several C

residues to the 3' end of the newly synthesized DNA. RT CapExtension exploits this feature. The reverse transcription reaction is first run with only a lower-strand primer. After about 1 hour, a primer ending in
5 GGG (USP-GGG) and more RTase are added. This causes the lower-strand cDNA to be extended by the reverse complement of the USP-GGG up to the final GGG. Using one primer identical to part of the attached synthetic
10 of known sequence at the 3' end of the sense strand, all the V genes are amplified irrespective of their V gene subclass.

In another preferred embodiment, synthetic sequences may be added by Rapid Amplification of cDNA
15 Ends (RACE) (see Frohman, M.A., Dush, M.K., & Martin, G.R. (1988) Proc. Natl. Acad. Sci. USA (85): 8998-9002).

FIG. 1 shows a schematic of RACE amplification of antibody heavy and light chains.
20 First, mRNA is selected by treating total or poly(A+) RNA with calf intestinal phosphatase (CIP) to remove the 5'-phosphate from all molecules that have them such as ribosomal RNA, fragmented mRNA, tRNA and genomic DNA. Full length mRNA (containing a protective 7-methyl cap structure) is unaffected. The RNA is then
25 treated with tobacco acid pyrophosphatase (TAP) to remove the cap structure from full length mRNAs leaving a 5'-monophosphate group. Next, a synthetic RNA adaptor is ligated to the RNA population, only
30 molecules which have a 5-phosphate (uncapped, full length mRNAs) will accept the adaptor. Reverse transcriptase reactions using an oligodT primer, and nested PCR (using one adaptor primer (located in the 5'

synthetic adaptor) and one primer for the gene) are then used to amplify the desired transcript.

In a preferred embodiment of this invention, the upper strand or lower strand primer may be also
5 biotinylated or labeled at the 5' end with one of a) free amino group, b) thiol, c) carboxylic acid and d) another group not found in DNA that can react to form a strong bond to a known partner as an insoluble medium. These can then be used to immobilize the labeled strand
10 after amplification. The immobilized DNA can be either single or double-stranded.

After amplification (using e.g., RT CapExtension or RACE), the DNAs of this invention are rendered single-stranded. For example, the strands can
15 be separated by using a biotinylated primer, capturing the biotinylated product on streptavidin beads, denaturing the DNA, and washing away the complementary strand. Depending on which end of the captured DNA is wanted, one will choose to immobilize either the upper
20 (sense) strand or the lower (antisense) strand.

To prepare the single-stranded amplified DNAs for cloning into genetic packages so as to effect display of, or for expression of, the peptides, polypeptides or proteins encoded, at least in part, by
25 those DNAs, they must be manipulated to provide ends suitable for cloning and display and/or expression. In particular, any 5' untranslated regions and mammalian signal sequences must be removed and replaced, in frame, by a suitable signal sequence that functions in
30 the display or expression host. Additionally, parts of the variable domains (in antibody genes) may be removed and replaced by synthetic segments containing synthetic diversity. The diversity of other gene families may likewise be expanded with synthetic diversity.

According to the methods of this invention, there are two ways to manipulate the single-stranded DNAs for display and/or expression. The first method comprises the steps of:

- 5 (i) contacting the nucleic acid with a single-stranded oligonucleotide, the oligonucleotide being functionally complementary to the nucleic acid in the region in which cleavage is desired and including a sequence that with its complement in the nucleic acid forms a restriction endonuclease recognition site that on restriction results in cleavage of the nucleic acid at the desired location; and
- 10
- 15 (ii) cleaving the nucleic acid solely at the recognition site formed by the complementation of the nucleic acid and the oligonucleotide;

the contacting and the cleaving steps being performed

- 20 at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur
- 25 at the chosen temperature and at the desired location, and the cleavage being carried out using a restriction endonuclease that is active at the chosen temperature.

In this first method, short oligonucleotides are annealed to the single-stranded DNA so that

- 30 restriction endonuclease recognition sites formed within the now locally double-stranded regions of the DNA can be cleaved. In particular, a recognition site

For antibody genes, this can be done using a catalog of germline sequences. See, e.g.,

For example, Table 1 depicts the DNA sequences of the FR3 regions of the 51 known human VH germline genes. In this region, the genes contain restriction endonuclease recognition sites shown in Table 2. Restriction endonucleases that cleave a large fraction of germline genes at the same site are preferred over endonucleases that cut at a variety of sites. Furthermore, it is preferred that there be only one site for the restriction endonucleases within the region to which the short oligonucleotide binds on the single-stranded DNA, e.g., about 10 bases on either side of the restriction endonuclease recognition site.

Finally, in the methods of this invention restriction endonucleases that are active between about 37°C and about 75°C are used. Preferably, restriction

endonucleases that are active between about 45°C and about 75°C may be used. More preferably, enzymes that are active above 50°C, and most preferably active about 55°C, are used. Such temperatures maintain the nucleic acid sequence to be cleaved in substantially single-stranded form.

Enzymes shown in Table 2 that cut many of the heavy chain FR3 germline genes at a single position include: *MaeIII*(24@4), *Tsp45I*(21@4), *HphI*(44@5),
10 *BsaJI*(23@65), *AluI*(23@47), *BlpI*(21@48), *DdeI*(29@58),
BglIII(10@61), *MslI*(44@72), *BsiEI*(23@74), *EaeI*(23@74),
EagI(23@74), *HaeIII*(25@75), *Bst4CI*(51@86),
HpyCH4III(51@86), *HinfI*(38@2), *MlyI*(18@2), *PleI*(18@2),
MnlI(31@67), *HpyCH4V*(21@44), *BsmAI*(16@11), *BpmI*(19@12),
15 *XmnI*(12@30), and *SacI*(11@51). (The notation used means, for example, that *BsmAI* cuts 16 of the FR3 germline genes with a restriction endonuclease recognition site beginning at base 11 of FR3.)

For cleavage of human heavy chains in FR3,
20 the preferred restriction endonucleases are: *Bst4CI* (or *TaaI* or *HpyCH4III*), *BlpI*, *HpyCH4V*, and *MslI*. Because ACNGT (the restriction endonuclease recognition site for *Bst4CI*, *TaaI*, and *HpyCH4III*) is found at a consistent site in all the human FR3 germline genes,
25 one of those enzymes is the most preferred for capture of heavy chain CDR3 diversity. *BlpI* and *HpyCH4V* are complementary. *BlpI* cuts most members of the VH1 and VH4 families while *HpyCH4V* cuts most members of the VH3, VH5, VH6, and VH7 families. Neither enzyme cuts
30 VH2s, but this is a very small family, containing only three members. Thus, these enzymes may also be used in preferred embodiments of the methods of this invention.

The restriction endonucleases *HpyCH4III*,
Bst4CI, and *TaaI* all recognize 5'-ACnGT-3' and cut
upper strand DNA after n and lower strand DNA before
the base complementary to n. This is the most
5 preferred restriction endonuclease recognition site for
this method on human heavy chains because it is found
in all germline genes. Furthermore, the restriction
endonuclease recognition region (ACnGT) matches the
second and third bases of a tyrosine codon (tay) and
10 the following cysteine codon (tgy) as shown in Table 3.
These codons are highly conserved, especially the
cysteine in mature antibody genes.

Table 4 E shows the distinct oligonucleotides
of length 22 (except the last one which is of length
15 20) bases. Table 5 C shows the analysis of 1617 actual
heavy chain antibody genes. Of these, 1511 have the
site and match one of the candidate oligonucleotides to
within 4 mismatches. Eight oligonucleotides account
for most of the matches and are given in Table 4 F.1.
20 The 8 oligonucleotides are very similar so that it is
likely that satisfactory cleavage will be achieved with
only one oligonucleotide (such as H43.77.97.1-02#1) by
adjusting temperature, pH, salinity, and the like. One
or two oligonucleotides may likewise suffice whenever
25 the germline gene sequences differ very little and
especially if they differ very little close to the
restriction endonuclease recognition region to be
cleaved. Table 5 D shows a repeat analysis of 1617
actual heavy chain antibody genes using only the 8
30 chosen oligonucleotides. This shows that 1463 of the
sequences match at least one of the oligonucleotides to
within 4 mismatches and have the site as expected.

10045674-1005007

Only 7 sequences have a second *HpyCH4III* restriction endonuclease recognition region in this region.

Another illustration of choosing an appropriate restriction endonuclease recognition site involves cleavage in FR1 of human heavy chains. Cleavage in FR1 allows capture of the entire CDR diversity of the heavy chain.

The germline genes for human heavy chain FR1 are shown in Table 6. Table 7 shows the restriction endonuclease recognition sites found in human germline genes FR1s. The preferred sites are *BsgI*(GTGCAG;39@4), *BsoFI*(GCngc;43@6,11@9,2@3,1@12), *TseI*(Gcwgc;43@6,11@9,2@3,1@12), *MspAII*(CMGckg;46@7,2@1), *PvuII*(CAGctg;46@7,2@1), *AluI*(AGct;48@82@2), *DdeI*(Ctnag;22@52,9@48), *HphI*(tcacc;22@80), *BssKI*(Nccngg;35@39,2@40), *BsaJI*(Ccnngg;32@40,2@41), *BstNI*(CCwgg;33@40), *ScrFI*(CCngg;35@40,2@41), *EcoO109I*(RGgnccy;22@46,11@43), *Sau96I*(Ggncc;23@47,11@44), *AvaII*(Ggwcc;23@47,4@44), *PpuMI*(RGgwccy;22@46,4@43), *BsmFI*(gtccc;20@48), *HinfI*(Gantc;34@16,21@56,21@77), *TfiI*(21@77), *MlyI*(GAGTC;34@16), *MlyI*(gactc;21@56), and *AlwNI*(CAGnnnctg;22@68). The more preferred sites are *MspAI* and *PvuII*. *MspAI* and *PvuII* have 46 sites at 7-12 and 2 at 1-6. To avoid cleavage at both sites, oligonucleotides are used that do not fully cover the site at 1-6. Thus, the DNA will not be cleaved at that site. We have shown that DNA that extends 3, 4, or 5 bases beyond a *PvuII*-site can be cleaved efficiently.

Another illustration of choosing an appropriate restriction endonuclease recognition site involves cleavage in FR1 of human kappa light chains. Table 8 shows the human kappa FR1 germline genes and

Table 9 shows restriction endonuclease recognition sites that are found in a substantial number of human kappa FR1 germline genes at consistent locations. Of the restriction endonuclease recognition sites listed, 5 *Bsm*AI and *Pfl*FI are the most preferred enzymes. *Bsm*AI sites are found at base 18 in 35 of 40 germline genes. *Pfl*FI sites are found in 35 of 40 germline genes at base 12.

Another example of choosing an appropriate 10 restriction endonuclease recognition site involves cleavage in FR1 of the human lambda light chain. Table 10 shows the 31 known human lambda FR1 germline gene sequences. Table 11 shows restriction endonuclease recognition sites found in human lambda FR1 germline 15 genes. *Hinf*I and *Dde*I are the most preferred restriction endonucleases for cutting human lambda chains in FR1.

After the appropriate site or sites for cleavage are chosen, one or more short oligonucleotides 20 are prepared so as to functionally complement, alone or in combination, the chosen recognition site. The oligonucleotides also include sequences that flank the recognition site in the majority of the amplified genes. This flanking region allows the sequence to 25 anneal to the single-stranded DNA sufficiently to allow cleavage by the restriction endonuclease specific for the site chosen.

The actual length and sequence of the oligonucleotide depends on the recognition site and the 30 conditions to be used for contacting and cleavage. The length must be sufficient so that the oligonucleotide is functionally complementary to the single-stranded DNA over a large enough region to allow the two strands

to associate such that cleavage may occur at the chosen temperature and at the desired location.

Typically, the oligonucleotides of this preferred method of the invention are about 17 to about 5 30 nucleotides in length. Below about 17 bases, annealing is too weak and above 30 bases there can be a loss of specificity. A preferred length is 18 to 24 bases.

Oligonucleotides of this length need not be 10 identical complements of the germline genes. Rather, a few mismatches taken may be tolerated. Preferably, however, no more than 1-3 mismatches are allowed. Such mismatches do not adversely affect annealing of the oligonucleotide to the single-stranded DNA. Hence, the 15 two DNAs are said to be functionally complementary.

The second method to manipulate the single-stranded DNAs of this invention for display and/or expression comprises the steps of:

(i) contacting the nucleic acid with a 20 partially double-stranded oligonucleotide, the single-stranded region of the oligonucleotide being functionally complementary to the nucleic acid in the region in which cleavage is desired, and the 25 double-stranded region of the oligonucleotide having a restriction endonuclease recognition site; and

(ii) cleaving the nucleic acid solely at 30 the cleavage site formed by the complementation of the nucleic acid and the single-stranded region of the oligonucleotide;

the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location, and the cleavage being carried out using a restriction endonuclease that is active at the chosen temperature.

As explained above, the cleavage site may be formed by the single-stranded portion of the partially double-stranded oligonucleotide duplexing with the single-stranded DNA, the cleavage site may be carried in the double-stranded portion of the partially double-stranded oligonucleotide, or the cleavage site may be introduced by the amplification primer used to amplify the single-stranded DNA-partially double-stranded oligonucleotide combination. In this embodiment, the first is preferred. And, the restriction endonuclease recognition site may be located in either the double-stranded portion of the oligonucleotide or introduced by the amplification primer, which is complementary to that double-stranded region, as used to amplify the combination.

Preferably, the restriction endonuclease site is that of a Type II-S restriction endonuclease, whose cleavage site is located at a known distance from its recognition site.

This second method, preferably, employs Universal Restriction Endonucleases ("URE"). UREs are partially double-stranded oligonucleotides. The single-stranded portion or overlap of the URE consists of a DNA adapter that is functionally complementary to the sequence to be cleaved in the single-stranded DNA.

The double-stranded portion consists of a restriction endonuclease recognition site, preferably type II-S.

The URE method of this invention is specific and precise and can tolerate some (e.g., 1-3) mismatches in the complementary regions, i.e., it is functionally complementary to that region. Further, conditions under which the URE is used can be adjusted so that most of the genes that are amplified can be cut, reducing bias in the library produced from those genes.

The sequence of the single-stranded DNA adapter or overlap portion of the URE typically consists of about 14-22 bases. However, longer or shorter adapters may be used. The size depends on the ability of the adapter to associate with its functional complement in the single-stranded DNA and the temperature used for contacting the URE and the single-stranded DNA at the temperature used for cleaving the DNA with the restriction enzyme. The adapter must be functionally complementary to the single-stranded DNA over a large enough region to allow the two strands to associate such that the cleavage may occur at the chosen temperature and at the desired location. We prefer single-stranded or overlap portions of 14-17 bases in length, and more preferably 18-20 bases in length.

The site chosen for cleavage using the URE is preferably one that is substantially conserved in the family of amplified DNAs. As compared to the first cleavage method of this invention, these sites do not need to be endonuclease recognition sites. However, like the first method, the sites chosen can be synthetic rather than existing in the native DNA. Such sites may be chosen by references to the sequences of

known antibodies or other families of genes. For example, the sequences of many germline genes are reported at <http://www.mrc-cpe.cam.ac.uk/imt-doc/restricted/ok.html>. For example, one preferred
5 site occurs near the end of FR3 -- codon 89 through the second base of codon 93. CDR3 begins at codon 95.

The sequences of 79 human heavy-chain genes are also available at <http://www.ncbi.nlm.nih.gov/entre2/nucleotide.html>.
10 This site can be used to identify appropriate sequences for URE cleavage according to the methods of this invention. See, e.g., Table 12B.

Most preferably, one or more sequences are identified using these sites or other available
15 sequence information. These sequences together are present in a substantial fraction of the amplified DNAs. For example, multiple sequences could be used to allow for known diversity in germline genes or for frequent somatic mutations. Synthetic degenerate
20 sequences could also be used. Preferably, a sequence(s) that occurs in at least 65% of genes examined with no more than 2-3 mismatches is chosen

URE single-stranded adapters or overlaps are then made to be complementary to the chosen regions.
25 Conditions for using the UREs are determined empirically. These conditions should allow cleavage of DNA that contains the functionally complementary sequences with no more than 2 or 3 mismatches but that do not allow cleavage of DNA lacking such sequences.

30 As described above, the double-stranded portion of the URE includes an endonuclease recognition site, preferably a Type II-S recognition site. Any enzyme that is active at a temperature necessary to maintain the single-stranded DNA substantially in that

form and to allow the single-stranded DNA adapter portion of the URE to anneal long enough to the single-stranded DNA to permit cleavage at the desired site may be used.

5 The preferred Type II-S enzymes for use in the URE methods of this invention provide asymmetrical cleavage of the single-stranded DNA. Among these are the enzymes listed in Table 13. The most preferred Type II-S enzyme is *FokI*.

10 When the preferred *FokI* containing URE is used, several conditions are preferably used to effect cleavage:

- 15 1) Excess of the URE over target DNA should be present to activate the enzyme. URE present only in equimolar amounts to the target DNA would yield poor cleavage of ssDNA because the amount of active enzyme available would be limiting.
- 20 2) An activator may be used to activate part of the *FokI* enzyme to dimerize without causing cleavage. Examples of appropriate activators are shown in Table 14.
- 25 3) The cleavage reaction is performed at a temperature between 45°-75°C, preferably above 50°C and most preferably above 55°C.

 The UREs used in the prior art contained a 14-base single-stranded segment, a 10-base stem (containing a *FokI* site), followed by the palindrome of the 10-base stem. While such UREs may be used in the
30 methods of this invention, the preferred UREs of this invention also include a segment of three to eight bases (a loop) between the *FokI* restriction

endonuclease recognition site containing segments. In the preferred embodiment, the stem (containing the *FokI* site) and its palindrome are also longer than 10 bases. Preferably, they are 10-14 bases in length. Examples
5 of these "lollipop" URE adapters are shown in Table 15.

One example of using a URE to cleave an single-stranded DNA involves the FR3 region of human heavy chain. Table 16 shows an analysis of 840 full-length mature human heavy chains with the URE
10 recognition sequences shown. The vast majority (718/840=0.85) will be recognized with 2 or fewer mismatches using five UREs (VHS881-1.1, VHS881-1.2, VHS881-2.1, VHS881-4.1, and VHS881-9.1). Each has a 20-base adaptor sequence to complement the germline
15 gene, a ten-base stem segment containing a *FokI* site, a five base loop, and the reverse complement of the first stem segment. Annealing those adapters, alone or in combination, to single-stranded antisense heavy chain DNA and treating with *FokI* in the presence of, e.g.,
20 the activator FOKIact, will lead to cleavage of the antisense strand at the position indicated.

Another example of using a URE(s) to cleave a single-stranded DNA involves the FR1 region of the human Kappa light chains. Table 17 shows an analysis
25 of 182 full-length human kappa chains for matching by the four 19-base probe sequences shown. Ninety-six percent of the sequences match one of the probes with 2 or fewer mismatches. The URE adapters shown in Table 17 are for cleavage of the sense strand of kappa
30 chains. Thus, the adaptor sequences are the reverse complement of the germline gene sequences. The URE consists of a ten-base stem, a five base loop, the reverse complement of the stem and the complementation

sequence. The loop shown here is TTGTT, but other sequences could be used. Its function is to interrupt the palindrome of the stems so that formation of a lollypop monomer is favored over dimerization. Table 5 17 also shows where the sense strand is cleaved.

Another example of using a URE to cleave a single-stranded DNA involves the human lambda light chain. Table 18 shows analysis of 128 human lambda light chains for matching the four 19-base probes 10 shown. With three or fewer mismatches, 88 of 128 (69%) of the chains match one of the probes. Table 18 also shows URE adapters corresponding to these probes. Annealing these adapters to upper-strand ssDNA of lambda chains and treatment with *FokI* in the presence 15 of *FOKIact* at a temperature at or above 45°C will lead to specific and precise cleavage of the chains.

The conditions under which the short oligonucleotide sequences of the first method and the UREs of the second method are contacted with the 20 single-stranded DNAs may be empirically determined. The conditions must be such that the single-stranded DNA remains in substantially single-stranded form. More particularly, the conditions must be such that the single-stranded DNA does not form loops that may 25 interfere with its association with the oligonucleotide sequence or the URE or that may themselves provide sites for cleavage by the chosen restriction endonuclease.

The effectiveness and specificity of short 30 oligonucleotides (first method) and UREs (second method) can be adjusted by controlling the concentrations of the URE adapters/oligonucleotides and substrate DNA, the temperature, the pH, the concentration of metal ions, the ionic strength, the

concentration of chaotropes (such as urea and formamide), the concentration of the restriction endonuclease (e.g., *FokI*), and the time of the digestion. These conditions can be optimized with

5 synthetic oligonucleotides having: 1) target germline gene sequences, 2) mutated target gene sequences, or 3) somewhat related non-target sequences. The goal is to cleave most of the target sequences and minimal amounts of non-targets.

10 In accordance with this invention, the single-stranded DNA is maintained in substantially that form using a temperature between about 37°C and about 75°C. Preferably, a temperature between about 45°C and about 75°C is used. More preferably, a temperature
15 between 50°C and 60°C, most preferably between 55°C and 60°C, is used. These temperatures are employed both when contacting the DNA with the oligonucleotide or URE and when cleaving the DNA using the methods of this invention.

20 The two cleavage methods of this invention have several advantages. The first method allows the individual members of the family of single-stranded DNAs to be cleaved preferentially at one substantially conserved endonuclease recognition site. The method
25 also does not require an endonuclease recognition site to be built into the reverse transcription or amplification primers. Any native or synthetic site in the family can be used.

The second method has both of these
30 advantages. In addition, the preferred URE method allows the single-stranded DNAs to be cleaved at positions where no endonuclease recognition site naturally occurs or has been synthetically constructed.

Most importantly, both cleavage methods permit the use of 5' and 3' primers so as to maximize diversity and then cleavage to remove unwanted or deleterious sequences before cloning, display and/or expression.

After cleavage of the amplified DNAs using one of the methods of this invention, the DNA is prepared for cloning, display and/or expression. This is done by using a partially duplexed synthetic DNA adapter, whose terminal sequence is based on the specific cleavage site at which the amplified DNA has been cleaved.

The synthetic DNA is designed such that when it is ligated to the cleaved single-stranded DNA in proper reading frame so that the desired peptide, polypeptide or protein can be displayed on the surface of the genetic package and/or expressed. Preferably, the double-stranded portion of the adapter comprises the sequence of several codons that encode the amino acid sequence characteristic of the family of peptides, polypeptides or proteins up to the cleavage site. For human heavy chains, the amino acids of the 3-23 framework are preferably used to provide the sequences required for expression of the cleaved DNA.

Preferably, the double-stranded portion of the adapter is about 12 to 100 bases in length. More preferably, about 20 to 100 bases are used. The double-stranded region of the adapter also preferably contains at least one endonuclease recognition site useful for cloning the DNA into a suitable display and/or expression vector (or a recipient vector used to archive the diversity). This endonuclease restriction site may be native to the germline gene sequences used to extend the DNA sequence. It may be also constructed

using degenerate sequences to the native germline gene sequences. Or, it may be wholly synthetic.

The single-stranded portion of the adapter is complementary to the region of the cleavage in the
5 single-stranded DNA. The overlap can be from about 2 bases up to about 15 bases. The longer the overlap, the more efficient the ligation is likely to be. A preferred length for the overlap is 7 to 10. This allows some mismatches in the region so that diversity
10 in this region may be captured.

The single-stranded region or overlap of the partially duplexed adapter is advantageous because it allows DNA cleaved at the chosen site, but not other fragments to be captured. Such fragments would
15 contaminate the library with genes encoding sequences that will not fold into proper antibodies and are likely to be non-specifically sticky.

One illustration of the use of a partially duplexed adaptor in the methods of this invention
20 involves ligating such adaptor to a human FR3 region that has been cleaved, as described above, at 5'-ACnGT-3' using HpyCH4III, Bst4CI or TaaI.

Table 4 F.2 shows the bottom strand of the double-stranded portion of the adaptor for ligation to
25 the cleaved bottom-strand DNA. Since the HpyCH4III-Site is so far to the right (as shown in Table 3), a sequence that includes the AflIII-site as well as the XbaI site can be added. This bottom strand portion of the partially-duplexed adaptor, H43.XAExt,
30 incorporates both XbaI and AflIII-sites. The top strand of the double-stranded portion of the adaptor has neither site (due to planned mismatches in the segments opposite the XbaI and AflIII-Sites of H43.XAExt), but

will anneal very tightly to H43.XAExt. H43AExt contains only the *Afl*III-site and is to be used with the top strands H43.ABr1 and H43.ABr2 (which have intentional alterations to destroy the *Afl*III-site).

5 After ligation, the desired, captured DNA can be PCR amplified again, if desired, using in the preferred embodiment a primer to the downstream constant region of the antibody gene and a primer to part of the double-standard region of the adapter. The
10 primers may also carry restriction endonuclease sites for use in cloning the amplified DNA.

 After ligation, and perhaps amplification, of the partially double-stranded adapter to the single-stranded amplified DNA, the composite DNA is cleaved at
15 'chosen 5' and 3' endonuclease recognition sites.

 The cleavage sites useful for cloning depend on the phage or phagemid or other vectors into which the cassette will be inserted and the available sites in the antibody genes. Table 19 provides restriction
20 endonuclease data for 75 human light chains. Table 20 shows corresponding data for 79 human heavy chains. In each Table, the endonucleases are ordered by increasing frequency of cutting. In these Tables, Nch is the number of chains cut by the enzyme and Ns is the number
25 of sites (some chains have more than one site).

 From this analysis, *Sfi*I, *Not*I, *Afl*III, *Apa*LI, and *Asc*I are very suitable. *Sfi*I and *Not*I are preferably used in pCES1 to insert the heavy-chain display segment. *Apa*LI and *Asc*I are preferably used in
30 pCES1 to insert the light-chain display segment.

*Bst*EII-sites occur in 97% of germ-line JH genes. In rearranged V genes, only 54/79 (68%) of heavy-chain genes contain a *Bst*EII-Site and 7/61 of

these contain two sites. Thus, 47/79 (59%) contain a single *BstEII*-Site. An alternative to using *BstEII* is to cleave via UREs at the end of JH and ligate to a synthetic oligonucleotide that encodes part of CH1.

5 One example of preparing a family of DNA sequences using the methods of this invention involves capturing human CDR 3 diversity. As described above, mRNAs from various autoimmune patients are reverse transcribed into lower strand cDNA. After the top
10 strand RNA is degraded, the lower strand is immobilized and a short oligonucleotide used to cleave the cDNA upstream of CDR3. A partially duplexed synthetic DNA adapter is then annealed to the DNA and the DNA is amplified using a primer to the adapter and a primer to
15 the constant region (after FR4). The DNA is then cleaved using *BstEII* (in FR4) and a restriction endonuclease appropriate to the partially double-stranded adapter (e.g., *XbaI* and *AflIII* (in FR3)). The DNA is then ligated into a synthetic VH skeleton such
20 as 3-23.

 One example of preparing a single-stranded DNA that was cleaved using the URE method involves the human Kappa chain. The cleavage site in the sense strand of this chain is depicted in Table 17. The
25 oligonucleotide kapextURE is annealed to the oligonucleotides (kaBR01UR, kaBR02UR, kaBR03UR, and kaBR04UR) to form a partially duplex DNA. This DNA is then ligated to the cleaved soluble kappa chains. The ligation product is then amplified using primers
30 kapextUREPCR and ckForeAsc (which inserts a AscI site after the end of C kappa). This product is then cleaved with *ApaLI* and *AscI* and ligated to similarly cut recipient vector.

Another example involves the cleavage of
lambda light chains, illustrated in Table 18. After
cleavage, an extender (ON_LamEx133) and four bridge
oligonucleotides (ON_LamB1-133, ON_LamB2-133, ON_LamB3-133,
5 and ON_LamB4-133) are annealed to form a partially duplex
DNA. That DNA is ligated to the cleaved lambda-chain
sense strands. After ligation, the DNA is amplified
with ON_Lam133PCR and a forward primer specific to the
lambda constant domain, such as CL2ForeAsc or
10 CL7ForeAsc (Table 130).

In human heavy chains, one can cleave almost
all genes in FR4 (downstream, i.e., toward the 3' end
of the sense strand, of CDR3) at a *Bst*EII-Site that
occurs at a constant position in a very large fraction
15 of human heavy-chain V genes. One then needs a site in
FR3, if only CDR3 diversity is to be captured, in FR2,
if CDR2 and CDR3 diversity is wanted, or in FR1, if all
the CDR diversity is wanted. These sites are
preferably inserted as part of the partially double-
20 stranded adaptor.

The preferred process of this invention is to
provide recipient vectors (e.g., for display and/or
expression) having sites that allow cloning of either
light or heavy chains. Such vectors are well known and
25 widely used in the art. A preferred phage display
vector in accordance with this invention is phage
MALIA3. This displays in gene III. The sequence of
the phage MALIA3 is shown in Table 21A (annotated) and
Table 21B (condensed).

30 The DNA encoding the selected regions of the
light or heavy chains can be transferred to the vectors
using endonucleases that cut either light or heavy
chains only very rarely. For example, light chains may

be captured with *Apa*I and *Asc*I. Heavy-chain genes are preferably cloned into a recipient vector having *Sfi*I, *Nco*I, *Xba*I, *Afl*III, *Bst*EII, *Apa*I, and *Not*I sites. The light chains are preferably moved into the library as
5 *Apa*I-*Asc*I fragments. The heavy chains are preferably moved into the library as *Sfi*I-*Not*I fragments.

Most preferably, the display is had on the surface of a derivative of M13 phage. The most preferred vector contains all the genes of M13, an
10 antibiotic resistance gene, and the display cassette. The preferred vector is provided with restriction sites that allow introduction and excision of members of the diverse family of genes, as cassettes. The preferred vector is stable against rearrangement under the growth
15 conditions used to amplify phage.

In another embodiment of this invention, the diversity captured by the methods of the present invention may be displayed and/or expressed in a phagemid vector (e.g., pCES1) that displays and/or
20 expresses the peptide, polypeptide or protein. Such vectors may also be used to store the diversity for subsequent display and/or expression using other vectors or phage.

In another embodiment of this invention, the
25 diversity captured by the methods of the present invention may be displayed and/or expressed in a yeast vector.

In another embodiment, the mode of display may be through a short linker to anchor domains -- one
30 possible anchor comprising the final portion of M13 III ("IIIstump") and a second possible anchor being the full length III mature protein.

The IIIstump fragment contains enough of M13

III to assemble into phage but not the domains involved in mediating infectivity. Because the w.t. III proteins are present the phage is unlikely to delete the antibody genes and phage that do delete these
5 segments receive only a very small growth advantage. For each of the anchor domains, the DNA encodes the w.t. AA sequence, but differs from the w.t. DNA sequence to a very high extent. This will greatly reduce the potential for homologous recombination
10 between the anchor and the w.t. gene that is also present (see Example 6).

Most preferably, the present invention uses a complete phage carrying an antibiotic-resistance gene (such as an ampicillin-resistance gene) and the display
15 cassette. Because the w.t. *iii* and possibly *viii* genes are present, the w.t. proteins are also present. The display cassette is transcribed from a regulatable promoter (e.g., P_{LacZ}). Use of a regulatable promoter allows control of the ratio of the fusion display gene
20 to the corresponding w.t. coat protein. This ratio determines the average number of copies of the display fusion per phage (or phagemid) particle.

Another aspect of the invention is a method of displaying peptides, polypeptides or proteins (and
25 particularly Fabs) on filamentous phage. In the most preferred embodiment this method displays FABs and comprises:

- a) obtaining a cassette capturing a diversity of segments of DNA encoding the elements:

30 $P_{reg}::RBS1::SS1::VL::CL::stop::RBS2::SS2::VH::CH1::$
linker::anchor::stop::,

where P_{reg} is a regulatable promoter, RBS1 is a first

ribosome binding site, SS1 is a signal sequence operable in the host strain, VL is a member of a diverse set of light-chain variable regions, CL is a light-chain constant region, stop is one or more stop
5 codons, RBS2 is a second ribosome binding site, SS2 is a second signal sequence operable in the host strain, VH is a member of a diverse set of heavy-chain variable regions, CH1 is an antibody heavy-chain first constant domain, linker is a sequence of amino acids of one to
10 about 50 residues, anchor is a protein that will assemble into the filamentous phage particle and stop is a second example of one or more stop codons; and
b) positioning that cassette within the phage genome to maximize the viability of the phage
15 and to minimize the potential for deletion of the cassette or parts thereof.

The DNA encoding the anchor protein in the above preferred cassette should be designed to encode
20 the same (or a closely related) amino acid sequence as is found in one of the coat proteins of the phage, but with a distinct DNA sequence. This is to prevent unwanted homologous recombination with the w.t. gene. In addition, the cassette should be placed in the
25 intergenic region. The positioning and orientation of the display cassette can influence the behavior of the phage.

In one embodiment of the invention, a transcription terminator may be placed after the second
30 stop of the display cassette above (e.g., Trp). This will reduce interaction between the display cassette and other genes in the phage antibody display vector.

In another embodiment of the methods of this invention, the phage or phagemid can display and/or

express proteins other than Fab, by replacing the Fab portions indicated above, with other protein genes.

Various hosts can be used the display and/or expression aspect of this invention. Such hosts are well known in the art. In the preferred embodiment, where Fabs are being displayed and/or expressed, the preferred host should grow at 30°C and be RecA⁻ (to reduce unwanted genetic recombination) and EndA⁻ (to make recovery of RF DNA easier). It is also preferred that the host strain be easily transformed by electroporation.

XL1-Blue MRF' satisfies most of these preferences, but does not grow well at 30°C. XL1-Blue MRF' does grow slowly at 38°C and thus is an acceptable host. TG-1 is also an acceptable host although it is RecA⁺ and EndA⁺. XL1-Blue MRF' is more preferred for the intermediate host used to accumulate diversity prior to final construction of the library.

After display and/or expression, the libraries of this invention may be screened using well known and conventionally used techniques. The selected peptides, polypeptides or proteins may then be used to treat disease. Generally, the peptides, polypeptides or proteins for use in therapy or in pharmaceutical compositions are produced by isolating the DNA encoding the desired peptide, polypeptide or protein from the member of the library selected. That DNA is then used in conventional methods to produce the peptide, polypeptides or protein it encodes in appropriate host cells, preferably mammalian host cells, e.g., CHO cells. After isolation, the peptide, polypeptide or protein is used alone or with pharmaceutically acceptable compositions in therapy to treat disease.

EXAMPLES

Example 1: RACE amplification of heavy and light chain antibody repertoires from autoimmune patients.

Total RNA was isolated from individual blood
5 samples (50 ml) of 11 patients using a RNazol™ kit
(CINNA/Biotech), as described by the manufacturer. The
patients were diagnosed as follows:

1. SLE and phospholipid syndrome
2. limited systemic sclerosis
- 10 3. SLE and Sjogren syndrome
4. Limited Systemic sclerosis
5. Rheumatoid Arthritis with active vasculitis
6. Limited systemic sclerosis and Sjogren Syndrome
7. Rheumatoid Arthritis and (not active) vasculitis
- 15 8. SLE and Sjogren syndrome
9. SLE
10. SLE and (active) glomerulonephritis
11. Polyarthrititis/ Raynauds Phenomen

From these 11 samples of total RNA, Poly-A+ RNA was
20 isolated using Promega PolyATtract® mRNA Isolation kit
(Promega).

250 ng of each poly-A+ RNA sample was used to
amplify antibody heavy and light chains with the
GeneAacer™ kit (Invitrogen cat no. L1500-01). A
25 schematic overview of the RACE procedure is shown in
FIG. 3.

Using the general protocol of the GeneAacer™
kit, an RNA adaptor was ligated to the 5'end of all
mRNAs. Next, a reverse transcriptase reaction was
30 performed in the presence of oligo(dT15) specific

primer under conditions described by the manufacturer in the GeneAacer™ kit.

1/5 of the cDNA from the reverse transcriptase reaction was used in a 20 ul PCR reaction. For amplification of the heavy chain IgM repertoire, a forward primer based on the CH1 chain of IgM [HuCmFOR] and a backward primer based on the ligated synthetic adaptor sequence [5'A] were used. (See Table 22)

For amplification of the kappa and lambda light chains, a forward primer that contains the 3' coding-end of the cDNA [HuCkFor and HuCLFor2+HuCLfor7] and a backward primer based on the ligated synthetic adapter sequence [5'A] was used (See Table 22).

Specific amplification products after 30 cycles of primary PCR were obtained.

FIG. 4 shows the amplification products obtained after the primary PCR reaction from 4 different patient samples. 8 ul primary PCR product from 4 different patients was analyzed on a agarose gel [labeled 1,2, 3 and 4]. For the heavy chain, a product of approximately 950 nt is obtained while for the kappa and lambda light chains the product is approximately 850 nt. M1-2 are molecular weight markers.

PCR products were also analyzed by DNA sequencing [10 clones from the lambda, kappa or heavy chain repertoires]. All sequenced antibody genes recovered contained the full coding sequence as well as the 5' leader sequence and the V gene diversity was the expected diversity (compared to literature data).

50 ng of all samples from all 11 individual amplified samples were mixed for heavy, lambda light or kappa light chains and used in secondary PCR reactions.

In all secondary PCRs approximately 1 ng

template DNA from the primary PCR mixture was used in multiple 50 ul PCR reactions [25 cycles].

For the heavy chain, a nested biotinylated forward primer [HuCm-Nested] was used, and a nested
5 5'end backward primer located in the synthetic adapter-sequence [5'NA] was used. The 5'end lower-strand of the heavy chain was biotinylated.

For the light chains, a 5'end biotinylated nested primer in the synthetic adapter was used [5'NA]
10 in combination with a 3'end primer in the constant region of Ckappa and Clambda, extended with a sequence coding for the AscI restriction site [kappa: HuCkForAscI, Lambda: HuCL2-FOR-ASC + HuCL7-FOR-ASC]. [5'end Top strand DNA was biotinylated]. After
15 gel-analysis the secondary PCR products were pooled and purified with Promega Wizzard PCR cleanup. Approximately 25 ug biotinylated heavy chain, lambda and kappa light chain DNA was isolated from the 11 patients.

20 **Example 2: Capturing kappa chains with BsmAI.**

A repertoire of human-kappa chain mRNAs was prepared using the RACE method of Example 1 from a collection of patients having various autoimmune
25 diseases.

This Example followed the protocol of Example 1. Approximately 2 micrograms (ug) of human kappa-chain (Igkappa) gene RACE material with biotin attached to 5'-end of upper strand was immobilized as in Example
30 1 on 200 microliters (µL) of Seradyn magnetic beads. The lower strand was removed by washing the DNA with 2 aliquots 200 µL of 0.1 M NaOH (pH 13) for 3 minutes for the first aliquot followed by 30 seconds for the second

aliquot. The beads were neutralized with 200 μ L of 10 mM Tris (pH 7.5) 100 mM NaCl. The short oligonucleotides shown in Table 23 were added in 40 fold molar excess in 100 μ L of NEB buffer 2 (50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl₂, 1 mM dithiothreitol pH 7.9) to the dry beads. The mixture was incubated at 95°C for 5 minutes then cooled down to 55°C over 30 minutes. Excess oligonucleotide was washed away with 2 washes of NEB buffer 3 (100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl₂, 1 mM dithiothreitol pH 7.9). Ten units of BsmAI (NEB) were added in NEB buffer 3 and incubated for 1 h at 55°C. The cleaved downstream DNA was collected and purified over a Qiagen PCR purification column (FIGs. 5 and 6).

FIG. 5 shows an analysis of digested kappa single-stranded DNA. Approximately 151.5 pmol of adapter was annealed to 3.79 pmol of immobilized kappa single-stranded DNA followed by digestion with 15 U of BsmAI. The supernatant containing the desired DNA was removed and analyzed by 5% polyacrylamide gel along with the remaining beads which contained uncleaved full length kappa DNA. 189 pmol of cleaved single-stranded DNA was purified for further analysis. Five percent of the original full length ssDNA remained on the beads.

FIG. 6 shows an analysis of the extender - cleaved kappa ligation. 180 pmol of pre-annealed bridge/extender was ligated to 1.8 pmol of BsmAI digested single-stranded DNA. The ligated DNA was purified by Qiagen PCR purification column and analyzed on a 5% polyacrylamide gel. Results indicated that the ligation of extender to single-stranded DNA was 95% efficient.

A partially double-stranded adaptor was prepared using the oligonucleotide shown in Table 23.

The adaptor was added to the single-stranded DNA in 100 fold molar excess along with 1000 units of T4 DNA ligase and incubated overnight at 16°C. The excess oligonucleotide was removed with a Qiagen PCR purification column. The ligated material was amplified by PCR using the primers kapPCRT1 and kapfor shown in Table 23 for 10 cycles with the program shown in Table 24.

The soluble PCR product was run on a gel and showed a band of approximately 700 n, as expected (FIGs. 7 and 8). The DNA was cleaved with enzymes ApaLI and AscI, gel purified, and ligated to similarly cleaved vector pCES1.

FIG. 7 shows an analysis of the PCR product from the extender-kappa amplification. Ligated extender-kappa single-stranded DNA was amplified with primers specific to the extender and to the constant region of the light chain. Two different template concentrations, 10 ng versus 50 ng, were used as template and 13 cycles were used to generate approximately 1.5 ug of dsDNA as shown by 0.8% agarose gel analysis.

FIG. 8 shows an analysis of the purified PCR product from the extender-kappa amplification. Approximately 5 ug of PCR amplified extender-kappa double-stranded DNA was run out on a 0.8% agarose gel, cut out, and extracted with a GFX gel purification column. By gel analysis, 3.5 ug of double-stranded DNA was prepared.

The assay for capturing kappa chains with BsmA1 was repeated and produced similar results. FIG 9A shows the DNA after it was cleaved and collected and purified over a Qiagen PCR purification column. FIG. 9B shows the partially double-stranded adaptor

ligated to the single-stranded DNA. This ligated material was then amplified (FIG. 9C). The gel showed a band of approximately 700 n.

Table 25 shows the DNA sequence of a kappa
5 light chain captured by this procedure. Table 26 shows
a second sequence captured by this procedure. The
closest bridge sequence was complementary to the
sequence 5'-agccacc-3', but the sequence captured reads
5'-Tgccacc-3', showing that some mismatch in the
10 overlapped region is tolerated.

Example 3: Construction of Synthetic CDR1 and CDR2 Diversity in V-3-23 VH Framework.

Synthetic diversity in Complementary
Determinant Region (CDR) 1 and 2 was created in the 3-
15 23 VH framework in a two step process: first, a vector
containing the 3-23 VH framework was constructed; and
then, a synthetic CDR 1 and 2 was assembled and cloned
into this vector.

For construction of the 3-23 VH framework, 8
20 oligonucleotides and two PCR primers (long
oligonucleotides - TOPFR1A, BOTFR1B, BOTFR2, BOTFR3, F06,
BOTFR4, ON-vgC1, and ON-vgC2 and primers - SFPRMET and
BOTPCRPRIM, shown in Table 27) that overlap were
designed based on the Genebank sequence of 3-23 VH
25 framework region. The design incorporated at least one
useful restriction site in each framework region, as
shown in Table 27. In Table 27, the segments that were
synthesized are shown as bold, the overlapping regions
are underscored, and the PCR priming regions at each
30 end are underscored.

A mixture of these 8 oligos was combined at a final concentration of 2.5uM in a 20ul PCR reaction. The PCR mixture contained 200uM dNTPs, 2.5mM MgCl₂, 0.02U *Pfu Turbo*TM DNA Polymerase, 1U Qiagen HotStart Taq
5 DNA Polymerase, and 1X Qiagen PCR buffer. The PCR program consisted of 10 cycles of 94°C for 30s, 55°C for 30s, and 72°C for 30s.

The assembled 3-23 VH DNA sequence was then amplified, using 2.5ul of a 10-fold dilution from the
10 initial PCR in 100ul PCR reaction. The PCR reaction contained 200uM dNTPs, 2.5mM MgCl₂, 0.02U *Pfu Turbo*TM DNA Polymerase, 1U Qiagen HotStart Taq DNA Polymerase, 1X Qiagen PCR Buffer and 2 outside primers (SFPRMET and BOTPCRPRIM) at a concentration of 1uM. The PCR program
15 consisted of 23 cycles at 94°C for 30s, 55°C for 30s, and 72°C for 60s. The 3-23 VH DNA sequence was digested and cloned into pCES1 (phagemid vector) using the *SfiI* and *BstEII* restriction endonuclease sites. All restriction enzymes mentioned herein were supplied
20 by New England BioLabs, Beverly, MA and used as per the manufacturer's instructions.

Stuffer sequences (shown in Table 28 and Table 29) were introduced into pCES1 to replace CDR1/CDR2 sequences (900 bases between *BspEI* and *XbaI*
25 RE sites) and CDR3 sequences (358 bases between *AflIII* and *BstEII*) prior to cloning the CDR1/CDR2 diversity. This new vector was termed pCES5 and its sequence is given in Table 29.

Having stuffers in place of the CDRs avoids
30 the risk that a parental sequence would be over-represented in the library. The stuffer sequences are fragments from the penicillase gene of *E. coli*. The CDR1-2 stuffer contains restriction sites for *BglII*,

10045674 1002501

Bsu36I, *BclI*, *XcmI*, *MluI*, *PvuII*, *HpaI*, and *HincII*, the underscored sites being unique within the vector pCES5. The stuffer that replaces CDR3 contains the unique restriction endonuclease site *RsrII*.

- 5 A schematic representation of the design for CDR1 and CDR2 synthetic diversity is shown FIG. 10. The design was based on the presence of mutations in DP47/3-23 and related germline genes. Diversity was designed to be introduced at the positions within CDR1
- 10 and CDR2 indicated by the numbers in FIG. 10. The diversity at each position was chosen to be one of the three following schemes: 1 = ADEFGHIKLMNPQRSTVWY; 2 = YRWVGS; 3 = PS, in which letters encode equimolar mixes of the indicated amino acids.
- 15 For the construction of the CDR1 and CDR2 diversity, 4 overlapping oligonucleotides (ON-vgC1, ON_Br12, ON_CD2Xba, and ON-vgC2, shown in Table 27 and Table 30) encoding CDR1/2, plus flanking regions, were designed. A mixture of these 4 oligos was combined at
- 20 a final concentration of 2.5uM in a 40ul PCR reaction. Two of the 4 oligos contained variegated sequences positioned at the CDR1 and the CDR2. The PCR mixture contained 200uM dNTPs, 2.5U Pwo DNA Polymerase (Roche), and 1X Pwo PCR buffer with 2mM MgSO₄. The PCR program
- 25 consisted of 10 cycles at 94°C for 30s, 60°C for 30s, and 72°C for 60s. This assembled CDR1/2 DNA sequence was amplified, using 2.5ul of the mixture in 100ul PCR reaction. The PCR reaction contained 200uM dNTPs, 2.5U Pwo DNA Polymerase, 1X Pwo PCR Buffer with 2mM MgSO₄, and
- 30 2 outside primers at a concentration of 1uM. The PCR program consisted of 10 cycles at 94°C for 30s, 60°C for 30s, and 72°C for 60s. These variegated sequences were digested and cloned into the 3-23 VH framework in place of the CDR1/2 stuffer.

10045674-100504

We obtained approximately 7×10^7 independent transformants. CDR3 diversity either from donor populations or from synthetic DNA can be cloned into the vector containing synthetic CDR1 and CDR 2
5 diversity.

A schematic representation of this procedure is shown in FIG. 11. A sequence encoding the FR-regions of the human V3-23 gene segment and CDR regions with synthetic diversity was made by oligonucleotide
10 assembly and cloning via *BspE1* and *Xba1* sites into a vector that complements the FR1 and FR3 regions. Into this library of synthetic VH segments, the complementary VH-CDR3 sequence (top right) was cloned via *Xba1* and *BstE1* sites. The resulting cloned CH
15 genes contain a combination of designed synthetic diversity and natural diversity (see FIG. 11).

Example 4: Cleavage and ligation of the lambda light chains with *HinfI*.

A schematic of the cleavage and ligation of
20 antibody light chains is shown in FIGS. 12A and 12B. Approximately 2 ug of biotinylated human Lambda DNA prepared as described in Example 1 was immobilized on 200 ul Seradyn magnetic beads. The lower strand was removed by incubation of the DNA with 200 ul of 0.1 M
25 NaOH (pH=13) for 3 minutes, the supernatant was removed and an additional washing of 30 seconds with 200 ul of 0.1 M NaOH was performed. Supernatant was removed and the beads were neutralized with 200 ul of 10 mM Tris (pH=7.5), 100 mM NaCl. 2 additional washes with 200 ul
30 NEB2 buffer 2, containing 10 mM Tris (pH=7.9), 50 mM NaCl, 10 mM MgCl₂ and 1 mM dithiothreitol, were

performed. After immobilization, the amount of ssDNA was estimated on a 5% PAGE-UREA gel.

About 0.8 ug ssDNA was recovered and incubated in 100 ul NEB2 buffer 2 containing 80 molar
5 fold excess of an equimolar mix of ON_Lam1aB7,
ON_Lam2aB7, ON_Lam3lB7 and ON_Lam3rB7 [each oligo in
20 fold molar excess] (see Table 31).

The mixture was incubated at 95° C for 5
minutes and then slowly cooled down to 50° C over a
10 period of 30 minutes. Excess of oligonucleotide was
washed away with 2 washes of 200 ul of NEB buffer 2.
4 U/ug of *Hinf I* was added and incubated for 1 hour at
50° C. Beads were mixed every 10 minutes.

After incubation the sample was purified over
15 a Qiagen PCR purification column and was subsequently
analysed on a 5% PAGE-urea gel (see FIG. 13A, cleavage
was more than 70% efficient).

A schematic of the ligation of the cleaved
light chains is shown in FIG. 12B. A mix of
20 bridge/extender pairs was prepared from the Brg/Ext
oligo's listed in Table 31 (total molar excess 100
fold) in 1000 U of T4 DNA Ligase (NEB) and incubated
overnight at 16° C. After ligation of the DNA, the
excess oligonucleotide was removed with a Qiagen PCR
25 purification column and ligation was checked on a
Urea-PAGE gel (see FIG. 13B; ligation was more than 95%
efficient).

Multiple PCRs were performed containing 10 ng
of the ligated material in an 50 ul PCR reaction using
30 25 pMol ON lamP1ePCR and 25 pmol of an equimolar mix
of Hu-CL2AscI/HuCL7AscI primer (see Example 1).

PCR was performed at 60° C for 15 cycles
using Pfu polymerase. About 1 ug of dsDNA was recovered

per PCR (see FIG. 13C) and cleaved with *Apa*I and *Asc*I for cloning the lambda light chains in pCES2.

Example 5: Capture of human heavy-chain CDR3 population.

5

A schematic of the cleavage and ligation of antibody light chains is shown in FIGs. 14A and 14B.

Approximately 3 ug of human heavy-chain (IgM) gene RACE material with biotin attached to 5'-end of
10 lower strand was immobilized on 300 uL of Seradyn magnetic beads. The upper strand was removed by washing the DNA with 2 aliquots 300 uL of 0.1 M NaOH (pH 13) for 3 minutes for the first aliquot followed by 30 seconds for the second aliquot. The beads were
15 neutralized with 300 uL of 10 mM Tris (pH 7.5) 100 mM NaCl. The REaptors (oligonucleotides used to make single-stranded DNA locally double-stranded) shown in Table 32 were added in 30 fold molar excess in 200 uL of NEB buffer 4 (50 mM Potassium Acetate, 20 mM
20 Tris-Acetate, 10 mM Magnesium Acetate, 1 mM dithiothreitol pH 7.9) to the dry beads. The REaptors were incubated with the single-stranded DNA at 80 °C for 5 minutes then cooled down to 55 °C over 30 minutes. Excess REaptors were washed away with 2
25 washes of NEB buffer 4. Fifteen units of HpyCH4III (NEB) were added in NEB buffer 4 and incubated for 1 hour at 55 °C. The cleaved downstream DNA remaining on the beads was removed from the beads using a Qiagen Nucleotide removal column (see FIG. 15).

30

The Bridge/Extender pairs shown in Table 33 were added in 25 molar excess along with 1200 units of T4 DNA ligase and incubated overnight at 16 °C. Excess

Bridge/Extender was removed with a Qiagen PCR purification column. The ligated material was amplified by PCR using primers H43.XAExtPCR2 and Hucumnest shown in Table 34 for 10 cycles with the program shown in Table 35.

The soluble PCR product was run on a gel and showed a band of approximately 500 n, as expected (see FIG. 15B). The DNA was cleaved with enzymes *SfiI* and *NotI*, gel purified, and ligated to similarly cleaved vector PCES1.

Example 6: Description of Phage Display Vector CJRA05, a member of the library built in vector DY3F7.

Table 36 contains an annotated DNA sequence of a member of the library, CJRA05, see FIG. 16. Table 36 is to be read as follows: on each line everything that follows an exclamation mark "!" is a comment. All occurrences of A, C, G, and T before "!" are the DNA sequence. Case is used only to show that certain bases constitute special features, such as restriction sites, ribosome binding sites, and the like, which are labeled below the DNA. CJRA05 is a derivative of phage DY3F7, obtained by cloning an *ApaI* to *NotI* fragment into these sites in DY3F31. DY3F31 is like DY3F7 except that the light chain and heavy chain genes have been replaced by "stuffer" DNA that does not code for any antibody. DY3F7 contains an antibody that binds streptavidin, but did not come from the present library.

The phage genes start with gene ii and continue with genes x, v, vii, ix, viii, iii, vi, i, and iv. Gene iii has been slightly modified in that

eight codons have been inserted between the signal sequence and the mature protein and the final amino acids of the signal sequence have been altered. This allows restriction enzyme recognition sites *EagI* and
5 *XbaI* to be present. Following gene iv is the phage origin of replication (ori). After ori is bla which confers resistance to ampicillin (ApR). The phage genes and bla are transcribed in the same sense.

After bla, is the Fab cassette (illustrated
10 in FIG. 17) comprising:

- a) PlacZ promoter,
- b) A first Ribosome Binding Site (RBS1),
- c) The signal sequence form M13 iii,
- d) An *ApaLI* RERS,
- 15 e) A light chain (a kappa L20::JK1 shortened by one codon at the V-J boundary in this case),
- f) An *AscI* RERS,
- g) A second Ribosome Binding Site (RBS2),
- h) A signal sequence, preferably PelB, which
20 contains,
- i) An *SfiI* RERS,
- j) A synthetic 3-23 V region with diversity in CDR1 and CDR2,
- k) A captured CDR3,
- 25 l) A partially synthetic J region (FR4 after *BstEII*),
- m) CH1,
- n) A *NotI* RERS,
- o) A His6 tag,
- p) A cMyc tag,
- 30 q) An amber codon,
- r) An anchor DNA that encodes the same amino-acid sequence as codons 273 to 424 of M13 iii (as shown in Table 37).

- s) Two stop codons,
- t) An *AvrII* RERS, and
- u) A *trp* terminator.

The anchor (item r) encodes the same amino-acid sequence as do codons 273 to 424 of M13 iii but the DNA is approximately as different as possible from the wild-type DNA sequence. In Table 36, the III' stump runs from base 8997 to base 9455. Below the DNA, as comments, are the differences with wild-type iii for the comparable codons with "!W.T" at the ends of these lines. Note that Met and Trp have only a single codon and must be left as is. These AA types are rare. Ser codons can be changed at all three base, while Leu and Arg codons can be changed at two.

In most cases, one base change can be introduced per codon. This has three advantages: 1) recombination with the wild-type gene carried elsewhere on the phage is less likely, 2) new restriction sites can be introduced, facilitating construction; and 3) sequencing primers that bind in only one of the two regions can be designed.

The fragment of M13 III shown in CJRA05 is the preferred length for the anchor segment. Alternative longer or shorter anchor segments defined by reference to whole mature III protein may also be utilized.

The sequence of M13 III consists of the following elements: Signal Sequence::Domain 1 (D1)::Linker 1 (L1)::Domain 2 (D2)::Linker 2 (L2)::Domain 3 (D3)::Transmembrane Segment (TM):: Intracellular anchor (IC) (see Table 38).

The pIII anchor (also known as *trpIII*) preferably consists of D2::L2::D3::TM::IC. Another embodiment for the pIII anchor consists of

D2':::L2::D3::TM::IC (where D2' comprises the last 21 residues of D2 with the first 109 residues deleted). A further embodiment of the pIII anchor consists of D2'(C>S)::L2::D3::TM::IC (where D2'(C>S) is D2' with the single C converted to S), and d) D3::TM::IC.

Table 38 shows a gene fragment comprising the *NotI* site, His6 tag, cMyc tag, an amber codon, a recombinant enterokinase cleavage site, and the whole of mature M13 III protein. The DNA used to encode this sequence is intentionally very different from the DNA of wild-type gene iii as shown by the lines denoted "W.T." containing the w.t. bases where these differ from this gene. III is divided into domains denoted "domain 1", "linker 1", "domain 2", "linker 2", "domain 3", "transmembrane segment", and "intracellular anchor".

Alternative preferred anchor segments (defined by reference to the sequence of Table 38) include:

- 20 codons 1-29 joined to codons 104-435, deleting domain 1 and retaining linker 1 to the end;
 - codons 1-38 joined to codons 104-435, deleting domain 1 and retaining the rEK cleavage site plus linker 1 to the end from III;
- 25 codons 1-29 joined to codons 236-435, deleting domain 1, linker 1, and most of domain 2 and retaining linker 2 to the end;
 - codons 1-38 joined to codons 236-435, deleting domain 1, linker 1, and most of domain 2 and retaining linker 2 to the end and the rEK cleavage site;
- 30 codons 1-29 joined to codons 236-435 and changing codon 240 to Ser(e.g., agc), deleting domain 1, linker 1, and most of domain 2 and retaining linker 2 to the end; and

codons 1-38 joined to codons 236-435 and changing codon 240 to Ser(e.g., agc), deleting domain 1, linker 1, and most of domain 2 and retaining linker 2 to the end and the rEK cleavage site.

5 The constructs would most readily be made by methods similar to those of Wang and Wilkinson (Biotechniques 2001: 31(4)722-724) in which PCR is used to copy the vector except the part to be deleted and matching restriction sites are introduced or retained
10 at either end of the part to be kept. Table 39 shows the oligonucleotides to be used in deleting parts of the III anchor segment. The DNA shown in Table 38 has an *NheI* site before the DINDDRMA recombinant enterokinase cleavage site (rEKCS). If *NheI* is used in
15 the deletion process with this DNA, the rEKCS site would be lost. This site could be quite useful in cleaving Fabs from the phage and might facilitate capture of very high-affinity antibodies. One could mutagenize this sequence so that the *NheI* site would
20 follow the rEKCS site, an Ala Ser amino-acid sequence is already present. Alternatively, one could use *SphI* for the deletions. This would involve a slight change in amino acid sequence but would be of no consequence.

Example 7 : Selection of antigen binders from an
25 **enriched library of human antibodies using phage vector DY3F31.**

In this example the human antibody library used is described in de Haard et al., (Journal of Biological Chemistry, 274 (26): 18218-30 (1999)). This
30 library, consisting of a large non-immune human Fab phagemid library, was first enriched on antigen, either

on streptavidin or on phenyl-oxazolone (phOx). The methods for this are well known in the art. Two preselected Fab libraries, the first one selected once on immobilized phOx-BSA (R1-ox) and the second one
5 selected twice on streptavidin (R2-strep), were chosen for recloning.

These enriched repertoires of phage antibodies, in which only a very low percentage have binding activity to the antigen used in selection, were
10 confirmed by screening clones in an ELISA for antigen binding. The selected Fab genes were transferred from the phagemid vector of this library to the DY3F31 vector via *ApaI*-*NotI* restriction sites.

DNA from the DY3F31 phage vector was
15 pretreated with ATP dependent DNase to remove chromosomal DNA and then digested with *ApaI* and *NotI*. An extra digestion with *AscI* was performed in between to prevent self-ligation of the vector. The *ApaI*/*NotI* Fab fragment from the preselected libraries was
20 subsequently ligated to the vector DNA and transformed into competent XL1-blue MRF' cells.

Libraries were made using vector:insert ratios of 1:2 for phOx-library and 1:3 for STREP library, and using 100 ng ligated DNA per 50 µl of
25 electroporation-competent cells (electroporation conditions : one shock of 1700 V, 1 hour recovery of cells in rich SOC medium, plating on ampicillin-containing agar plates).

This transformation resulted in a library
30 size of 1.6×10^6 for R1-ox in DY3F31 and 2.1×10^6 for R2-strep in DY3F31. Sixteen colonies from each library were screened for insert, and all showed the correct size insert (± 1400 bp) (for both libraries).

Phage was prepared from these Fab libraries as follows. A representative sample of the library was inoculated in medium with ampicillin and glucose, and at OD 0.5, the medium exchanged for ampicillin and 1 mM IPTG. After overnight growth at 37 °C, phage was harvested from the supernatant by PEG-NaCl precipitation. Phage was used for selection on antigen. R1-ox was selected on phOx-BSA coated by passive adsorption onto immunotubes and R2-strep on streptavidin coated paramagnetic beads (Dynal, Norway), in procedures described in de Haard et. al. and Marks et. al., Journal of Molecular Biology, 222(3): 581-97 (1991). Phage titers and enrichments are given in Table 40.

Clones from these selected libraries, dubbed R2-ox and R3-strep respectively, were screened for binding to their antigens in ELISA. 44 clones from each selection were picked randomly and screened as phage or soluble Fab for binding in ELISA. For the libraries in DY3F31, clones were first grown in 2TY-2% glucose-50 µg/ml AMP to an OD600 of approximately 0.5, and then grown overnight in 2TY-50 µg/ml AMP +/- 1mM IPTG. Induction with IPTG may result in the production of both phage-Fab and soluble Fab. Therefore the (same) clones were also grown without IPTG. Table 41 shows the results of an ELISA screening of the resulting supernatant, either for the detection of phage particles with antigen binding (Anti-M13 HRP = anti-phage antibody), or for the detection of human Fabs, be it on phage or as soluble fragments, either with using the anti-myc antibody 9E10 which detects the myc-tag that every Fab carries at the C-terminal end of the heavy chain followed by a HRP-labeled rabbit-anti-Mouse serum (column 9E10/RAM-HRP), or with

anti-light chain reagent followed by a HRP-labeled goat-anti-rabbit antiserum(anti-CK/CL Gar-HRP).

The results shows that in both cases antigen-binders are identified in the library, with as
5 Fabs on phage or with the anti-Fab reagents (Table 41). IPTG induction yields an increase in the number of positives. Also it can be seen that for the phOx-clones, the phage ELISA yields more positives than the soluble Fab ELISA, most likely due to the avid
10 binding of phage. Twenty four of the ELISA-positive clones were screened using PCR of the Fab-insert from the vector, followed by digestion with *BstNI*. This yielded 17 different patterns for the phOx-binding Fab's in 23 samples that were correctly analyzed, and 6
15 out of 24 for the streptavidin binding clones. Thus, the data from the selection and screening from this pre-enriched non-immune Fab library show that the DY3F31 vector is suitable for display and selection of Fab fragments, and provides both soluble Fab and Fab on
20 phage for screening experiments after selection.

Example 8: Selection of Phage-antibody libraries on streptavidin magnetic beads.

The following example describes a selection in which one first depletes a sample of the library of
25 binders to streptavidin and optionally of binders to a non-target (*i.e.*, a molecule other than the target that one does not want the selected Fab to bind). It is hypothesized that one has a molecule, termed a "competitive ligand", which binds the target and that
30 an antibody which binds at the same site would be especially useful.

For this procedure Streptavidin Magnetic Beads (Dyna) were blocked once with blocking solution (2% Marvel Milk, PBS (pH 7.4), 0.01% Tween-20 ("2%MPBST")) for 60 minutes at room temperature and
5 then washed five times with 2%MPBST. 450 μ L of beads were blocked for each depletion and subsequent selection set.

Per selection, 6.25 μ L of biotinylated depletion target (1 mg/mL stock in PBST) was added to
10 0.250 mL of washed, blocked beads (from step 1). The target was allowed to bind overnight, with tumbling, at 4°C. The next day, the beads are washed 5 times with PBST.

Per selection, 0.010 mL of biotinylated
15 target antigen (1 mg/mL stock in PBST) was added to 0.100 mL of blocked and washed beads (from step 1). The antigen was allowed to bind overnight, with tumbling, at 4°C. The next day, the beads were washed 5 times with PBST.

20 In round 1, 2×10^{12} up to 10^{13} plaque forming units (pfu) per selection were blocked against non-specific binding by adding to 0.500 mL of 2%MPBS (=2%MPBST without Tween) for 1 hr at RT (tumble). In later rounds, 1011 pfu per selection were blocked as
25 done in round 1.

Each phage pool was incubated with 50 μ L of depletion target beads (final wash supernatant removed just before use) on a Labquake rotator for 10 min at room temperature. After incubation, the phage
30 supernatant was removed and incubated with another 50 μ L of depletion target beads. This was repeated 3 more times using depletion target beads and twice using blocked streptavidin beads for a total of 7 rounds of

10045974 1005007

A small sample of each depleted library pool was taken for titering. Each library pool was added to 0.100 mL of target beads (final wash supernatant was removed just before use) and allowed to incubate for 2 hours at room temperature (tumble).

After the first selection elution, the beads can be eluted again with 0.300 mL of non-biotinylated target (1 mg/mL) for 1 hr at RT on a Labquake rotator. Eluted phage are added to 0.450 mL Minimal A salts.

Three eluates (competitor from 1st selection, target from 1st selection and neutralized TEA elution from 2nd selection) were kept separate and a small aliquot taken from each for titering. 0.500 mL Minimal A salts were added to the remaining bead aliquots after competitor and target elution and after TEA elution. Take a small aliquot from each was taken for tittering.

Each elution and each set of eluted beads was
30 mixed with 2X YT and an aliquot (e.g., 1 mL with 1. E
10/mL) of XL1-Blue MRF' E. coli cells (or other F' cell
line) which had been chilled on ice after having been
grown to mid-logarithmic phase, starved and

concentrated (see procedure below - "Mid-Log prep of XL-1 blue MRF' cells for infection").

After approximately 30 minutes at room temperature, the phage/cell mixtures were spread onto
5 Bio-Assay Dishes (243 X 243 X 18 mm, Nalge Nunc) containing 2XYT, 1mM IPTG agar. The plates were incubated overnight at 30°C. The next day, each amplified phage culture was harvested from its respective plate. The plate was flooded with 35 mL TBS
10 or LB, and cells were scraped from the plate. The resuspended cells were transferred to a centrifuge bottle. An additional 20 mL TBS or LB was used to remove any cells from the plate and pooled with the cells in the centrifuge bottle. The cells were
15 centrifuged out, and phage in the supernatant was recovered by PEG precipitation. Over the next day, the amplified phage preps were titered.

In the first round, two selections yielded five amplified eluates. These amplified eluates were
20 panned for 2-3 more additional rounds of selection using ~1. E 12 input phage/round. For each additional round, the depletion and target beads were prepared the night before the round was initiated.

For the elution steps in subsequent rounds,
25 all elutions up to the elution step from which the amplified elution came from were done, and the previous elutions were treated as washes. For the bead infection amplified phage, for example, the competitive ligand and target elutions were done and
30 then tossed as washes (see below). Then the beads were used to infect E. coli. Two pools, therefore, yielded a total of 5 final elutions at the end of the selection.

10045674 102501

1st selection set

- A. Ligand amplified elution: elute w/ ligand
for 1 hr, keep as elution
- 5 B. Target amplified elution: elute w/ ligand
for 1 hr, toss as wash elute w/ target for 1
hr, keep as elution
- C. Bead infect. amp. elution: elute w/
ligand for 1 hr, toss as wash elute w/ target
10 for 1 hr, toss as wash elute w/ cell
infection, keep as elution

2nd selection set

- A. TEA amplified elution; elute w/ TEA
10min, keep as elution
- 15 B. Bead infect. amp. elution; elute w/
TEA 10min, toss as wash elute w/ cell
infection, keep as elution

Mid-log prep of XL1 blue MRF' cells for infection

(based on Barbas et al. Phage Display manual procedure)

- 20 Culture XL1 blue MRF' in NZCYM (12.5 mg/mL
tet) at 37°C and 250 rpm overnight. Started a 500 mL
culture in 2 liter flask by diluting cells 1/50 in
NZCYM/tet (10 mL overnight culture added) and incubated
at 37°C at 250 rpm until OD600 of 0.45 (1.5-2 hrs) was
25 reached. Shaking was reduced to 100 rpm for 10 min.
When OD600 reached between 0.55-0.65, cells were
transferred to 2 x 250 mL centrifuge bottles,
centrifuged at 600 g for 15 min at 4°C. Supernatant

was poured off. Residual liquid was removed with a pipette.

The pellets were gently resuspended (not pipetting up and down) in the original volume of 1 X
5 Minimal A salts at room temp. The resuspended cells were transferred back into 2-liter flask, shaken at 100 rpm for 45 min at 37°C. This process was performed in order to starve the cells and restore pili. The cells were transferred to 2 x 250 mL centrifuge bottles, and
10 centrifuged as earlier.

The cells were gently resuspended in ice cold Minimal A salts (5 mL per 500 mL original culture). The cells were put on ice for use in infections as soon as possible.

15 The phage eluates were brought up to 7.5 mL with 2XYT medium and 2.5 mL of cells were added. Beads were brought up to 3 mL with 2XYT and 1 mL of cells were added. Incubated at 37°C for 30 min. The cells were plated on 2XYT, 1 mM IPTG agar large NUNC plates
20 and incubated for 18 hr at 30°C.

Example 9: Incorporation of synthetic region in FR1/3 region.

Described below are examples for incorporating of fixed residues in antibody sequences
25 for light chain kappa and lambda genes, and for heavy chains. The experimental conditions and oligonucleotides used for the examples below have been described in previous examples (e.g., Examples 3 & 4).

The process for incorporating fixed FR1
30 residues in an antibody lambda sequence consists of 3 steps (see FIG. 18): (1) annealing of single-stranded

DNA material encoding VL genes to a partially complementary oligonucleotide mix (indicated with Ext and Bridge), to anneal in this example to the region encoding residues 5-7 of the FR1 of the lambda genes
5 (indicated with X..X; within the lambda genes the overlap may sometimes not be perfect); (2) ligation of this complex; (3) PCR of the ligated material with the indicated primer ('PCRpr') and for example one primer based within the VL gene. In this process the first few
10 residues of all lambda genes will be encoded by the sequences present in the oligonucleotides (Ext., Bridge or PCRpr). After the PCR, the lambda genes can be cloned using the indicated restriction site for ApaLI.

The process for incorporating fixed FR1
15 residues in an antibody kappa sequence (FIG. 19) consists of 3 steps : (1) annealing of single-stranded DNA material encoding VK genes to a partially complementary oligonucleotide mix (indicated with Ext and Bri), to anneal in this example to the region
20 encoding residues 8-10 of the FR1 of the kappa genes (indicated with X..X; within the kappa genes the overlap may sometimes not be perfect) ; (2) ligation of this complex; (3) PCR of the ligated material with the indicated primer ('PCRpr') and for example one primer
25 based within the VK gene. In this process the first few (8) residues of all kappa genes will be encoded by the sequences present in the oligonucleotides (Ext., Bridge or PCRpr.). After the PCR, the kappa genes can be cloned using the indicated restriction site for ApaLI.

30 The process of incorporating fixed FR3 residues in a antibody heavy chain sequence (FIG. 20) consists of 3 steps : (1) annealing of single-stranded DNA material encoding part of the VH genes (for example encoding FR3, CDR3 and FR4 regions) to a partially

complementary oligonucleotide mix (indicated with Ext and Bridge), to anneal in this example to the region encoding residues 92-94 (within the FR3 region) of VH genes (indicated with X..X; within the VH genes the
5 overlap may sometimes not be perfect); (2) ligation of this complex; (3) PCR of the ligated material with the indicated primer ('PCRpr') and for example one primer based within the VH gene (such as in the FR4 region). In this process certain residues of all VH genes will
10 be encoded by the sequences present in the oligonucleotides used here, in particular from PCRpr (for residues 70-73), or from Ext/Bridge oligonucleotides (residues 74-91). After the PCR, the partial VH genes can be cloned using the indicated
15 restriction site for *XbaI*.

It will be understood that the foregoing is only illustrative of the principles of this invention and that various modifications can be made by those skilled in the art without departing from the scope of
20 and spirit of the invention.

Table 1: Human GLG FR3 sequences

! VH1

	!	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80
		agg	gtc	acc	atg	acc	agg	gac	acg	tcc	atc	agc	aca	gcc	tac	atg
5	!	81	82	82a	82b	82c	83	84	85	86	87	88	89	90	91	92
		gag	ctg	agc	agg	ctg	aga	tct	gac	gac	acg	gcc	gtg	tat	tac	tgt
	!	93	94	95												
		gcg	aga	ga	! 1-02# 1											
		aga	gtc	acc	att	acc	agg	gac	aca	tcc	gcg	agc	aca	gcc	tac	atg
10		gag	ctg	agc	agc	ctg	aga	tct	gaa	gac	acg	gct	gtg	tat	tac	tgt
		gcg	aga	ga	! 1-03# 2											
		aga	gtc	acc	atg	acc	agg	aac	acc	tcc	ata	agc	aca	gcc	tac	atg
		gag	ctg	agc	agc	ctg	aga	tct	gag	gac	acg	gcc	gtg	tat	tac	tgt
		gcg	aga	gg	! 1-08# 3											
15		aga	gtc	acc	atg	acc	aca	gac	aca	tcc	acg	agc	aca	gcc	tac	atg
		gag	ctg	agg	agc	ctg	aga	tct	gac	gac	acg	gcc	gtg	tat	tac	tgt
		gcg	aga	ga	! 1-18# 4											
		aga	gtc	acc	atg	acc	gag	gac	aca	tct	aca	gac	aca	gcc	tac	atg
		gag	ctg	agc	agc	ctg	aga	tct	gag	gac	acg	gcc	gtg	tat	tac	tgt
20		gca	aca	ga	! 1-24# 5											
		aga	gtc	acc	att	acc	agg	gac	agg	tct	atg	agc	aca	gcc	tac	atg
		gag	ctg	agc	agc	ctg	aga	tct	gag	gac	aca	gcc	atg	tat	tac	tgt
		gca	aga	ta	! 1-45# 6											
		aga	gtc	acc	atg	acc	agg	gac	acg	tcc	acg	agc	aca	gtc	tac	atg
25		gag	ctg	agc	agc	ctg	aga	tct	gag	gac	acg	gcc	gtg	tat	tac	tgt
		gcg	aga	ga	! 1-46# 7											
		aga	gtc	acc	att	acc	agg	gac	atg	tcc	aca	agc	aca	gcc	tac	atg
		gag	ctg	agc	agc	ctg	aga	tcc	gag	gac	acg	gcc	gtg	tat	tac	tgt
		gcg	gca	ga	! 1-58# 8											
30		aga	gtc	acg	att	acc	gcg	gac	gaa	tcc	acg	agc	aca	gcc	tac	atg
		gag	ctg	agc	agc	ctg	aga	tct	gag	gac	acg	gcc	gtg	tat	tac	tgt
		gcg	aga	ga	! 1-69# 9											
		aga	gtc	acg	att	acc	gcg	gac	aaa	tcc	acg	agc	aca	gcc	tac	atg
		gag	ctg	agc	agc	ctg	aga	tct	gag	gac	acg	gcc	gtg	tat	tac	tgt
35		gcg	aga	ga	! 1-e# 10											
		aga	gtc	acc	ata	acc	gcg	gac	acg	tct	aca	gac	aca	gcc	tac	atg
		gag	ctg	agc	agc	ctg	aga	tct	gag	gac	acg	gcc	gtg	tat	tac	tgt
		gca	aca	ga	! 1-f# 11											

10045674.103501

agg ctc acc atc acc aag gac acc tcc aaa aac cag gtg gtc ctt
aca atg acc aac atg gac cct gtg gac aca gcc aca tat tac tgt
gca cac aga c! 2-05# 12

5 agg ctc acc atc tcc aag gac acc tcc aaa agc cag gtg gtc ctt
acc atg acc aac atg gac cct gtg gac aca gcc aca tat tac tgt
gca cgg ata c! 2-26# 13

```

agg ctc acc atc tcc aag gac acc tcc aaa aac cag gtg gtc ctt
aca atg acc aac atg gac cct gtg gac aca gcc acg tat tac tgt
10 gca cgq ata c! 2-70# 14

```

cga ttc acc atc tcc aga gac aac gcc aag aac tca ctg tat ctg
caa atg aac agc ctg aga gcc gag gac acg gct gtg tat tac tgt
gcg aga ga ! 3-07# 15

15 cga ttc acc atc tcc aga gac aac gcc aag aac tcc ctg tat ctg
 caa atg aac agt ctg aga gct gag gac acg gcc ttg tat tac tgt
 gca aaa gat a! 3-09#16

20 cga ttc acc atc tcc agg gac aac gcc aag aac tca ctg tat ctg
caa atg aac agc ctg aga gcc gag gac acg gcc gtg tat tac tgt
gcg aqa ga ! 3-11# 17

cga ttc acc atc tcc aga gaa aat gcc aag aac tcc ttg tat ctt
caa atg aac agc ctg aga gcc ggg gac acg gct gtg tat tac tgt
gca aqa ga ! 3-13# 18

25 aga ttc acc atc tca aga gat gat tca aaa aac acg ctg tat ctg
 caa atg aac agc ctg aaa acc gag gac aca gcc gtg tat tac tgt
 acc aca ga ! 3-15# 19

cga ttc acc atc tcc aga gac aac gcc aag aac tcc ctg tat ctg
caa atg aac agt ctg aga gcc gag gac acg gcc ttg tat cac tgt
gcg aga ga ! 3-20# 20

30 cga ttc acc atc tcc aga gac aac gcc aag aac tca ctg tat ctg
caa atg aac agc ctg aga gcc gag gac acg gct gtg tat tac tgt
gcg aga ga ! 3-21# 21

cgg ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctg
caa atg aac agc ctg aga gcc gag gac acg gcc gta tat tac tgt
35 gcg aaa ga ! 3-23# 22

cga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctg
caa atg aac agc ctg aga gct gag gac acg gct gtg tat tac tgt
gcg aaa ga ! 3-30# 23

40 cga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctg
 caa atg aac agc ctg aga gct gaq qac acg gct gtg tat tac tgt

gcg aga ga ! 3303# 24
cga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctg
caa atg aac agc ctg aga gct gag gac acg gct gtg tat tac tgt
gcg aaa ga ! 3305# 25
5 cga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctg
caa atg aac agc ctg aga gcc gag gac acg gct gtg tat tac tgt
gcg aga ga ! 3-33# 26
cga ttc acc atc tcc aga gac aac agc aaa aac tcc ctg tat ctg
caa atg aac agt ctg aga act gag gac acc gcc ttg tat tac tgt
10 gca aaa gat a! 3-43#27
cga ttc acc atc tcc aga gac aat gcc aag aac tca ctg tat ctg
caa atg aac agc ctg aga gac gag gac acg gct gtg tat tac tgt
gcg aga ga ! 3-48# 28
aga ttc acc atc tca aga gat ggt tcc aaa agc atc gcc tat ctg
15 caa atg aac agc ctg aaa acc gag gac aca gcc gtg tat tac tgt
act aga ga ! 3-49# 29
cga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctt
caa atg aac agc ctg aga gcc gag gac acg gcc gtg tat tac tgt
gcg aga ga ! 3-53# 30
20 aga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctt
caa atg gcc agc ctg aga gct gag gac atg gct gtg tat tac tgt
gcg aga ga ! 3-64# 31
aga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctt
caa atg aac agc ctg aga gct gag gac acg gct gtg tat tac tgt
25 gcg aga ga ! 3-66# 32
aga ttc acc atc tca aga gat gat tca aag aac tca ctg tat ctg
caa atg aac agc ctg aaa acc gag gac acg gcc gtg tat tac tgt
gct aga ga ! 3-72# 33
agg ttc acc atc tcc aga gat gat tca aag aac acg gcg tat ctg
30 caa atg aac agc ctg aaa acc gag gac acg gcc gtg tat tac tgt
act aga ca ! 3-73# 34
cga ttc acc atc tcc aga gac aac gcc aag aac acg ctg tat ctg
caa atg aac agt ctg aga gcc gag gac acg gct gtg tat tac tgt
gca aga ga ! 3-74# 35
35 aga ttc acc atc tcc aga gac aat tcc aag aac acg ctg cat ctt
caa atg aac agc ctg aga gct gag gac acg gct gtg tat tac tgt
aag aaa ga ! 3-d# 36
! VH4
40 cga gtc acc ata tca gta gac aag tcc aag aac cag ttc tcc ctg
aag ctg agc tct gtg acc gcc gcg gac acg gcc gtg tat tac tgt

10045674-1000001

gcg aga ga ! 4-04# 37
cga gtc acc atg tca gta gac acg tcc aag aac cag ttc tcc ctg
aag ctg agc tct gtg acc gcc gtg gac acg gcc gtg tat tac tgt
gcg aga aa ! 4-28# 38
5 cga gtt acc ata tca gta gac acg tct aag aac cag ttc tcc ctg
aag ctg agc tct gtg act gcc gcg gac acg gcc gtg tat tac tgt
gcg aga ga ! 4301# 39
cga gtc acc ata tca gta gac agg tcc aag aac cag ttc tcc ctg
aag ctg agc tct gtg acc gcc gcg gac acg gcc gtg tat tac tgt
10 gcc aga ga ! 4302# 40
cga gtt acc ata tca gta gac acg tcc aag aac cag ttc tcc ctg
aag ctg agc tct gtg act gcc gca gac acg gcc gtg tat tac tgt
gcc aga ga ! 4304# 41
cga gtt acc ata tca gta gac acg tct aag aac cag ttc tcc ctg
15 aag ctg agc tct gtg act gcc gcg gac acg gcc gtg tat tac tgt
gcg aga ga ! 4-31# 42
cga gtc acc ata tca gta gac acg tcc aag aac cag ttc tcc ctg
aag ctg agc tct gtg acc gcc gcg gac acg gct gtg tat tac tgt
gcg aga ga ! 4-34# 43
20 cga gtc acc ata tcc gta gac acg tcc aag aac cag ttc tcc ctg
aag ctg agc tct gtg acc gcc gca gac acg gct gtg tat tac tgt
gcg aga ca ! 4-39# 44
cga gtc acc ata tca gta gac acg tcc aag aac cag ttc tcc ctg
aag ctg agc tct gtg acc gct gcg gac acg gcc gtg tat tac tgt
25 gcg aga ga ! 4-59# 45
cga gtc acc ata tca gta gac acg tcc aag aac cag ttc tcc ctg
aag ctg agc tct gtg acc gct gcg gac acg gcc gtg tat tac tgt
gcg aga ga ! 4-61# 46
cga gtc acc ata tca gta gac acg tcc aag aac cag ttc tcc ctg
30 aag ctg agc tct gtg acc gcc gca gac acg gcc gtg tat tac tgt
gcg aga ga ! 4-b# 47
! VH5
cag gtc acc atc tca gcc gac aag tcc atc agc acc gcc tac ctg
cag tgg agc agc ctg aag gcc tcg gac acc gcc atg tat tac tgt
35 gcg aga ca ! 5-51# 48
cac gtc acc atc tca gct gac aag tcc atc agc act gcc tac ctg
cag tgg agc agc ctg aag gcc tcg gac acc gcc atg tat tac tgt
gcg aga ! 5-a# 49
! VH6
40 cga ata acc atc aac cca gac aca tcc aag aac cag ttc tcc ctg

10045674-100501

cag ctg aac tct gtg act ccc gag gac acg gct gtg tat tac tgt
gca aga ga ! 6-1# 50

! VH7

5 cgg ttt gtc ttc tcc ttg gac acc tct gtc agc acg gca tat ctg
cag atc tgc agc cta aag gct gag gac act gcc gtg tat tac tgt
gcg aga ga ! 74.1# 51

10045674 102501

Table 2: Enzymes that either cut 15 or more human GLGs or have 5+-base recognition in FR3

Typical entry:

	REname	Recognition	#sites
	GLGid#:base#	GLGid#:base#	GLGid#:base#.....
5	BstEII	Ggtnacc	2
	1:	3 48: 3	
	There are 2 hits at base# 3		
10	MaeIII	gtnac	36
	1:	4 2: 4 3: 4 4: 4 5: 4 6: 4	
	7:	4 8: 4 9: 4 10: 4 11: 4 37: 4	
	37:	58 38: 4 38: 58 39: 4 39: 58 40: 4	
	40:	58 41: 4 41: 58 42: 4 42: 58 43: 4	
15	43:	58 44: 4 44: 58 45: 4 45: 58 46: 4	
	46:	58 47: 4 47: 58 48: 4 49: 4 50: 58	
	There are 24 hits at base# 4		
	Tsp45I	gtsac	33
20	1:	4 2: 4 3: 4 4: 4 5: 4 6: 4	
	7:	4 8: 4 9: 4 10: 4 11: 4 37: 4	
	37:	58 38: 4 38: 58 39: 58 40: 4 40: 58	
	41:	58 42: 58 43: 4 43: 58 44: 4 44: 58	
	45:	4 45: 58 46: 4 46: 58 47: 4 47: 58	
25	48:	4 49: 4 50: 58	
	There are 21 hits at base# 4		
	HphI	tcacc	45
30	1:	5 2: 5 3: 5 4: 5 5: 5 6: 5	
	7:	5 8: 5 11: 5 12: 5 12: 11 13: 5	
	14:	5 15: 5 16: 5 17: 5 18: 5 19: 5	
	20:	5 21: 5 22: 5 23: 5 24: 5 25: 5	
	26:	5 27: 5 28: 5 29: 5 30: 5 31: 5	
	32:	5 33: 5 34: 5 35: 5 36: 5 37: 5	
35	38:	5 40: 5 43: 5 44: 5 45: 5 46: 5	
	47:	5 48: 5 49: 5	
	There are 44 hits at base# 5		

100456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100

26

5

There are 1 hits at base# 48 Could cause raggedness.

37

15

There are 14 hits at base# 14

42

25

30 There are 11 hits at base# 52 Only 5 bases from 47

21

35

There are 21 hits at base# 48


```
5  There are 11 hits at base# 64
   There are 4 hits at base# 57
   There are 2 hits at base# 67 Could be ragged.
```

```

15      38: 72      39: 72      40: 72      41: 72      42: 72      43: 72
      44: 72      45: 72      46: 72      47: 72      48: 72      49: 72
      50: 72      51: 72
      There are 44 hits at base# 72

```

25 **There are 23 hits at base# 74**

There are 23 hits at base# 74

33: 74 34: 74 37: 74 38: 74 39: 74 40: 74

41: 74 42: 74 45: 74 46: 74 47: 74

There are 23 hits at base# 74

HaeIII GGcc

27

5 1: 75 3: 75 4: 75 5: 75 7: 75 8: 75
 9: 75 10: 75 11: 75 16: 75 17: 75 20: 75
 22: 75 30: 75 33: 75 34: 75 37: 75 38: 75
 39: 75 40: 75 41: 75 42: 75 45: 75 46: 75
 47: 75 48: 63 49: 63

10 There are 25 hits at base# 75

Bst4CI ACNgt 65°C

63 Sites There is a third isoschismer

1: 86 2: 86 3: 86 4: 86 5: 86 6: 86
 7: 34 7: 86 8: 86 9: 86 10: 86 11: 86
 15 12: 86 13: 86 14: 86 15: 36 15: 86 16: 53
 16: 86 17: 36 17: 86 18: 86 19: 86 20: 53
 20: 86 21: 36 21: 86 22: 0 22: 86 23: 86
 24: 86 25: 86 26: 86 27: 53 27: 86 28: 36
 28: 86 29: 86 30: 86 31: 86 32: 86 33: 36
 20 33: 86 34: 86 35: 53 35: 86 36: 86 37: 86
 38: 86 39: 86 40: 86 41: 86 42: 86 43: 86
 44: 86 45: 86 46: 86 47: 86 48: 86 49: 86
 50: 86 51: 0 51: 86

There are 51 hits at base# 86 All the other sites are well away

25

HpyCH4III ACNgt

63

1: 86 2: 86 3: 86 4: 86 5: 86 6: 86
 7: 34 7: 86 8: 86 9: 86 10: 86 11: 86
 12: 86 13: 86 14: 86 15: 36 15: 86 16: 53
 30 16: 86 17: 36 17: 86 18: 86 19: 86 20: 53
 20: 86 21: 36 21: 86 22: 0 22: 86 23: 86
 24: 86 25: 86 26: 86 27: 53 27: 86 28: 36
 28: 86 29: 86 30: 86 31: 86 32: 86 33: 36
 33: 86 34: 86 35: 53 35: 86 36: 86 37: 86
 35 38: 86 39: 86 40: 86 41: 86 42: 86 43: 86
 44: 86 45: 86 46: 86 47: 86 48: 86 49: 86
 50: 86 51: 0 51: 86

1005674-103601

HinfI Gantc

5

10

MlyI GAGTCNNNNNn

15

There are 18 hits at base# 2

20

PleI gagtc

18

There are 18 hits at base# 2

25

AciI Ccgc

24

There are 8 hits at base# 62

There are 8 hits at base# 65

There are 3 hits at base# 14

There are 3 hits at base# 74

There are 1 hits at base# 26

35

There are 1 hits at base# 35

-"- Gcgg

11

8: 91 9: 16 10: 16 11: 16 37: 67 39: 67

There are 1 hits at base# 91

10

15

25

30

35

46: 64 48: 53 49: 53 50: 45 51: 53

There are 13 hits at base# 53

MnlI gagg

34

5 3: 67 3: 95 4: 51 5: 16 5: 67 6: 67
 7: 67 8: 67 9: 67 10: 67 11: 67 15: 67
 16: 67 17: 67 19: 67 20: 67 21: 67 22: 67
 23: 67 24: 67 25: 67 26: 67 27: 67 28: 67
 29: 67 30: 67 31: 67 32: 67 33: 67 34: 67

10 35: 67 36: 67 50: 67 51: 67

There are 31 hits at base# 67

HpyCH4V TGca

34

5: 90 6: 90 11: 90 12: 90 13: 90 14: 90
 15 15: 44 16: 44 16: 90 17: 44 18: 90 19: 44
 20: 44 21: 44 22: 44 23: 44 24: 44 25: 44
 26: 44 27: 44 27: 90 28: 44 29: 44 33: 44
 34: 44 35: 44 35: 90 36: 38 48: 44 49: 44
 50: 44 50: 90 51: 44 51: 52

20 There are 21 hits at base# 44

There are 1 hits at base# 52

AccI GTmkac

13 5-base recognition

7: 37 11: 24 37: 16 38: 16 39: 16 40: 16
 25 41: 16 42: 16 43: 16 44: 16 45: 16 46: 16
 47: 16

There are 11 hits at base# 16

SacII CCGCgg

8 6-base recognition

30 9: 14 10: 14 11: 14 37: 65 39: 65 40: 65
 42: 65 43: 65

There are 5 hits at base# 65

There are 3 hits at base# 14

TfiI Gawtc

24

9: 22 15: 2 16: 2 17: 2 18: 2 19: 2
 19: 22 20: 2 21: 2 23: 2 24: 2 25: 2

```
26:  2   27:  2   28:  2   29:  2   30:  2   31:  2
32:  2   33:  2   33: 22   34: 22   35:  2   36:  2
There are 20 hits at base# 2
```

5	BsmAI Nnnnnngagac			19		
15: 11	16: 11	20: 11	21: 11	22: 11	23: 11	
24: 11	25: 11	26: 11	27: 11	28: 11	28: 56	
30: 11	31: 11	32: 11	35: 11	36: 11	44: 87	
48: 87						

10 There are 16 hits at base# 11

```

      BpmI  ctccag                      19
      15: 12   16: 12   17: 12   18: 12   20: 12   21: 12
      22: 12   23: 12   24: 12   25: 12   26: 12   27: 12
15    28: 12   30: 12   31: 12   32: 12   34: 12   35: 12
      36: 12
      There are 19 hits at base# 12

```

```

XmnI  GAANNnnttc                12
20  37: 30   38: 30   39: 30   40: 30   41: 30   42: 30
    43: 30   44: 30   45: 30   46: 30   47: 30   50: 30
There are 12 hits at base# 30

```

```

      BsrI  NCcagt                12
25    37: 32   38: 32   39: 32   40: 32   41: 32   42: 32
      43: 32   44: 32   45: 32   46: 32   47: 32   50: 32
      There are 12 hits at base# 32

```

```

BanII  GRGcYc              11
30  37: 51  38: 51  39: 51  40: 51  41: 51  42: 51
    43: 51  44: 51  45: 51  46: 51  47: 51
    There are 11 hits at base# 51

```

```

      Ecl136I GAGctc              11
35  37: 51  38: 51  39: 51  40: 51  41: 51  42: 51
      43: 51  44: 51  45: 51  46: 51  47: 51
      There are 11 hits at base# 51

```

- 129 -

SacI GAGCTc

11

37: 51 38: 51 39: 51 40: 51 41: 51 42: 51

43: 51 44: 51 45: 51 46: 51 47: 51

There are 11 hits at base# 51

10045674.102501

Table 3: Synthetic 3-23 FR3 of human heavy chains showing positions of possible cleavage sites

! Sites engineered into the synthetic gene are shown in upper case DNA

! with the RE name between vertical bars (as in | XbaI |).

5 ! RERSs frequently found in GLGs are shown below the synthetic sequence

! with the name to the right (as in gtn ac=MaeIII(24), indicating that

! 24 of the 51 GLGs contain the site).

10 !

! |---FR3---

! 89 90 (codon

! # in

! R F

15 synthetic 3-23)

! Allowed DNA

! |cgc|ttc| 6

! |cgn|tty|

! |agr|

! ga ntc =

20 HinfI(38)

! ga gtc =

PleI(18)

! ga wtc =

TfiI(20)

25 ! gtn ac =

MaeIII(24)

! gts ac =

Tsp45I(21)

! tc acc. =

30 HphI(44)

! -----FR3-----

! 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105

! T I S R D N S K N T L Y L Q M

35 |act|atc|TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|

51

!allowed|acn|ath|tcn|cgn|gay|aay|tcn|aar|aay|acn|ttr|tay|ttr|car|atg|

! |agy|agr| |agy| |ctn| |ctn|

! | ga|gac = BsmAI(16) ag ct =

40 AluI(23)

10045674 " 102501

```

!           c|tcc ag = BpmI(19)           g ctn agc =
BlpI(21)
!           |           |           g aan nnn ttc = XmnI(12)
!           | XbaI  |           tg ca =
5 HpyCH4V(21)
!
!           ---FR3----->|
!           106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
!           N   S   L   R   A   E   D   T   A   V   Y   Y   C   A   K
10 |aac|agC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|tgc|gct|aaa| 96
!allowed|aay|tcn|ttr|cgn|gcn|gar|gay|acn|gcn|gtn|tay|tay|tgy|gcn|aar|
!           |agy|ctn|agr|           |           |
!           |           |   cc nng g = BsaJI(23)           ac ngt = Bst4CI(51)
!           |           |   aga tct = BglII(10)           |           ac ngt =
15 HpyCH4III(51)
!           |           |   Rga tcY = BstYI(11)           |           ac ngt = TaaI(51)
!           |           |           c ayn nnn rtc = MslI(44)
!           |           |           cg ryc g = BsiEI(23)
!           |           |           yg gcc r = EaeI(23)
20 !           |           |           cg gcc g = EagI(23)
!           |           |           |g gcc = HaeIII(25)
!           |           |           gag g = MnlI(31)|
!           |AflII |           | PstI |

```

1005674.1005674

Table 4: REaptors, Extenders, and Bridges used for Cleavage and Capture of Human Heavy Chains in FR3.

A: HpyCH4V Probes of actual human HC genes

!HpyCH4V in FR3 of human HC, bases 35-56; only those with TGca site

5	TGca;10,				
	RE recognition:tgca			of length 4 is expected at	
10					
	1		6-1	agttotccctgcagctgaactc	
	2	3-11,3-07,3-21,3-72,3-48		cactgtatctgcaaatgaacag	
10	3	3-09,3-43,3-20		ccctgtatctgcaaatgaacag	
	4		5-51	ccgcctacctgcagtggagcag	
	5	3-15,3-30,3-30.5,3-30.3,3-74,3-23,3-33		cgctgtatctgcaaatgaacag	
	6		7-4.1	cggcatatctgcagatctgcag	
	7		3-73	cggcgtatctgcaaatgaacag	
15	8		5-a	ctgcctacctgcagtggagcag	
	9		3-49	tcgcctatctgcaaatgaacag	

B: HpyCH4V REaptors, Extenders, and Bridges

B.1 REaptors

! Cutting HC lower strand:

20 ! TmKeller for 100 mM NaCl, zero formamide

! Eaptors for cleavage

		T_m^W	T_m^K
(ON_HCFR36-1)	5'-agttctcccTGCAgctgaactc-3'	68.0	64.5
(ON_HCFR36-1A)	5'-ttctcccTGCAgctgaactc-3'	62.0	62.5
(ON_HCFR36-1B)	5'-ttctcccTGCAgctgaac-3'	56.0	59.9
25 (ON_HCFR33-15)	5'-cgctgtatcTGCAaatgaacag-3'	64.0	60.8
(ON_HCFR33-15A)	5'-ctgtatcTGCAaatgaacag-3'	56.0	56.3
(ON_HCFR33-15B)	5'-ctgtatcTGCAaatgaac-3'	50.0	53.1
(ON_HCFR33-11)	5'-cactgtatcTGCAaatgaacag-3'	62.0	58.9
(ON_HCFR35-51)	5'-ccgcctaccTGCAgtggagcag-3'	74.0	70.1

30 !

B.2 Segment of synthetic 3-23 gene into which captured CDR3 is to be cloned

! XbaI...

!D323* cgCttcacTaag tcT_aqa gac aaC tcT aag aaT acT ctC taC

35 ! scab..... designed gene 3-23 gene.....

!

! HpyCH4V

! ... AflIII...

! Ttg caG atg aac agc TtA agG . . .
!
!

B.3 Extender and Bridges

5 ! Extender (bottom strand):

!
(ON_HCHpyEx01) 5'-cAagTAgAgAgTATTcTTAgAgTTgTcTcTAqAcTTAgTgAAgcg-3'
! ON_HCHpyEx01 is the reverse complement of
! 5'-cgCttcacTaag tcT aqa gac aaC tcT aag aaT acT ctC taC Ttg -3'

10 !

! Bridges (top strand, 9-base overlap):

!
(ON_HCHpyBr016-1) 5'-cgCttcacTaag tcT aqa gac aaC tcT aag-
aaT acT ctC taC Ttg CAgctgaac-3' {3'-term C is

15 blocked}

!
! 3-15 et al. + 3-11

(ON_HCHpyBr023-15) 5'-cgCttcacTaag tcT aqa gac aaC tcT aag-
aaT acT ctC taC Ttg CAaatgaac-3' {3'-term C is

20 blocked}

!

! 5-51

(ON_HCHpyBr045-51) 5'-cgCttcacTaag tcT aqa gac aaC tcT aag-
aaT acT ctC taC Ttg CAgtaggagc-3' {3'-term C is

25 blocked}

!

! PCR primer (top strand)

!

(ON_HCHpyPCR) 5'-cgCttcacTaag tcT aqa gac-3'

30 !

C: BspI Probes from human HC GLGs

1	1-58, 1-03, 1-08, 1-69, 1-24, 1-45, 1-46, 1-f, 1-e
	acatggaGCTGAGCagcctgag
2	1-02
35	acatggaGCTGAGCaggctgag
3	1-18
	acatggagctgaggagcctgag

4 5-51,5-a
acctgcagtggagcagcctgaa
5 3-15,3-73,3-49,3-72
atctgcaaatgaacagcctgaa
5 6 3303,3-33,3-07,3-11,3-30,3-21,3-23,3305,3-48
atctgcaaatgaacagcctgag
7 3-20,3-74,3-09,3-43
atctgcaaatgaacagtctgag
8 74.1
10 atctgcagatctgcagcctaaa
9 3-66,3-13,3-53,3-d
atcttcaaatgaacagcctgag
10 3-64
atcttcaaatgggcagcctgag
15 11 4301,4-28,4302,4-04,4304,4-31,4-34,4-39,4-59,4-61,4-b
ccctgaaGCTGAGCtctgtgac
12 6-1
ccctgcagctgaactctgtgac
13 2-70,2-05
20 tccttacaatgaccaacatgga
14 2-26
tccttaccatgaccaacatgga

D: B1pI REadaptors, Extenders, and Bridges

D.1 REadaptors

		T _m ^W	T _m ^K
25	(BlpF3HC1-58) 5'-ac atg gaG CTG AGC agc ctg ag-3'	70	66.
			4
	(BlpF3HC6-1) 5'-cc ctg aag ctg agc tct gtg ac-3'	70	66.
			4
30	! BlpF3HC6-1 matches 4-30.1, not 6-1.		

D.2 Segment of synthetic 3-23 gene into which captured CDR3 is to be cloned

!
BlpI
35 ! XbaI...
... ..
!D323* cgCttcacTaag TCT AGA gac aaC tcT aag aaT acT ctC taC Ttg
caG atg aac

```

!
!                               AflIII...
!                               aqC TTA AGG

```

D.3 Extender and Bridges

```

5      ! Bridges
      (BlpF3Br1) 5'-cgCttcacTcag tct aga gaT aaC AGT aaA aaT acT TtG-
                taC Ttg caG Ctg a|GC agc ctg-3'
      (BlpF3Br2) 5'-cgCttcacTcag tct aga gaT aaC AGT aaA aaT acT TtG-
                taC Ttg caG Ctg a|gc tct gtg-3'
10     !                                     | lower strand is cut here
      ! Extender
      (BlpF3Ext) 5' -
      TcAgcTgcAAgTAcAAAgTATTTTAcTgTTATcTcTAgAcTgAgTgAAgcg-3'
      ! BlpF3Ext is the reverse complement of:
15     ! 5'-cgCttcacTcag tct aga gaT aaC AGT aaA aaT acT TtG taC Ttg caG
      Ctg a-3'
      !
      (BlpF3PCR) 5'-cgCttcacTcag tct aga gaT aaC-3'

```

E: HpyCH4III Distinct GLG sequences surrounding site, bases 77-98

20	1	102#1,118#4,146#7,169#9,1e#10,311#17,353#30,404#37,4301
		ccgtgtattactgtgcgagaga
	2	103#2,307#15,321#21,3303#24,333#26,348#28,364#31,366#32
		ctgtgtattactgtgcgagaga
	3	108#3
25		ccgtgtattactgtgcgagagg
	4	124#5,1f#11
		ccgtgtattactgtgcaacaga
	5	145#6
		ccatgtattactgtgcaagata
30	6	158#8
		ccgtgtattactgtgcggcaga
	7	205#12
		ccacatattactgtgcacacag
	8	226#13
35		ccacatattactgtgcacggat
	9	270#14
		ccacgtattactgtgcacgqat

	10	309#16,343#27
	ccttggtattactgtgcaaaaga	
	11	313#18,374#35,61#50
	ctgtgtattactgtgcaagaga	
5	12	315#19
	ccgtgtattactgtaccacaga	
	13	320#20
	ccttggtatcactgtgcgagaga	
	14	323#22
10	ccgtatattactgtgcgaaaga	
	15	330#23,3305#25
	ctgtgtattactgtgcgaaaga	
	16	349#29
	ccgtgtattactgtactagaga	
15	17	372#33
	ccgtgtattactgtgctagaga	
	18	373#34
	ccgtgtattactgtactagaca	
	19	3d#36
20	ctgtgtattactgtaagaaaga	
	20	428#38
	ccgtgtattactgtgcgagaaa	
	21	4302#40,4304#41
	ccgtgtattactgtgccagaga	
25	22	439#44
	ctgtgtattactgtgcgagaca	
	23	551#48
	ccatgtattactgtgcgagaca	
	24	5a#49
30	ccatgtattactgtgcgaga	

F: HpyCH4III REaptors, Extenders, and Bridges

F.1 REaptors

	! ONs for cleavage of HC(lower) in FR3(bases 77-97)										
	! For cleavage with HpyCH4III, Bst4CI, or TaaI										
35	! cleavage is in lower chain before base 88.										
	!	77	788	888	888	889	999	999	9		
	!	78	901	234	567	890	123	456	7	T _m ^W	
	T _m ^K										
	(H43.77.97.1-02#1)	5'	-cc	gtg	tat	tAC	TGT	gcg	aga	g-3'	6462.6
40	(H43.77.97.1-03#2)	5'	-cc	gtg	tat	tAC	TGT	gcg	aga	g-3'	6260.6
	(H43.77.97.108#3)	5'	-cc	gtg	tat	tAC	TGT	gcg	aga	g-3'	6462.6
	(H43.77.97.323#22)	5'	-cc	gta	tat	tac	tgt	gcg	aaa	g-3'	6058.7
	(H43.77.97.330#23)	5'	-cc	gtg	tat	tac	tgt	gcg	aaa	g-3'	6058.7
	(H43.77.97.439#44)	5'	-cc	gtg	tat	tac	tgt	gcg	aga	g-3'	6260.6

(H43.77.97.551#48) 5'-cc atg tat tac tgt gcg aga c-3' 6260.6
 (H43.77.97.5a#49) 5'-cc atg tat tAC TGT gcg aga c-3' 5858.3

F.2 Extender and Bridges

! XbaI and AflII sites in bridges are bunged

5 (H43.XABr1) 5'-gggtgtagtga-
 |TCT|AGt|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|-
 |aac|agC|TTt|AGg|qct|qag|qac|aCT|GCA|Gtc|tac|tat|tgt|gcg|aga-3'

(H43.XABr2) 5'-gggtgtagtga-
 |TCT|AGt|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|-
 10 |aac|agC|TTt|AGg|qct|qag|qac|aCT|GCA|Gtc|tac|tat|tgt|gcg|aaa-3'

(H43.XAExt) 5'-ATAgTAgAcT gcAgTgTccT cAgcccTTAA gcTgTTcATc
 TgcAAgTAgA-

gAgTATTcTT AgAgTTgTcT cTAgATcAcT AcAcc-3'

!H43.XAExt is the reverse complement of

15 ! 5'-gggtgtagtga-
 ! |TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|-
 ! |aac|agC|TTA|AGg|qct|qag|qac|aCT|GCA|Gtc|tac|tat|-3'

(H43.XAPCR) 5'-gggtgtagtga |TCT|AGA|gac|aac-3'

! XbaI and AflII sites in bridges are bunged

20 (H43.ABr1) 5'-gggtgtagtga-
 |aac|agC|TTt|AGg|qct|qag|qac|aCT|GCA|Gtc|tac|tat|tgt|gcg|aga-3'
 (H43.ABr2) 5'-gggtgtagtga-

|aac|agC|TTt|AGg|qct|qag|qac|aCT|GCA|Gtc|tac|tat|tgt|gcg|aaa-3'

(H43.AExt) 5'-ATAgTAgAcTgcAgTgTccTcAgcccTTAAgcTgTTTcActAcAcc-3'

25 !(H43.AExt) is the reverse complement of 5'-gggtgtagtga-
 ! |aac|agC|TTA|AGg|qct|qag|qac|aCT|GCA|Gtc|tac|tat|-3'

(H43.APCR) 5'-gggtgtagtga |aac|agC|TTA|AGg|qct|q-3'

10045674.100501

Table 5: Analysis of frequency of matching REDaptors in actual V genes

A: HpyCHAV in HC at bases 35-56

Number of mismatches..... Number															

Id	Probe	dotted probe
6-1	agttctcccTGCAGctgaactc	agttctcccTGCAGctgaactc
3-11	cactgtatcTGCAAatgaacag	cac.g.at.....aa.....ag
3-09	ccctgtatcTGCAAatgaacag	ccc.g.at.....aa.....ag
5-51	ccgcctaccTGCAGtggagcag	ccgc..a.....tg..g.ag

THE GENE

- 140 -

8	3	0	2	0	1	0	0	0	0	0	0	0	74.1	atctgcagatctgcagcctaaa
9	23	18	2	2	1	0	0	0	0	0	0	0	3-66	atcttcaaatgaacagcctgag
10	2	1	0	1	0	0	0	0	0	0	0	0	3-64	atcttcaaatggcagcctgag
11	486	249	78	81	38	21	10	4	4	1	467	4301	ccctgaagctgagctctgtgac	ccctgaagctgagctctgtgac
12	16	6	3	1	0	1	1	3	1	0	1	6-1	ccctgcagctgaactctgtgac	ccctgcagctgaactctgtgac
13	28	15	8	2	2	1	0	0	0	0	0	2-70	tccttacaatgaccaacatgga	tccttacaatgaccaacatgga
14	2	0	2	0	0	0	0	0	0	0	0	2-26	tccttaccatgaccaacatgga	tccttaccatgaccaacatgga

601

- 141 -

Name	Full sequence	Dot mode
1-58	acatggaGCTGAGCagcctgag	acatggaGCTGAGCagcctgag
1-02	acatgga gctgag cagcctgagg....
1-18	acatggagctgaggagcctgagg.....
5-51	acctgcagtgagcagcctgaa	.c..c..tg.....a
3-15	atctgcaaatgaacagcctgaa	.tc..C.aa...a.....a
3-30.3	atctgcaaatgaacagcctgag	.tc..C.aa...a.....
3-20	atctgcaaatgaacagctctgag	.tc..C.aa...a...t....
7-4.1	atctgcagatctgcagcctaaa	.tc..C..a.ct.....a.a
3-66	atcttcaaatgaacagcctgag	.tc.tc.aa...a.....
3-64	atcttcaaatgggcagcctgag	.tc.tc.aa..g.....
4-30.1	ccctgaagctgagctctgtgac	c.c..a.....tctg...c
6-1	ccctgcagctgaactctgtgac	c.c..c.....a.tctg...c
2-70	tccttacaatgaccaacatgga	t.c.tacaa...c..a..ga
2-26	tccttaccatgaccaacatgga	t.c.tacca...c..a..ga

Seqs with the expected RE site only..... 597 (counting sequences with 4 or fewer mismatches)

Seqs with only an unexpected site..... 2

Seqs with both expected and unexpected.... 2

Seqs with no sites..... 686

20 C:HpyCH4III, Bst4CI, or TaaI in HC

In scoring whether the RE site of interest is present, only ONs that have 4 or fewer mismatches are counted.

Sequence Analysis

- 143 -

Id		Ntot	0	1	2	3	4	5	6	7	8	Ncut	acndt		acndt		
5	1	244	78	92	43	18	10	1	2	0	0	241	102#1,1	ccg	gtattACTG	tcgagaga	
	2	457	69	150	115	66	34	11	8	3	1	434	103#2,3	ctg	gtattactg	cgagaga	
	3	173	52	45	36	22	14	3	0	0	1	169	108#3	ccg	gtattactg	tcgagagg	
	4	16	0	3	2	2	1	6	0	1	1	8	124#5,1	ccg	gtattactg	tgcacaga	
10	5	4	0	0	1	0	1	1	0	1	0	2	145#6	cca	gtattactg	tgcagata	
	6	15	1	0	1	0	6	4	1	1	1	8	158#8	ccg	gtattactg	tcggcaga	
	7	23	4	8	5	2	2	1	1	0	0	21	205#12	cca	catattactg	tcacacag	
	8	9	1	1	1	0	3	2	1	0	0	6	226#13	cca	catattactg	tcacggat	
15	9	7	1	3	1	1	0	0	1	0	0	6	270#14	cca	cg	tattactg	tcacggat
	10	23	7	3	5	5	2	1	0	0	0	22	309#16,	cct	gtattactg	tgcacaaaga	
	11	35	5	10	7	6	3	3	0	1	0	31	313#18,	ctg	gtattactg	tgcacagaga	
	12	18	2	3	2	2	6	1	0	2	0	15	315#19	ccg	gtattactg	taccacaga	
20	13	3	1	2	0	0	0	0	0	0	0	3	320#20	cct	gtatcactg	tcgagaga	
	14	117	29	23	28	22	8	4	2	1	0	110	323#22	ccg	tattactg	tcgcaaga	
	15	75	21	25	13	9	1	4	2	0	0	69	330#23,	ctg	gtattactg	tcgcaaga	
	16	14	2	2	2	3	0	3	1	1	0	9	349#29	ccg	gtattactg	tactagaga	
20	17	2	0	0	1	0	0	1	0	0	0	1	372#33	ccg	gtattactg	tgc	tagaga
	18	1	0	0	1	0	0	0	0	0	0	1	373#34	ccg	gtattactg	tactagaca	
	19	2	0	0	0	0	0	0	0	0	2	0	3d#36	ctg	gtattactg	taagaaga	
	20	34	4	9	9	4	5	3	0	0	0	31	428#38	ccg	gtattactg	tcgagaaa	
20	21	17	5	4	2	2	3	1	0	0	0	16	4302#40	ccg	gtattactg	tcgccagaga	
	22	75	15	17	24	7	10	1	1	0	0	73	439#44	ctg	gtattactg	tcgcagaca	
	23	40	14	15	4	5	1	0	1	0	0	39	551#48	cca	gtattactg	tcgcagaca	

	24	213	26	56	60	42	20	7	2	0	0	204	5a#49
--	----	-----	----	----	----	----	----	---	---	---	---	-----	-------

ccatgtattactgtgcgagaAA ..a.....AA

Group	337	471	363	218	130	58	23	11	6				
-------	-----	-----	-----	-----	-----	----	----	----	---	--	--	--	--

Cumulative	337	808	1171	1389	1519	1577	1600	1611	1617				
------------	-----	-----	------	------	------	------	------	------	------	--	--	--	--

- 5
- Seqs with the expected RE site only.....1511
 - Seqs with only an unexpected site..... 0
 - Seqs with both expected and unexpected.... 8
 - Seqs with no sites..... 0

100456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100

Table 5D:

Analysis repeated using only 8 best REaptors

	Id	Ntot	0	1	2	3	4	5	6	7	8+						
5	1	301	78	101	54	32	16	9	10	1	0	281 102#1					
			ccgtgtattactgtgcgagaga														
	2	493	69	155	125	73	37	14	11	3	6	459 103#2					
			ctgtgtattactgtgcgagaga														
	3	189	52	45	38	23	18	5	4	1	3	176 108#3					
10			ccgtgtattactgtgcgagagg														
	4	127	29	23	28	24	10	6	5	2	0	114 323#22					
			ccgtatattactgtgcgaaaga														
	5	78	21	25	14	11	1	4	2	0	0	72 330#23					
			ctgtgtattactgtgcgaaaga														
						6	79	15	17	25	8	11	1	2	0	0	76
15	439#44		ctgtgtattactgtgcgagaca														
	7	43	14	15	5	5	3	0	1	0	0	42 551#48					
			ccatgtattactgtgcgagaca														
	8	307	26	63	72	51	38	24	14	13	6	250 5a#49					
			ccatgtattactgtgcgaga														
20	1	102#1	ccgtgtattactgtgcgagaga					ccgtgtattactgtgcgagaga									
	2	103#2	ctgtgtattactgtgcgagaga					.t.....									
	3	108#3	ccgtgtattactgtgcgagagg				g									
	4	323#22	ccgtatattactgtgcgaaaga				a.....a...									
	5	330#23	ctgtgtattactgtgcgaaaga					.t.....a...									
25	6	439#44	ctgtgtattactgtgcgagaca					.t.....c.									
	7	551#48	ccatgtattactgtgcgagaca					..a.....c.									
	8	5a#49	ccatgtattactgtgcgagaAA					..a.....AA									

Seqs with the expected RE site only.....1463 / 1617

Seqs with only an unexpected site..... 0

30 Seqs with both expected and unexpected.... 7

Seqs with no sites..... 0

Table 6: Human HC GLG FR1 Sequences

VH Exon - Nucleotide sequence alignment

VH1

5	1-02	CAG GTG CAG CTG GTG CAG TCT GGG GCT GAG GTG AAG AAG CCT GGG GCC TCA GTG AAG
		GTC TCC TGC AAG GCT TCT GGA TAC ACC TTC ACC
	1-03	cag gtC cag ctT gtg cag tct ggg gct gag gtg aag aag cct ggg gcc tca gtg aag
		gtT tcc tgc aag gct tct gga tac acc ttc acT
	1-08	cag gtg cag ctg gtg cag tct ggg gct gag gtg aag aag cct ggg gcc tca gtg aag
		gtc tcc tgc aag gct tct gga tac acc ttc acc
10	1-18	cag gtT cag ctg gtg cag tct ggA gct gag gtg aag aag cct ggg gcc tca gtg aag
		gtc tcc tgc aag gct tct ggT tac acc ttT acc
	1-24	cag gtC cag ctg gtA cag tct ggg gct gag gtg aag aag cct ggg gcc tca gtg aag
		gtc tcc tgc aag gTt tcC gga tac acc Ctc acT
15	1-45	cag Atg cag ctg gtg cag tct ggg gct gag gtg aag aag Act ggg Tcc tca gtg aag
		gtT tcc tgc aag gct tcC gga tac acc ttc acc
	1-46	cag gtg cag ctg gtg cag tct ggg gct gag gtg aag aag cct ggg gcc tca gtg aag
		gtT tcc tgc aag gCA tct gga tac acc ttc acc
	1-58	caA Atg cag ctg gtg cag tct ggg Cct gag gtg aag aag cct ggg Acc tca gtg aag
		gtc tcc tgc aag gct tct gga tTc acc ttT acT
20	1-69	cag gtg cag ctg gtg cag tct ggg gct gag gtg aag aag cct ggg Tcc tcG gtg aag
		gtc tcc tgc aag gct tct gga GGc acc ttc aGc
	1-e	cag gtg cag ctg gtg cag tct ggg gct gag gtg aag aag cct ggg Tcc tcG gtg aag
		gtc tcc tgc aag gct tct gga GGc acc ttc aGc
25	1-f	Gag gtC cag ctg gtA cag tct ggg gct gag gtg aag aag cct ggg gcT Aca gtg aaA
		Atc tcc tgc aag gTt tct gga tac acc ttc acc

VH2

	2-05	CAG ATC ACC TTG AAG GAG TCT GGT CCT ACG CTG GTG AAA CCC ACA CAG ACC CTC ACG
		CTG ACC TGC ACC TTC TCT GGG TTC TCA CTC AGC
30	2-26	cag Gtc acc ttg aag gag tct ggt cct GTg ctg gtg aaa ccc aca Gag acc ctc acg
		ctg acc tgc acc Gtc tct ggg ttc tca ctc agc
	2-70	cag Gtc acc ttg aag gag tct ggt cct Gcg ctg gtg aaa ccc aca cag acc ctc acA
		ctg acc tgc acc ttc tct ggg ttc tca ctc agc

VH3

35	3-07	GAG GTG CAG CTG GTG GAG TCT GGG GGA GGC TTG GTC CAG CCT GGG GGG TCC CTG AGA
		CTC TCC TGT GCA GCC TCT GGA TTC ACC TTT AGT
	3-09	gaA gtg cag ctg gtg gag tct ggg gga ggc ttg gtA cag cct ggC Agg tcc ctg aga
		ctc tcc tgt gca gcc tct gga ttc acc ttt GAt
	3-11	Cag gtg cag ctg gtg gag tct ggg gga ggc ttg gtc Aag cct ggA ggg tcc ctg aga
		ctc tcc tgt gca gcc tct gga ttc acc ttC agt
40	3-13	gag gtg cag ctg gtg gag tct ggg gga ggc ttg gtA cag cct ggg ggg tcc ctg aga
		ctc tcc tgt gca gcc tct gga ttc acc ttC agt
	3-15	gag gtg cag ctg gtg gag tct ggg gga ggc ttg gtA Aag cct ggg ggg tcc ctT aga
		ctc tcc tgt gca gcc tct gga ttc acT ttC agt

THE **NEW** **YORK** **PUBLIC** **LIBRARY** **ASTEN LENOX TILDEN FOUNDATIONS**

4-30.4 cag gtg cag ctg cag gag tcg ggc cca gga ctg gtg aag cct tcA CAg acc ctg tcc
ctc acc tgc Act gtc tct ggt ggc tcc atc agc

4-31 cag gtg cag ctg cag gag tcg ggc cca gga ctg gtg aag cct tcA CAg acc ctg tcc
ctc acc tgc Act gtc tct ggt ggc tcc atc agc

5 4-34 cag gtg cag ctA cag Cag tGg ggc Gca gga ctg Ttg aag cct tcg gAg acc ctg tcc
ctc acc tgc gct gtc tAt ggt ggG tcc Ttc agT

4-39 cag Ctg cag ctg cag gag tcg ggc cca gga ctg gtg aag cct tcg gAg acc ctg tcc
ctc acc tgc Act gtc tct ggt ggc tcc atc agc

4-59 cag gtg cag ctg cag gag tcg ggc cca gga ctg gtg aag cct tcg gAg acc ctg tcc
ctc acc tgc Act gtc tct ggt ggc tcc atc agT

10 4-61 cag gtg cag ctg cag gag tcg ggc cca gga ctg gtg aag cct tcg gAg acc ctg tcc
ctc acc tgc Act gtc tct ggt ggc tcc Gtc agc

4-b cag gtg cag ctg cag gag tcg ggc cca gga ctg gtg aag cct tcg gAg acc ctg tcc
ctc acc tgc gct gtc tct ggt TAc tcc atc agc

15 VH5

5-51 GAG GTG CAG CTG GTG CAG TCT GGA GCA GAG GTG AAA AAG CCC GGG GAG TCT CTG AAG
ATC TCC TGT AAG GGT TCT GGA TAC AGC TTT ACC

5-a gaA gtg cag ctg gtg cag tct gga gca gag gtg aaa aag ccc ggg gag tct ctg aGg
atc tcc tgt aag ggt tct gga tac agc ttt acc

20 VH6

6-1 CAG GTA CAG CTG CAG CAG TCA GGT CCA GGA CTG GTG AAG CCC TCG CAG ACC CTC TCA
CTC ACC TGT GCC ATC TCC GGG GAC AGT GTC TCT

VH7

7-4.1 CAG GTG CAG CTG GTG CAA TCT GGG TCT GAG TTG AAG AAG CCT GGG GCC TCA GTG AAG
GTT TCC TGC AAG GCT TCT GGA TAC ACC TTC ACT

25

10045674 = 1005604

Table 7: RERS sites in Human HC GLG FR1s where there are at least 20 GLGs cut

BsgI GTGCAG

71 (cuts 16/14 bases to right)

	1: 4	1: 13	2: 13	3: 4	3: 13	4: 13
	6: 13	7: 4	7: 13	8: 13	9: 4	9: 13
5	10: 4	10: 13	15: 4	15: 65	16: 4	16: 65
	17: 4	17: 65	18: 4	18: 65	19: 4	19: 65
	20: 4	20: 65	21: 4	21: 65	22: 4	22: 65
	23: 4	23: 65	24: 4	24: 65	25: 4	25: 65
	26: 4	26: 65	27: 4	27: 65	28: 4	28: 65
10	29: 4	30: 4	30: 65	31: 4	31: 65	32: 4
	32: 65	33: 4	33: 65	34: 4	34: 65	35: 4
	35: 65	36: 4	36: 65	37: 4	38: 4	39: 4
	41: 4	42: 4	43: 4	45: 4	46: 4	47: 4
	48: 4	48: 13	49: 4	49: 13	51: 4	

15 **There are 39 hits at base# 4**

There are 21 hits at base# 65

-- ctgcac

9

	12: 63	13: 63	14: 63	39: 63	41: 63	42: 63
20	44: 63	45: 63	46: 63			

BbvI GCAGC

65

	1: 6	3: 6	6: 6	7: 6	8: 6	9: 6
	10: 6	15: 6	15: 67	16: 6	16: 67	17: 6
	17: 67	18: 6	18: 67	19: 6	19: 67	20: 6
25	20: 67	21: 6	21: 67	22: 6	22: 67	23: 6
	23: 67	24: 6	24: 67	25: 6	25: 67	26: 6
	26: 67	27: 6	27: 67	28: 6	28: 67	29: 6
	30: 6	30: 67	31: 6	31: 67	32: 6	32: 67
	33: 6	33: 67	34: 6	34: 67	35: 6	35: 67
30	36: 6	36: 67	37: 6	38: 6	39: 6	40: 6
	41: 6	42: 6	43: 6	44: 6	45: 6	46: 6
	47: 6	48: 6	49: 6	50: 12	51: 6	

There are 43 hits at base# 6 Bolded sites very near sites

listed below

35 There are 21 hits at base# 67

-- gctgc

13

37: 9	38: 9	39: 9	40: 3	40: 9	41: 9
42: 9	44: 3	44: 9	45: 9	46: 9	47: 9

50: 9

There are 11 hits at base# 9

BsoFI GCngc

78

5 1: 6 3: 6 6: 6 7: 6 8: 6 9: 6
10: 6 15: 6 15: 67 16: 6 16: 67 17: 6
17: 67 18: 6 18: 67 19: 6 19: 67 20: 6
20: 67 21: 6 21: 67 22: 6 22: 67 23: 6
23: 67 24: 6 24: 67 25: 6 25: 67 26: 6
10 26: 67 27: 6 27: 67 28: 6 28: 67 29: 6
30: 6 30: 67 31: 6 31: 67 32: 6 32: 67
33: 6 33: 67 34: 6 34: 67 35: 6 35: 67
36: 6 36: 67 37: 6 37: 9 38: 6 38: 9
39: 6 39: 9 40: 3 40: 6 40: 9 41: 6
15 41: 9 42: 6 42: 9 43: 6 44: 3 44: 6
44: 9 45: 6 45: 9 46: 6 46: 9 47: 6
47: 9 48: 6 49: 6 50: 9 50: 12 51: 6

There are 43 hits at base# 6 These often occur together.

There are 11 hits at base# 9

20 There are 2 hits at base# 3

There are 21 hits at base# 67

TseI Gcwgc

78

1: 6 3: 6 6: 6 7: 6 8: 6 9: 6
25 10: 6 15: 6 15: 67 16: 6 16: 67 17: 6
17: 67 18: 6 18: 67 19: 6 19: 67 20: 6
20: 67 21: 6 21: 67 22: 6 22: 67 23: 6
23: 67 24: 6 24: 67 25: 6 25: 67 26: 6
26: 67 27: 6 27: 67 28: 6 28: 67 29: 6
30 30: 6 30: 67 31: 6 31: 67 32: 6 32: 67
33: 6 33: 67 34: 6 34: 67 35: 6 35: 67
36: 6 36: 67 37: 6 37: 9 38: 6 38: 9
39: 6 39: 9 40: 3 40: 6 40: 9 41: 6
41: 9 42: 6 42: 9 43: 6 44: 3 44: 6
35 44: 9 45: 6 45: 9 46: 6 46: 9 47: 6
47: 9 48: 6 49: 6 50: 9 50: 12 51: 6

There are 43 hits at base# 6 Often together.

There are 11 hits at base# 9

There are 48 hits at base# 8

There are 2 hits at base# 2

DdeI Ctnag

48

5 1: 26 1: 48 2: 26 2: 48 3: 26 3: 48
4: 26 4: 48 5: 26 5: 48 6: 26 6: 48
7: 26 7: 48 8: 26 8: 48 9: 26 10: 26
11: 26 12: 85 13: 85 14: 85 15: 52 16: 52
17: 52 18: 52 19: 52 20: 52 21: 52 22: 52
10 23: 52 24: 52 25: 52 26: 52 27: 52 28: 52
29: 52 30: 52 31: 52 32: 52 33: 52 35: 30
35: 52 36: 52 40: 24 49: 52 51: 26 51: 48

There are 22 hits at base# 52 52 and 48 never together.

There are 9 hits at base# 48

15 There are 12 hits at base# 26 26 and 24 never together.

HphI tcacc

42

1: 86 3: 86 6: 86 7: 86 8: 80 11: 86
12: 5 13: 5 14: 5 15: 80 16: 80 17: 80
20 18: 80 20: 80 21: 80 22: 80 23: 80 24: 80
25: 80 26: 80 27: 80 28: 80 29: 80 30: 80
31: 80 32: 80 33: 80 34: 80 35: 80 36: 80
37: 59 38: 59 39: 59 40: 59 41: 59 42: 59
43: 59 44: 59 45: 59 46: 59 47: 59 50: 59

25 There are 22 hits at base# 80 80 and 86 never together

There are 5 hits at base# 86

There are 12 hits at base# 59

BssKI Nccngg

50

30 1: 39 2: 39 3: 39 4: 39 5: 39 7: 39
8: 39 9: 39 10: 39 11: 39 15: 39 16: 39
17: 39 18: 39 19: 39 20: 39 21: 29 21: 39
22: 39 23: 39 24: 39 25: 39 26: 39 27: 39
28: 39 29: 39 30: 39 31: 39 32: 39 33: 39
35 34: 39 35: 19 35: 39 36: 39 37: 24 38: 24
39: 24 41: 24 42: 24 44: 24 45: 24 46: 24
47: 24 48: 39 48: 40 49: 39 49: 40 50: 24
50: 73 51: 39

There are 35 hits at base# 39 39 and 40 together twice.

There are 2 hits at base# 40

BsaJI Ccnngg 47

5	1: 40	2: 40	3: 40	4: 40	5: 40	7: 40
	8: 40	9: 40	9: 47	10: 40	10: 47	11: 40
	15: 40	18: 40	19: 40	20: 40	21: 40	22: 40
	23: 40	24: 40	25: 40	26: 40	27: 40	28: 40
	29: 40	30: 40	31: 40	32: 40	34: 40	35: 20
10	35: 40	36: 40	37: 24	38: 24	39: 24	41: 24
	42: 24	44: 24	45: 24	46: 24	47: 24	<u>48: 40</u>
	<u>48: 41</u>	<u>49: 40</u>	<u>49: 41</u>	50: 74	51: 40	

There are 32 hits at base# 40 40 and 41 together twice

There are 2 hits at base# 41

15 There are 9 hits at base# 24

There are 2 hits at base# 47

BstNI CCwgg 44

PspGI ccwgg

20 ScrFI(\$M.HpaII) CCwgg

	1: 40	2: 40	3: 40	4: 40	5: 40	7: 40
	8: 40	9: 40	10: 40	11: 40	15: 40	16: 40
	17: 40	18: 40	19: 40	20: 40	21: 30	21: 40
	22: 40	23: 40	24: 40	25: 40	26: 40	27: 40
25	28: 40	29: 40	30: 40	31: 40	32: 40	33: 40
	34: 40	35: 40	36: 40	37: 25	38: 25	39: 25
	41: 25	42: 25	44: 25	45: 25	46: 25	47: 25
	50: 25	51: 40				

There are 33 hits at base# 40

30

ScrFI CCnngg 50

	1: 40	2: 40	3: 40	4: 40	5: 40	7: 40
	8: 40	9: 40	10: 40	11: 40	15: 40	16: 40
	17: 40	18: 40	19: 40	20: 40	21: 30	21: 40
35	22: 40	23: 40	24: 40	25: 40	26: 40	27: 40
	28: 40	29: 40	30: 40	31: 40	32: 40	33: 40
	34: 40	35: 20	35: 40	36: 40	37: 25	38: 25
	39: 25	41: 25	42: 25	44: 25	45: 25	46: 25

30: 46 31: 46 32: 46 33: 46 34: 46 35: 46
36: 46 37: 46 43: 79

There are 22 hits at base# 46 43 and 46 never occur together.

There are 4 hits at base# 43

5

BsmFI GGGAC 3

8: 43 37: 46 50: 77

-"- gtccc 33

15: 48 16: 48 17: 48 1: 0 1: 0 20: 48
10 21: 48 22: 48 23: 48 24: 48 25: 48 26: 48
27: 48 28: 48 29: 48 30: 48 31: 48 32: 48
33: 48 34: 48 35: 48 36: 48 37: 54 38: 54
39: 54 40: 54 41: 54 42: 54 43: 54 44: 54
45: 54 46: 54 47: 54

15 **There are 20 hits at base# 48**

There are 11 hits at base# 54

HinfI Gantc 80

8: 77 12: 16 13: 16 14: 16 15: 16 15: 56
20 15: 77 16: 16 16: 56 16: 77 17: 16 17: 56
17: 77 18: 16 18: 56 18: 77 19: 16 19: 56
19: 77 20: 16 20: 56 20: 77 21: 16 21: 56
21: 77 22: 16 22: 56 22: 77 23: 16 23: 56
23: 77 24: 16 24: 56 24: 77 25: 16 25: 56
25 25: 77 26: 16 26: 56 26: 77 27: 16 27: 26
27: 56 27: 77 28: 16 28: 56 28: 77 29: 16
29: 56 29: 77 30: 56 31: 16 31: 56 31: 77
32: 16 32: 56 32: 77 33: 16 33: 56 33: 77
34: 16 35: 16 35: 56 35: 77 36: 16 36: 26
30 36: 56 36: 77 37: 16 38: 16 39: 16 40: 16
41: 16 42: 16 44: 16 45: 16 46: 16 47: 16
48: 46 49: 46

There are 34 hits at base# 16

35 TfiI Gawtc 21

8: 77 15: 77 16: 77 17: 77 18: 77 19: 77
20: 77 21: 77 22: 77 23: 77 24: 77 25: 77

10045674 = 10045674

33: 77 35: 77 36: 77

5	MlyI	GAGTC	38				
	12: 16	13: 16	14: 16	15: 16	16: 16	17: 16	
	18: 16	19: 16	20: 16	21: 16	22: 16	23: 16	
	24: 16	25: 16	26: 16	27: 16	27: 26	28: 16	
	29: 16	31: 16	32: 16	33: 16	34: 16	35: 16	
0	36: 16	36: 26	37: 16	38: 16	39: 16	40: 16	
	41: 16	42: 16	44: 16	45: 16	46: 16	47: 16	
	48: 46	49: 46					

15	-"-	GACTC		21		
	15: 56	16: 56	17: 56	18: 56	19: 56	20: 56
	21: 56	22: 56	23: 56	24: 56	25: 56	26: 56
	27: 56	28: 56	29: 56	30: 56	31: 56	32: 56
	33: 56	35: 56	36: 56			

PleI gagtc			38			
12: 16	13: 16	14: 16	15: 16	16: 16	17: 16	
18: 16	19: 16	20: 16	21: 16	22: 16	23: 16	
24: 16	25: 16	26: 16	27: 16	27: 26	28: 16	
29: 16	31: 16	32: 16	33: 16	34: 16	35: 16	
36: 16	36: 26	37: 16	38: 16	39: 16	40: 16	
41: 16	42: 16	44: 16	45: 16	46: 16	47: 16	
48: 46	49: 46					

- " gactc	21				
15: 56	16: 56	17: 56	18: 56	19: 56	20: 56
21: 56	22: 56	23: 56	24: 56	25: 56	26: 56
27: 56	28: 56	29: 56	30: 56	31: 56	32: 56
33: 56	35: 56	36: 56			

AlwNI CAGNNNctg			26		
15: 68	16: 68	17: 68	18: 68	19: 68	20: 68

- 158 -

21: 68	22: 68	23: 68	24: 68	25: 68	26: 68
27: 68	28: 68	29: 68	30: 68	31: 68	32: 68
33: 68	34: 68	35: 68	36: 68	39: 46	40: 46
41: 46	42: 46				

5 **There are 22 hits at base# 68**

10045674.1002501

Table 8: Kappa FR1 GLGs

	!	1	2	3	4	5	6	7	8	9	10	11	12	
		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCC	TCC	CTG	TCT	
	!	13	14	15	16	17	18	19	20	21	22	23		
5		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	O12
		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCC	TCC	CTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	O2
		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCC	TCC	CTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	O18
10		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCC	TCC	CTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	O8
		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCC	TCC	CTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	A20
		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCC	TCC	CTG	TCT	
15		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	A30
		AAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCT	GCC	ATG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGT	!	L14
		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCC	TCA	CTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGT	!	L1
20		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCC	TCA	CTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGT	!	L15
		GCC	ATC	CAG	TTG	ACC	CAG	TCT	CCA	TCC	TCC	CTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	L4
		GCC	ATC	CAG	TTG	ACC	CAG	TCT	CCA	TCC	TCC	CTG	TCT	
25		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	L18
		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCT	TCC	GTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGT	!	L5
		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCT	TCT	GTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGT	!	L19
30		GAC	ATC	CAG	TTG	ACC	CAG	TCT	CCA	TCC	TTC	CTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	L8
		GCC	ATC	CGG	ATG	ACC	CAG	TCT	CCA	TTC	TCC	CTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	L23
		GCC	ATC	CGG	ATG	ACC	CAG	TCT	CCA	TCC	TCA	TTC	TCT	
35		GCA	TCT	ACA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGT	!	L9

10045674-102501

	GTC ATC TGG ATG ACC CAG TCT CCA TCC TTA CTC TCT	
	GCA TCT ACA GGA GAC AGA GTC ACC ATC AGT TGT !	L24
	GCC ATC CAG ATG ACC CAG TCT CCA TCC TCC CTG TCT	
	GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGC !	L11
5	GAC ATC CAG ATG ACC CAG TCT CCT TCC ACC CTG TCT	
	GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGC !	L12
	GAT ATT GTG ATG ACC CAG ACT CCA CTC TCC CTG CCC	
	GTC ACC CCT GGA GAG CCG GCC TCC ATC TCC TGC !	O11
	GAT ATT GTG ATG ACC CAG ACT CCA CTC TCC CTG CCC	
10	GTC ACC CCT GGA GAG CCG GCC TCC ATC TCC TGC !	O1
	GAT GTT GTG ATG ACT CAG TCT CCA CTC TCC CTG CCC	
	GTC ACC CTT GGA CAG CCG GCC TCC ATC TCC TGC !	A17
	GAT GTT GTG ATG ACT CAG TCT CCA CTC TCC CTG CCC	
	GTC ACC CTT GGA CAG CCG GCC TCC ATC TCC TGC !	A1
15	GAT ATT GTG ATG ACC CAG ACT CCA CTC TCT CTG TCC	
	GTC ACC CCT GGA CAG CCG GCC TCC ATC TCC TGC !	A18
	GAT ATT GTG ATG ACC CAG ACT CCA CTC TCT CTG TCC	
	GTC ACC CCT GGA CAG CCG GCC TCC ATC TCC TGC !	A2
	GAT ATT GTG ATG ACT CAG TCT CCA CTC TCC CTG CCC	
20	GTC ACC CCT GGA GAG CCG GCC TCC ATC TCC TGC !	A19
	GAT ATT GTG ATG ACT CAG TCT CCA CTC TCC CTG CCC	
	GTC ACC CCT GGA GAG CCG GCC TCC ATC TCC TGC !	A3
	GAT ATT GTG ATG ACC CAG ACT CCA CTC TCC TCA CCT	
	GTC ACC CTT GGA CAG CCG GCC TCC ATC TCC TGC !	A23
25	GAA ATT GTG TTG ACG CAG TCT CCA GGC ACC CTG TCT	
	TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC !	A27
	GAA ATT GTG TTG ACG CAG TCT CCA GCC ACC CTG TCT	
	TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC !	A11
	GAA ATA GTG ATG ACG CAG TCT CCA GCC ACC CTG TCT	
30	GTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC !	L2
	GAA ATA GTG ATG ACG CAG TCT CCA GCC ACC CTG TCT	
	GTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC !	L16
	GAA ATT GTG TTG ACA CAG TCT CCA GCC ACC CTG TCT	
	TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC !	L6
35	GAA ATT GTG TTG ACA CAG TCT CCA GCC ACC CTG TCT	

10045674-102501

	TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC !	L20
	GAA ATT GTA ATG ACA CAG TCT CCA GCC ACC CTG TCT	
	TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC !	L25
	GAC ATC GTG ATG ACC CAG TCT CCA GAC TCC CTG GCT	
5	GTG TCT CTG GGC GAG AGG GCC ACC ATC AAC TGC !	B3
	GAA ACG ACA CTC ACG CAG TCT CCA GCA TTC ATG TCA	
	GCG ACT CCA GGA GAC AAA GTC AAC ATC TCC TGC !	B2
	GAA ATT GTG CTG ACT CAG TCT CCA GAC TTT CAG TCT	
	GTG ACT CCA AAG GAG AAA GTC ACC ATC ACC TGC !	A26
10	GAA ATT GTG CTG ACT CAG TCT CCA GAC TTT CAG TCT	
	GTG ACT CCA AAG GAG AAA GTC ACC ATC ACC TGC !	A10
	GAT GTT GTG ATG ACA CAG TCT CCA GCT TTC CTC TCT	
	GTG ACT CCA GGG GAG AAA GTC ACC ATC ACC TGC !	A14

10045674-100504

Table 9 RERS sites found in Human Kappa FR1 GIGs

	MslI	FokI --> <-- -->	PfFI	BsrI	BsmAI	MnlI	HpyCH 4V
VKI							
O12 1-69	3	3 23	12 49	15	18 47	26	36
O2 101-169	103	103 123	112 149	115	118 147	126	136
O18 201-269	203	203 223	212 249	215	218 247	226	236
O8 301-369	303	303 323	312 349	315	318 347	326	336
A20 401-469	403	403 423	412 449	415	418 447	426	436
A30 501-569	503	503 523	512 549	515	518 547	526	536
L14 601-669	603	603	612 649	615	618 647	-	636
L1 701-769	703	703 723	712 749	715	718 747	726	736
L15 801-869	803	803 823	812 849	815	818 847	826	836
L4 901-969	-	903 923	912 949	906 915	918 947	926	936
L18 1001-1069	-	1003	1012 1049	1006 1015	1018 1047	1026	1036
L5 1101-1169	1103	-	1112 1149	1115	1118 1147	-	1136
L19 1201-1269	1203	1203	1212 1249	1215	1218 1247	-	1236
L8 1301-1369	-	1303 1323	1312 1349	1306 1315	1318 1347	-	1336
L23 1401-1469	1403	1403 1408	1412 1449	1415	1418 1447	-	1436
L9 1501-1569	1503	1503 1508 1523	1512 1549	1515	1518 1547	1526	1536

- 163 -

	Msl	FokI --> <-- -->	PflFI	BsrI	BsmAI	MnlI	HpyCH 4V
L24 1601-1669	1603	1608 1623	1612 1649	1615	1618 1647	-	1636
L11 1701-1769	1703	1703 1723	1712 1749	1715	1718 1747	1726	1736
L12 1801-1869	1803	1803	1812 1849	1815	1818 1847	-	1836
VKII							
O11 1901-1969	-	-	-	-	-	1956	-
O1 2001-2069	-	-	-	-	-	2056	-
A17 2101-2169	-	-	2112	-	2118	2156	-
A1 2201-2269	-	-	2212	-	2218	2256	-
A18 2301-2369	-	-	-	-	-	2356	-
A2 2401-2469	-	-	-	-	-	2456	-
A19 2501-2569	-	-	2512	-	2518	2556	-
A3 2601-2669	-	-	2612	-	2618	2656	-
A23 2701-2769	-	-	-	-	-	2729 2756	-
VKIII							
A27 2801-2869	-	-	2812	-	2818 2839	2860	-
A11 2901-2969	-	-	2912	-	2918 2939	2960	-
L2 3001-3069	-	-	3012	-	3018 3039	3060	-
L16 3101-3169	-	-	3112	-	3118 3139	3160	-

5

10

15

Table 9 RERS sites found in Human Kappa FR1 GLGs, continued

	SfaNI	SfcI	HinfI	MlyI --> --> <--	MaeIII Tsp45I same sites	HphI xx38 xx56 xx62	HpaII MspI xx06 xx52
VKI							
O12 1-69	37	41	53	53	55	56	-
O2 101-169	137	141	153	153	155	156	-
O18 201-269	237	241	253	253	255	256	-
O8 301-369	337	341	353	353	355	356	-
A20 401-469	437	441	453	453	455	456	-
A30 501-569	537	541	553	553	555	556	-
L14 601-669	637	641	653	653	655	656	-
L1 701-769	737	741	753	753	755	756	-
L15 801-869	837	841	853	853	855	856	-
L4 901-969	937	941	953	953	955	956	-
L18 1001-1069	1037	1041	1053	1053	1055	1056	-
L5 1101-1169	1137	1141	1153	1153	1155	1156	-
L19 1201-1269	1237	1241	1253	1253	1255	1256	-
L8 1301-1369	1337	1341	1353	1353	1355	1356	-
L23 1401-1469	1437	1441	1453	1453	1455	1456	1406

- 166 -

	SfaNI	SfcI	HinfI	MlyI --> --> <--	MaeIII Tsp45I same sites	HphI xx38 xx56 xx62	HpaII MspI xx06 xx52
L9 1501-1569	1537	1541	1553	1553	1555	1556	1506
L24 1601-1669	1637	1641	1653	1653	1655	1656	
L11 1701-1769	1737	1741	1753	1753	1755	1756	
L12 1801-1869	1837	1841	1853	1853	1855	1856	
VKII							
O11 1901-1969	-	-	1918	1918	1937	1938	1952
O1 2001-2069	-	-	2018	2018	2037	2038	2052
A17 2101-2169	-	-	2112	2112	2137	2138	2152
A1 2201-2269	-	-	2212	2212	2237	2238	2252
A18 2301-2369	-	-	2318	2318	2337	2338	2352
A2 2401-2469	-	-	2418	2418	2437	2438	2452
A19 2501-2569	-	-	2512	2512	2537	2538	2552
A3 2601-2669	-	-	2612	2612	2637	2638	2652
A23 2701-2769	-	-	2718	2718	2737	2731* 2738*	-
VKIII							
A27 2801-2869	-	-	-	-			-
A11 2901-2969	-	-	-	-			-

5

10

15

Table 9 RERS sites found in Human Kappa FR1, continued

	BsaI xx29 xx42 xx43	BssKI (NstII) xx22 xx30 xx43	BpmI xx20 xx41 xx44 --> --> <--	BsrFI Cac8I NaeI NgoMIV	HaeIII	Tsp509I
VKI						
O12 1-69	-	-	-	-	-	-
O2 101-169	-	-	-	-	-	-
O18 201-269	-	-	-	-	-	-
O8 301-369	-	-	-	-	-	-
A20 401-469	-	-	-	-	-	-
A30 501-569	-	-	-	-	-	-
L14 601-669	-	-	-	-	-	-
L1 701-769	-	-	-	-	-	-
L15 801-869	-	-	-	-	-	-
L4 901-969	-	-	-	-	-	-
L18 1001-1069	-	-	-	-	-	-
L5 1101-1169	-	-	-	-	-	-
L19 1201-1269	-	-	-	-	-	-
L8 1301-1369	-	-	-	-	-	-

5

10

15

- 169 -

	BsaJI xx29 xx42 xx43	BssKI (NstNI) xx22 xx30 xx43	BpmI xx20 xx41 xx44 --> --> <--	BsrFI Cac8I NaeI NgoMIV	HaeIII	Tsp509I
L23 1401-1469	-	-	-	-	-	-
L9 1501-1569	-	-	-	-	-	-
L24 1601-1669	-	-	-	-	-	-
L11 1701-1769	-	-	-	-	-	-
L12 1801-1869	-	-	-	-	-	-
VKII						
O11 1901-1969	1942	1943	1944	1951	1954	-
O1 2001-2069	2042	2043	2044	2051	2054	-
A17 2101-2169	2142	-	-	2151	2154	-
A1 2201-2269	2242	-	-	2251	2254	-
A18 2301-2369	2342	2343	-	2351	2354	-
A2 2401-2469	2442	2443	-	2451	2454	-
A19 2501-2569	2542	2543	2544	2551	2554	-
A3 2601-2669	2642	2643	2644	2651	2654	-
A23 2701-2769	2742	-	-	2751	2754	-
VKIII						

5

10

15

- 170 -

	BsaJI xx29 xx42 xx43	BssKI (NstNI) xx22 xx30 xx43	BpmI xx20 xx41 xx44 --> --> <--	BstFI Cac8I NaeI NgoMIV	HaeIII	Tsp509I
A27 2801-2869	2843	2822 2843	2820 2841	-	-	2803
A11 2901-2969	2943	2943	2920 2941	-	-	2903
L2 3001-3069	3043	3043	3041	-	-	-
L16 3101-3169	3143	3143	3120 3141	-	-	-
L6 3201-3269	3243	3243	3220 3241	-	-	3203
L20 3301-3369	3343	3343	3320 3341	-	-	3303
L25 3401-3469	3443	3443	3420 3441	-	-	3403
VKIV						
B3 3501-3569	3529	3530	3520	-	3554	
VKV						
B2 3601-3669		3643	3620 3641	-	-	
VKVI						
A26 3701-3769		-	3720	-	-	3703
A10 3801-3869		-	3820	-	-	3803
A14 3901-3969	3943	3943	3920 3941	-	-	-

Table 10 Lambda FR1 GLG sequences

! VL1

5 CAG TCT GTG CTG ACT CAG CCA CCC TCG GTG TCT GAA
GCC CCC AGG CAG AGG GTC ACC ATC TCC TGT ! 1a
cag tct gtg ctg acG cag ccG ccc tcA gtg tct gGG
gcc ccA Ggg cag agg gtc acc atc tcc tgC ! 1e
cag tct gtg ctg act cag cca ccc tcA gCg tct gGG
Acc ccc Ggg cag agg gtc acc atc tcT tgt ! 1c
cag tct gtg ctg act cag cca ccc tcA gCg tct gGG
10 Acc ccc Ggg cag agg gtc acc atc tcT tgt ! 1g
cag tct gtg Ttg acG cag ccG ccc tcA gtg tct gCG
gcc ccA GgA cag aAg gtc acc atc tcc tgC ! 1b

! VL2

15 CAG TCT GCC CTG ACT CAG CCT CCC TCC GCG TCC GGG
TCT CCT GGA CAG TCA GTC ACC ATC TCC TGC ! 2c
cag tct gcc ctg act cag cct cGc tcA gTg tcc ggg
tct cct gga cag tca gtc acc atc tcc tgc ! 2e
cag tct gcc ctg act cag cct Gcc tcc gTg tcT ggg
tct cct gga cag tcG Atc acc atc tcc tgc ! 2a2
20 cag tct gcc ctg act cag cct ccc tcc gTg tcc ggg
tct cct gga cag tca gtc acc atc tcc tgc ! 2d
cag tct gcc ctg act cag cct Gcc tcc gTg tcT ggg
tct cct gga cag tcG Atc acc atc tcc tgc ! 2b2

! VL3

25 TCC TAT GAG CTG ACT CAG CCA CCC TCA GTG TCC GTG
TCC CCA GGA CAG ACA GCC AGC ATC ACC TGC ! 3r
tcc tat gag ctg act cag cca cTc tca gtg tcA gtg
Gcc cTG gga cag acG gcc agG atT acc tgT ! 3j
tcc tat gag ctg acA cag cca ccc tcG gtg tcA gtg
30 tcc cca gga caA acG gcc agG atc acc tgc ! 3p
tcc tat gag ctg acA cag cca ccc tcG gtg tcA gtg
tcc cTa gga cag aTG gcc agG atc acc tgc ! 3a
tcT tCt gag ctg act cag GAC ccT GcT gtg tcT gtg
Gcc TTG gga cag aca gTc agG atc acA tgc ! 3l

10045674-102504

tcc tat gTg ctg act cag cca ccc tca gtg tcA gtg
 Gcc cca gga Aag acG gcc agG atT acc tgT ! 3h
 tcc tat gag ctg acA cag cTa ccc tcG gtg tcA gtg
 tcc cca gga cag aca gcc agG atc acc tgc ! 3e
 5 tcc tat gag ctg aTG cag cca ccc tcG gtg tcA gtg
 tcc cca gga cag acG gcc agG atc acc tgc ! 3m
 tcc tat gag ctg acA cag cca Tcc tca gtg tcA gtg
 tcT ccG gga cag aca gcc agG atc acc tgc ! V2-19
 ! VL4
 10 CTG CCT GTG CTG ACT CAG CCC CCG TCT GCA TCT GCC
 TTG CTG GGA GCC TCG ATC AAG CTC ACC TGC ! 4c
 cAg cct gtg ctg act caA TcA TcC tct gcC tct gct
 tCC ctg gga Tcc tcg Gtc aag ctc acc tgc ! 4a
 cAg cTt gtg ctg act caA TcG ccC tct gcC tct gcc
 15 tCC ctg gga gcc tcg Gtc aag ctc acc tgc ! 4b
 ! VL5
 CAG CCT GTG CTG ACT CAG CCA CCT TCC TCC TCC GCA
 TCT CCT GGA GAA TCC GCC AGA CTC ACC TGC ! 5e
 cag Gct gtg ctg act cag ccG Gct tcc CTc tcT gca
 20 tct cct gga gCa tcA gcc agT ctc acc tgc ! 5c
 cag cct gtg ctg act cag cca Tct tcc CAT tcT gca
 tct Tct gga gCa tcA gTc aga ctc acc tgc ! 5b
 ! VL6
 AAT TTT ATG CTG ACT CAG CCC CAC TCT GTG TCG GAG
 25 TCT CCG GGG AAG ACG GTA ACC ATC TCC TGC ! 6a
 ! VL7
 CAG ACT GTG GTG ACT CAG GAG CCC TCA CTG ACT GTG
 TCC CCA GGA GGG ACA GTC ACT CTC ACC TGT ! 7a
 cag Gct gtg gtg act cag gag ccc tca ctg act gtg
 30 tcc cca gga ggg aca gtc act ctc acc tgt ! 7b
 ! VL8
 CAG ACT GTG GTG ACC CAG GAG CCA TCG TTC TCA GTG
 TCC CCT GGA GGG ACA GTC ACA CTC ACT TGT ! 8a

10045674-102501

! VL9

CAG CCT GTG CTG ACT CAG CCA CCT TCT GCA TCA GCC
TCC CTG GGA GCC TCG GTC ACA CTC ACC TGC ! 9a

! VL10

5

CAG GCA GGG CTG ACT CAG CCA CCC TCG GTG TCC AAG
GGC TTG AGA CAG ACC GCC ACA CTC ACC TGC ! 10a

10045674.102501

! There are 31 lambda GLGs

25

10

1

20

There are 19 hits at base# 9

27

There are 23 hits at base# 12

25

There are 23 hits at base# 12

1

26: 34

DdeI Ctnag

32

1: 14 2: 24 3: 14 3: 24 4: 14 4: 24
5 5: 24 6: 14 7: 14 7: 24 8: 14 9: 14
10: 14 11: 14 11: 24 12: 14 12: 24 15: 5
15: 14 16: 14 16: 24 19: 24 20: 14 23: 14
24: 14 25: 14 26: 14 27: 14 28: 14 29: 30
30: 14 31: 14

10 There are 21 hits at base# 14

BsaJI Ccnngg

38

1: 23 1: 40 2: 39 2: 40 3: 39 3: 40
4: 39 4: 40 5: 39 11: 39 12: 38 12: 39
15 13: 23 13: 39 14: 23 14: 39 15: 38 16: 39
17: 23 17: 39 18: 23 18: 39 21: 38 21: 39
21: 47 22: 38 22: 39 22: 47 26: 40 27: 39
28: 39 29: 14 29: 39 30: 38 30: 39 30: 47
31: 23 31: 32

20 There are 17 hits at base# 39

There are 5 hits at base# 38

There are 5 hits at base# 40 Makes cleavage ragged.

MnlI cctc

35

1: 23 2: 23 3: 23 4: 23 5: 23 6: 19
25 6: 23 7: 19 8: 23 9: 19 9: 23 10: 23
11: 23 13: 23 14: 23 16: 23 17: 23 18: 23
19: 23 20: 47 21: 23 21: 29 21: 47 22: 23
22: 29 22: 35 22: 47 23: 26 23: 29 24: 27
27: 23 28: 23 30: 35 30: 47 31: 23

30 There are 21 hits at base# 23

There are 3 hits at base# 19

There are 3 hits at base# 29

There are 1 hits at base# 26

There are 1 hits at base# 27 These could make cleavage ragged.

35 ~"- gagg

7

100456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100

There are 4 hits at base# 39

There are 1 hits at base# 41

ScrFI CCngg

39

5 1: 41 2: 40 3: 40 3: 41 4: 40 4: 41
5: 40 6: 32 6: 40 7: 32 7: 40 8: 40
9: 32 9: 40 10: 40 11: 40 12: 39 12: 53
13: 40 13: 53 14: 53 16: 40 16: 53 17: 40
17: 53 18: 40 18: 53 19: 40 19: 53 21: 39
10 22: 39 23: 40 24: 40 26: 40 27: 40 28: 40
29: 15 29: 40 30: 39

There are 21 hits at base# 40

There are 4 hits at base# 39

There are 3 hits at base# 41

15

MaeIII gtnac

16

1: 52 2: 52 3: 52 4: 52 5: 52 6: 52
7: 52 9: 52 26: 52 27: 10 27: 52 28: 10
28: 52 29: 10 29: 52 30: 52
20 There are 13 hits at base# 52

Tsp45I gtsac

15

1: 52 2: 52 3: 52 4: 52 5: 52 6: 52
7: 52 9: 52 27: 10 27: 52 28: 10 28: 52
25 29: 10 29: 52 30: 52
There are 12 hits at base# 52

HphI tcacc

26

1: 53 2: 53 3: 53 4: 53 5: 53 6: 53
30 7: 53 8: 53 9: 53 10: 53 11: 59 13: 59
14: 59 17: 59 18: 59 19: 59 20: 59 21: 59
22: 59 23: 59 24: 59 25: 59 27: 59 28: 59
30: 59 31: 59
There are 16 hits at base# 59

10045674-102501

There are 10 hits at base# 53

	BspMI	ACCTGCNNNNn		14		
	11:	61	13:	61	14:	61
			17:	61	18:	61
					19:	61
5	20:	61	21:	61	22:	61
			23:	61	24:	61
					25:	61
	30:	61	31:	61		

There are 14 hits at base# 61 Goes into CDR1

10045674-102504

Table 12: Matches to URE FR3 adapters in 79 human HC.

A. List of Heavy-chains genes sampled

	AF008566	AF103367	HSA235674	HSU94417	S83240
	AF035043	AF103368	HSA235673	HSU94418	SABVH369
5	AF103026	AF103369	HSA240559	HSU96389	SADEIGVH
	af103033	AF103370	HSCB201	HSU96391	SAH2IGVH
	AF103061	af103371	HSIGGVHC	HSU96392	SDA3IGVH
	Af103072	AF103372	HSU44791	HSU96395	SIGVHTTD
	af103078	AF158381	HSU44793	HSZ93849	SUK4IGVH
10	AF103099	E05213	HSU82771	HSZ93850	
	AF103102	E05886	HSU82949	HSZ93851	
	AF103103	E05887	HSU82950	HSZ93853	
	AF103174	HSA235661	HSU82952	HSZ93855	
	AF103186	HSA235664	HSU82961	HSZ93857	
15	af103187	HSA235660	HSU86522	HSZ93860	
	AF103195	HSA235659	HSU86523	HSZ93863	
	af103277	HSA235678	HSU92452	MCOMFRAA	
	af103286	HSA235677	HSU94412	MCOMFRVA	
	AF103309	HSA235676	HSU94415	S82745	
20	af103343	HSA235675	HSU94416	S82764	

Table 12B. Testing all distinct GLGs from bases 89.1 to 93.2 of the heavy variable domain

	Id	Nb	0	1	2	3	4		SEQ ID
NO:									
25	1	38	15	11	10	0	2	Seq1	gtgtattactgtgc 25
	2	19	7	6	4	2	0	Seq2	gtAtattactgtgc 26
	3	1	0	0	1	0	0	Seq3	gtgtattactgtAA 27
	4	7	1	5	1	0	0	Seq4	gtgtattactgtAc 28
	5	0	0	0	0	0	0	Seq5	Ttgtattactgtgc 29
30	6	0	0	0	0	0	0	Seq6	TtgtatCactgtgc 30
	7	3	1	0	1	1	0	Seq7	ACAtattactgtgc 31
	8	2	0	2	0	0	0	Seq8	ACgtattactgtgc 32
	9	9	2	2	4	1	0	Seq9	ATgtattactgtgc 33
Group			26	26	21	4	2		
35	Cumulative		26	52	73	77	79		

Table 12C Most important URE recognition seqs in FR3 Heavy

	1	VHSzy1	GTGtattactgtgc	(ON_SHC103)	(SEQ ID NO:25)
	2	VHSzy2	GTAtattactgtgc	(ON_SHC323)	(SEQ ID NO:26)
	3	VHSzy4	GTGtattactgtac	(ON_SHC349)	(SEQ ID NO:28)
40	4	VHSzy9	ATGtattactgtgc	(ON_SHC5a)	(SEQ ID NO:33)

Table 12D, testing 79 human HC V genes with four probes

Number of sequences..... 79
Number of bases..... 29143

70045674.102501

		Number of mismatches									
		Id	Best	0	1	2	3	4	5		
5	1	39	15	11	10	1	2	0	Seq1	gtgtattactgtgc	(SEQ ID NO:25)
	2	22	7	6	5	3	0	1	Seq2	gtAtattactgtgc	(SEQ ID NO:26)
	3	7	1	5	1	0	0	0	Seq4	gtgtattactgtAc	(SEQ ID NO:28)
	4	11	2	4	4	1	0	0	Seq9	ATgtattactgtgc	(SEQ ID NO:33)
		Group	25	26	20	5	2				
10	Cumulative	25	51	71	76	78					

One sequence has five mismatches with sequences 2, 4, and 9; it is scored as best for 2.

Id is the number of the adapter.

Best is the number of sequence for which the identified adapter was the best available.

The rest of the table shows how well the sequences match the adapters. For example, there are 10 sequences that match VHSzyl(Id=1) with 2 mismatches and are worse for all other adapters. In this sample, 90% come within 2 bases of one of the four adapters.

10045674.102504

Table 13

The following list of enzymes was taken from
<http://rebase.neb.com/cgi-bin/asymmlist>.

- 5 I have removed the enzymes that a) cut within the recognition, b) cut on both sides of the recognition, or c) have fewer than 2 bases between recognition and closest cut site.

REBASE Enzymes
 04/13/2001

10	Type II restriction enzymes with asymmetric recognition sequences:			
	Enzymes	Recognition Sequence	Isoschizomers	Suppliers
	AarI	CACCTGCNNNN [^] NNNN ₋	-	y
	AceIII	CAGCTCNNNNNN [^] NNNN ₋	-	-
	Bbr7I	GAAGACNNNNNN [^] NNNN ₋	-	-
15	BbvI	GCAGCNNNNNN [^] NNNN ₋	-	y
	BbvII	GAAGACNN [^] NNNN ₋	-	-
	Bce83I	CTTGAGNNNNNNNNNNNNNN [^] NN ₋	-	-
	BceAI	ACGGCNNNNNNNNNNNN [^] NN ₋	-	y
	BceFI	ACGGCNNNNNNNNNNNN [^] N ₋	-	-
20	BciVI	GTATCCNNNNN [^] N ₋	BfuI	y
	BfiI	ACTGGGNNNN ₋ N [^]	BmrI	y
	BinI	GGATCNNNN [^] N ₋	-	-
	BscAI	GCATCNNNN [^] NN ₋	-	-
	BseRI	GAGGAGNNNNNNNN [^] NN ₋	-	y
25	BsmFI	GGGACNNNNNNNNNN [^] NNNN ₋	BspLU11III	y
	BspMI	ACCTGCNNNN [^] NNNN ₋	Acc36I	y
	EciI	GGCGANNNNNNNNNN [^] NN ₋	-	y
	Eco57I	CTGAAGNNNNNNNNNNNNNN [^] NN ₋	BspKT5I	y
	FauI	CCCGCNNNN [^] NN ₋	BstFZ438I	y
30	FokI	GGATGNNNNNNNNNN [^] NNNN ₋	BstPZ418I	y
	GsuI	CTGGAGNNNNNNNNNNNNNN [^] NN ₋	-	y
	HgaI	GACGCNNNN [^] NNNNN ₋	-	y
	HphI	GGTGANNNNNNN [^] N ₋	AsuHPI	y
	MboII	GAAGANNNNNNN [^] N ₋	-	y
35	MlyI	GAGTCNNNN [^] N ₋	SchI	y
	MmeI	TCCRACNNNNNNNNNNNNNNNN [^] NN ₋	-	-
	MnlI	CCTCNNNNNN [^] N ₋	-	y
	PleI	GAGTCNNNN [^] NN ₋	PpsI	y
	RleAI	CCCACANNNNNNNNNN [^] NNN ₋	-	-
40	SfaNI	GCATCNNNN [^] NNNN ₋	BspST5I	y
	SspD5I	GGTGANNNNNNNN [^] N ₋	-	-
	Sth132I	CCCGNNNN [^] NNNN ₋	-	-
	StsI	GGATGNNNNNNNNNN [^] NNNN ₋	-	-
	TaqII	GACCGANNNNNNNNNN [^] NN ₋ , CACCCANNNNNNNNNN [^] NN ₋	-	-
45	Tth111III	CAARCANNNNNNNNNN [^] NN ₋	-	-
	UbaPI	CGAACG	-	-

The notation is [^] means cut the upper strand and ₋ means cut the lower strand. If the upper and lower strand are cut at the same place, then only [^] appears.

Table 14
(FOKlact)

5'-cacatccgtg TTgTT cacggATgTg-3'

(VHEX881) 5'-AATAGTAGAC TgcAgTgTcc TcAgcccTTA AgcTgTTcAT cTgcAAgTAG-
AgAgTATtctT TAGAgTTgTc TcTAGAcTTA gTgAAgcg-3'

5 ! note that VHEX881 is the reverse complement of the ON below

[RC] 5'-cgCttcacTaag-

Scab.....

Synthetic 3-23 as in Table 206

|TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|-

XbaI...

|aac|agC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|t-3'

AflII...

5'-cgCttcacTaag-

15 (VHBA881) |TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|-
|aac|agC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|tgt gcg ag-3'

5'-cgCttcacTaag-

(VHBB881) |TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|-
|aac|agC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|tgt Acg ag-3'

(VH881FCR) 5'-cgCttcacTaag|TCT|AGA|gac|aac -3'

Table 15: Use of *FokI* as "Universal Restriction Enzyme"

FokI - for dsDNA, | represents sites of cleavage

sites of cleavage

5'-cacGGATGtg--nnnnnnn|nnnnnnn-3' (SEQ ID NO:15)
 3'-gtgCCTACac--nnnnnnnnnn|nnn-5' (SEQ ID NO:16)
 RECOG
 NITion of *FokI*

Case I

5'-...gtg|tatt-actgtgc..Substrate....-3' (SEQ ID NO:17)
 3'-cac-ataa|tgacacg-
 gtGTAGGcac\
 5'- caCATCCgtg/(SEQ ID NO:18)

Case II

5'-...gtgtatt|agac-tgc..Substrate....-3' (SEQ ID NO:19)
 -cacataa-tctg|acg-5'
 /gtgCCTACac
 \cacGGATGtg-3' (SEQ ID NO:20)

Case III (Case I rotated 180 degrees)

/gtgCCTACac-5'
 \cacGGATGtg-
 gtgtctt|acag-tcc-3' Adapter (SEQ ID NO:21)
 3'-...cacagaa-tgtc|agg..substrate....-5' (SEQ ID NO:22)

Case IV (Case II rotated 180 degrees)

3'- gtGTAGGcac\ (SEQ ID NO:23)
 -caCATCCgtg/
 5'-gag|tctc-actgagc
 Substrate 3'-...ctc-agag|tgactcg...-5' (SEQ ID NO:24)

Improved *FokI* adapters

FokI - for dsDNA, | represents sites of cleavage

Case I
 Stem 11, loop 5, stem 11, recognition 17

5'-...catgtg|tatt-actgtgc..Substrate....-3'
 3'-gtacac-ataa|tgacacg-
 gtGTAGGcacG T
 5'- caCATCCgtgc C
 TTT

Case II
Stem 10, loop 5, stem 10, recognition 18

```

5          5'-. . . . .gtgtatt|agac-tgctgcc..Substrate....-3'
          T TgtgCCTACac
          C cacGGATGtg-3'
          T T
  
```

Case III (Case I rotated 180 degrees)
Stem 11, loop 5, stem 11, recognition 20

```

10          T TgtgCCTACac-5'
          G AcacGGATGtg-
          T Tgtgtctt|acag-tccattctg-3' Adapter
          3'-. . . . .cacagaa-tgtc|aggtaagac..substrate....-5'
  
```

15 Case IV (Case II rotated 180 degrees)
Stem 11, loop 4, stem 11, recognition 17

```

20          3'- gtGTAGGcacc T
          Tgtgtctt|acag-tccattctg-3' Adapter
          5'-atcgag|tctc-actgagc
          Substrate 3'-. . . . .tagctc-agag|tgactcg....-5'
  
```

BseRI

```

25          | sites of cleavage
          5'-cacGAGGAGnnnnnnnnnn|nnnnn-3'
          3'-gtgctcctcnnnnnnnnn|nnnnnnn-5'
          RECOG
          NITion of BseRI
  
```

Stem 11, loop 5, stem 11, recognition 19

```

30          3'- . . . . .gaacat|cg-ttaagccagta . . . . .5'
          T-T cttgta-gc|aatcgggtcat-3'
          C GCTGAGGAGTC-
          T cgactcctcag-5' An adapter for BseRI to cleave the substrate above.
          T
  
```

70045674.702504

Table 16 Human heavy chains bases 88.1 to 94.2

Number of sequences..... 840

5	Id	Ntot	Number of Mismatches.....							Probe			
			0	1	2	3	4	5	6	7	Name	Sequence.....	Dot form.....
	1	364	152	97	76	26	7	4	2	0	VHS881-1.1	gctgtgtattactgtgcgag	gctgtgtattactgtgcgag
	2	265	150	60	33	13	5	4	0	0	VHS881-1.2	gccgtgtattactgtgcgag	..C.....
	3	96	14	34	16	10	5	7	9	1	VHS881-2.1	gccgtatattactgtgcgag	..C.a.....
	4	20	0	3	4	9	2	2	0	0	VHS881-4.1	gccgtgtattactgtgcgag	..C.....a....
	5	95	25	36	18	11	2	2	0	1	VHS881-9.1	gccatgtattactgtgcgag	..Ca.....
10	840	341	230	147	69	21	19	11	2				
		341	571	718	787	808	827	838	840				

88 89 90 91 92 93 94 95 Codon number as in Table 195

Recognition..... Stem..... Loop.....
 (VHS881-1.1) 5'-gctgtgtat|tact-gtgcgag cAcATccgTg TTgTT cAcgATgTg-3'
 (VHS881-1.2) 5'-gccgtgtat|tact-gtgcgag cAcATccgTg TTgTT cAcgATgTg-3'
 (VHS881-2.1) 5'-gccgtgtat|tact-gtgcgag cAcATccgTg TTgTT cAcgATgTg-3'
 (VHS881-4.1) 5'-gccgtgtat|tact-gtgcgag cAcATccgTg TTgTT cAcgATgTg-3'
 (VHS881-9.1) 5'-gccatgtat|tact-gtgcgag cAcATccgTg TTgTT cAcgATgTg-3'
 | site of substrate cleavage

(FOKIact) 5'-cAcATccgTg TTgTT cAcgATgTg-3'

(VHEX881) 5'-AATAGTAGAc TgcAgTgTcc TcAgcccTTA AgcTgTTcAT cTgcAAGTAG-

AgAgTATTcT TAGAgTTgTc TcTAGAcTTA gTgAAGc-3'

! note that VHEX881 is the reverse complement of the ON below

25 ! [RC] 5'-cgCttcacTaa-

! Scab.....

! Synthetic 3-23 as in Table 206

! |TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|-

! XbaI...

! |aac|agC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|t-3'
! AflII...
(VHBA881) 5'-cgCttcacTaag-
|TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|-
|aac|agC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|tgt|gcg|ag-3'
(VHBB881) 5'-cgCttcacTaag-
|TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|-
|aac|agC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|tgt|Acg|ag-3'
(VH881PCR) 5'-cgCttcacTaag|TCT|AGA|gac|aac-3'

Table 17: Kappa, bases 12-30

ID	Ntot	0	1	2	3	4	5	6	Name	Sequence.....	Dot Form.....
1	84	40	21	20	1	2	0	0	SK12O12	gaccagctctcatctcc	gaccagctctcatctcc
2	32	19	3	6	2	1	0	1	SK12A17	gactcagctccactctc	..t.....ct...
3	26	17	8	1	0	0	0	0	SK12A27	gacgcagctctccaggcacc	..g.....gg.a.
4	40	21	18	1	0	0	0	0	SK12A11	gacgcagctctccaggcacc	..g.....g.a.
182	97	50	28	3	3	0	1				
97	147	175	178	181	181	182					
10									URE adapters:		
									Stem.....	Loop. Stem.....	Recognition.....
									(SzKB1230-O12)	5'-cAcATccgTg	TTgTT cAcggATgTg ggAggATggAgAcTgggTc-3'
									[RC]	5'-gaccagctctcatctcc	cAcATccgTg AACAA cAcggATgTg-3'
15									Recognition.....	Stem.....	loop. Stem.....
										FokI.	
									Stem.....	Loop. Stem.....	Recognition.....
									(SzKB1230-A17)	5'-cAcATccgTg	TTgTT cAcggATgTg ggAggATggAgAcTgAgTc-3'
									[RC]	5'-gactcagctctcatctcc	cAcATccgTg AACAA cAcggATgTg-3'
20									Recognition.....	Stem.....	loop. Stem.....
										FokI.	
									Stem.....	Loop. Stem.....	Recognition.....
									(SzKB1230-A27)	5'-cAcATccgTg	TTgTT cAcggATgTg ggTgccTggAgAcTgccTc-3'
									[RC]	5'-gacgcagctctccaggcacc	cAcATccgTg AACAA cAcggATgTg-3'
25									Recognition.....	Stem.....	loop. Stem.....
										FokI.	
									Stem.....	Loop. Stem.....	Recognition.....
									(SzKB1230-A11)	5'-cAcATccgTg	TTgTT cAcggATgTg ggTggcTggAgAcTggcTc-3'
									[RC]	5'-gacgcagctctccaggcacc	cAcATccgTg AACAA cAcggATgTg-3'
30									Recognition.....	Stem.....	loop. Stem.....

FokI. FokI.

What happens in the upper strand:

(SzkB1230-O12*) 5'-gac cca gtc | tcc a-tc ctc c-3'
| Site of cleavage in substrate

5

(SzkB1230-A17*) 5'-gac tca gtc | tcc a-ct ctc c-3'

(SzkB1230-A27*) 5'-gac gca gtc | tcc a-gg cac c-3'

10

(SzkB1230-A11*) 5'-gac gca gtc | tcc a-gc cac c-3'

(kapextURE) 5' -ccTctactctTgTcAcAgTgcAcAA gAc ATc cAg-3' !sense strand
Scab.....ApaLI.

(kapextUREPCR) 5' -ccTctactctTgTcAcAgTg-3'
Scab.....

15 (kaBRO1UR) 5' -ggAggATggA cTggATgTcT' TgTgcAcTgT gAcAAgAgTA gAgg-3'
[RC] 5' -ccTctactctTgTcAcAgTgcAcAA gAc ATc cAg tcc a-tc ctc c-3' ON above is R.C. of this one
(kaBRO2UR) 5' -ggAggATggA cTggATgTcT' TgTgcAcTgT gAcAAgAgTA gAgg-3'
[RC] 5' -ccTctactctTgTcAcAgTgcAcAA gAc ATc cAg tcc a-ct ctc c-3' ON above is R.C. of this one
(kaBRO3UR) 5' -ggTgccTggA cTggATgTcT' TgTgcAcTgT gAcAAgAgTA gAgg-3'
[RC] 5' -ccTctactctTgTcAcAgTgcAcAA gAc ATc cAg tcc a-gg cac c-3' ON above is R.C. of this one
(kaBRO4UR) 5' -ggTggcTggA cTggATgTcT' TgTgcAcTgT gAcAAgAgTA gAgg-3'
[RC] 5' -ccTctactctTgTcAcAgTgcAcAA gAc ATc cAg tcc a-gc cac c-3' ON above is R.C. of this one
Scab.....ApaLI.

20

Table 18 Lambda URE adapters bases 13.3 to 19.3

Number of sequences..... 128										
Number of mismatches.....										
Number of mismatches..... Dot form.....										
Id	Ntot	0	1	2	3	4	5	6	7	8
1	58	45	7	1	0	0	2	2	1	VL133-2a2
2	16	10	1	0	1	0	1	0	2	VL133-3l
3	17	6	0	0	4	1	1	5	0	VL133-2c
4	37	3	0	10	4	4	3	7	4	2
5	128	64	8	11	5	8	5	11	11	5
64	72	83	88	96	101	112	123	128		
Stem..... loop. Stem..... Recognition.....										
(VL133-2a2)	5'-cAcATccgTg TTgTT cAcggATgTg gATcgAcTgTccAggAgAc-3'									
[RC]	5'-gtctctggacagtcagtc <u>cAcATccgTg</u> AAcAA <u>cAcggATgTg</u> -3'									
Recognition..... Stem..... Loop. Stem.....										
Stem..... loop. Stem..... Recognition.....										
(VL133-3l)	5'-cAcATccgTg TTgTT cAcggATgTg gAcTgTcTgTcccAAggcc-3'									
[RC]	5'-ggccttggacagacagtc <u>cAcATccgTg</u> AAcAA <u>cAcggATgTg</u> -3'									
Recognition..... Stem..... Loop. Stem.....										
Stem..... loop. Stem..... Recognition.....										
(VL133-2c)	5'-cAcATccgTg TTgTT cAcggATgTg gAcTgAcTgTccAggAgAc-3'									
[RC]	5'-gtctctggacagtcagtc <u>cAcATccgTg</u> AAcAA <u>cAcggATgTg</u> -3'									
Recognition..... Stem..... Loop. Stem.....										
Stem..... loop. Stem..... Recognition.....										
(VL133-1c)	5'-cAcATccgTg TTgTT cAcggATgTg gAcTgTcTgcccTggggcc-3'									
[RC]	5'-ggcccccaggcagagggtc <u>cAcATccgTg</u> AAcAA <u>cAcggATgTg</u> -3'									

What happens in the top strand:

```

|           | site of cleavage in the upper strand
(VL133-2a2*) 5'-g tct cct g|ga cag tcg atc
|
5 (VL133-3l*) 5'-g gcc ttg g|ga cag aca gtc
|
(VL133-2c*) 5'-g tct cct g|ga cag tca gtc
|
(VL133-1c*) 5'-g gcc cca g|gg cag agg gtc
10 |
| The following Extenders and Bridges all encode the AA sequence of 2a2 for codons 1-15
|           1
(ON_LamEx133) 5'-ccTcTgAcTgAgT gcA cAg -
|
15 |       2 3 4 5 6 7 8 9 10 11 12
      AGt gcT TtA acC caA ccG gcT AGT gtT AGC ggT-
|
|       13 14 15
      tcC ccG g! 2a2
20 |           1
(ON_LamB1-133) [RC] 5'-ccTcTgAcTgAgT gcA cAg -
|
|       2 3 4 5 6 7 8 9 10 11 12
      AGt gcT TtA acC caA ccG gcT AGT gtT AGC ggT-
25 |
|       13 14 15
      tcC ccG g ga cag tcg at-3'! 2a2 N.B. the actual seq is the
|                                     reverse complement of the
|                                     one shown.
30 |
(ON_LamB2-133) [RC] 5'-ccTcTgAcTgAgT gcA cAg -
|
|       2 3 4 5 6 7 8 9 10 11 12
      AGt gcT TtA acC caA ccG gcT AGT gtT AGC ggT-
35 |
|       13 14 15
      tcC ccG g ga cag aca gt-3'! 3l N.B. the actual seq is the
|                                     reverse complement of the
|                                     one shown.
40 |
(ON_LamB3-133) [RC] 5'-ccTcTgAcTgAgT gcA cAg -
|
|       2 3 4 5 6 7 8 9 10 11 12
      AGt gcT TtA acC caA ccG gcT AGT gtT AGC ggT-
45 |
|       13 14 15
      tcC ccG g ga cag tca gt -3'! 2c N.B. the actual seq is the
|                                     reverse complement of the
|                                     one shown.
50 |
(ON_LamB4-133) [RC] 5'-ccTcTgAcTgAgT gcA cAg -

```

10045674 "102501

```
!
!      2   3   4   5   6   7   8   9   10  11  12
      AGt gCt TtA acC caA ccG gCt AGT gtT AGC ggT-s
!
5  !      13  14  15
      tcC ccG g gg cag agg gt-3' ! 1c N.B. the actual seq is the
!                                     reverse complement of the
!                                     one shown.
!
10 (ON_Lam133PCR) 5'-ccTcTgAcTgAgT gCA cAg AGt gc-3'
```

10045674.102504

Table 19: Cleavage of 75 human light chains.

	Enzyme	Recognition*	Nch	Ns	Planned location of site
	AfeI	AGCgct	0	0	
5	AflII	Cttaag	0	0	HC FR3
	AgeI	Accggt	0	0	
	AscI	GGGcgccc	0	0	After LC
	BglII	Agatct	0	0	
	BsiWI	Cgtacg	0	0	
	BspDI	ATcgat	0	0	
10	BssHII	Gcgcg	0	0	
	BstBI	TTcgaa	0	0	
	DraIII	CACNNNgtg	0	0	
	EagI	Cggccg	0	0	
	FseI	GGCCGGcc	0	0	
15	FspI	TGCgca	0	0	
	HpaI	GTTaac	0	0	
	MfeI	Caattg	0	0	HC FR1
	MluI	Acgcgt	0	0	
	NcoI	Ccattg	0	0	Heavy chain signal
20	NheI	Ctagc	0	0	HC/anchor linker
	NotI	GCggccgc	0	0	In linker after HC
	NruI	TCGcga	0	0	
	PacI	TTAATtaa	0	0	
	PmeI	GTTTaaac	0	0	
25	PmlI	CACgtg	0	0	
	PvuI	CGATcg	0	0	
	SacII	CCGCgg	0	0	
	SalI	Gtcgac	0	0	
	SfiI	GGCCNNNNnggcc	0	0	Heavy Chain signal
30	SgfI	GCGATcgc	0	0	
	SnaBI	TACgta	0	0	
	StuI	AGGcct	0	0	
	XbaI	Tctaga	0	0	HC FR3
35	AatII	GACGTc	1	1	
	AclI	AAcgtt	1	1	
	AseI	ATtaat	1	1	
	BsmI	GAATGCN	1	1	
	BspEI	Tccgga	1	1	HC FR1
	BstXI	CCANNNNNntgg	1	1	HC FR2
40	DrdI	GACNNNNnngtc	1	1	
	HindIII	Aagctt	1	1	
	PciI	Acatgt	1	1	
	SapI	gaagagc	1	1	
	ScaI	AGTact	1	1	
45	SexAI	Accwgg	1	1	
	SpeI	Actagt	1	1	
	TliI	Ctcgag	1	1	
	XhoI	Ctcgag	1	1	
50	BcgI	cgannnnnntgc	2	2	
	BlpI	GCTnagc	2	2	
	BssSI	Ctcgtg	2	2	
	BstAPI	GCANNNNntgc	2	2	
	EspI	GCTnagc	2	2	
	KasI	Ggcgcc	2	2	
55	PflMI	CCANNNNntgg	2	2	
	XmnI	GAANNnnttc	2	2	
	ApaLI	Gtgcac	3	3	LC signal seq

10005674-100564

	NaeI	GCCggc	3	3	
	NgoMI	Gccggc	3	3	
	PvuII	CAGctg	3	3	
	RsrII	CGgwccg	3	3	
5	BsrBI	GAGcgg	4	4	
	BsrDI	GCAATGNNn	4	4	
	BstZ17I	GTAtac	4	4	
	EcoRI	Gaattc	4	4	
	SphI	GCATGc	4	4	
10	SspI	AATatt	4	4	
	AccI	GTmkac	5	5	
	BclI	Tgatca	5	5	
	BsmBI	Nnnnnngagacg	5	5	
	BsrGI	Tgtaca	5	5	
15	DraI	TTTaaa	6	6	
	NdeI	CATatg	6	6	HC FR4
	SwaI	ATTTaaat	6	6	
	BamHI	Ggatcc	7	7	
	SacI	GAGCTc	7	7	
20	BciVI	GTATCCNNNNNN	8	8	
	BsaBI	GATNNnnatc	8	8	
	NsiI	ATGCAt	8	8	
	Bsp120I	Gggccc	9	9	CH1
	ApaI	GGGCCc	9	9	CH1
25	PspOoMI	Gggccc	9	9	
	BspHI	Tcatga	9	11	
	EcoRV	GATatc	9	9	
	AhdI	GACNNNnngtc	11	11	
	BbsI	GAAGAC	11	14	
30	PsiI	TTAtaa	12	12	
	BsaI	GGTCTCnNNnn	13	15	
	XmaI	Cccggg	13	14	
	AvaI	Cycgrg	14	16	
	BglI	GCCNNNNnggc	14	17	
35	AlwNI	CAGNNNctg	16	16	
	BspMI	ACCTGC	17	19	
	XcmI	CCANNNNNnnnntgg	17	26	
	BstEII	Ggtnacc	19	22	HC FR4
	Sse8387I	CCTGCAGg	20	20	
40	AvrII	Cctagg	22	22	
	HincII	GTYrac	22	22	
	BsgI	GTGCAG	27	29	
	MscI	TGGcca	30	34	
	BseRI	NNnnnnnnnnctcctc	32	35	
45	Bsu36I	CCtnagg	35	37	
	PstI	CTGCAG	35	40	
	EciI	nnnnnnnnntccgcc	38	40	
	PpuMI	RGgwccy	41	50	
	StyI	Ccwwgg	44	73	
50	EcoO109I	RGgnccy	46	70	
	Acc65I	Ggtacc	50	51	
	KpnI	GGTACc	50	51	
	BpmI	ctccag	53	82	
	AvaII	Ggwcc	71	124	

55 * cleavage occurs in the top strand after the last upper-case base. For REs that cut palindromic sequences, the lower strand is cut at the symmetrical site.

Table 20: Cleavage of 79 human heavy chains

	Enzyme	Recognition	Nch	Ns	Planned location of site
	AfeI	AGCgct	0	0	
	AflII	Cttaag	0	0	HC FR3
5	AscI	GGcgcgcc	0	0	After LC
	BsiWI	Cgtacg	0	0	
	BspDI	ATcgat	0	0	
	BssHII	Gcgcg	0	0	
	FseI	GGCCGGcc	0	0	
10	HpaI	GTTaac	0	0	
	NheI	Gctagc	0	0	HC Linker
	NotI	GCggccgc	0	0	In linker, HC/anchor
	NruI	TCGcga	0	0	
	NsiI	ATGCA	0	0	
15	PacI	TTAATtaa	0	0	
	PciI	Acatgt	0	0	
	PmeI	GTTTaaac	0	0	
	PvuI	CGATcg	0	0	
	RsrII	CGgwccg	0	0	
20	SapI	gaagagc	0	0	
	SfiI	GGCCNNNNnggcc	0	0	HC signal seq
	SgfI	GCGATcgc	0	0	
	SwaI	ATTTaaat	0	0	
	AclI	AAcggt	1	1	
25	AgeI	Accggt	1	1	
	AseI	ATtaat	1	1	
	AvrII	Cctagg	1	1	
	BsmI	GAATGCN	1	1	
	BsrBI	GAGcgg	1	1	
30	BsrDI	GCAATGNNn	1	1	
	DraI	TTTaaa	1	1	
	FspI	TGCgca	1	1	
	HindIII	Aagctt	1	1	
	MfeI	Caattg	1	1	HC FR1
35	NaeI	GCCggc	1	1	
	NgoMI	Gccggc	1	1	
	SpeI	Actagt	1	1	
	Acc65I	Ggtacc	2	2	
	BstBI	TTcgaa	2	2	
40	KpnI	GGTACc	2	2	
	MluI	Acgcgt	2	2	
	NcoI	Ccatgg	2	2	In HC signal seq
	NdeI	CAtatg	2	2	HC FR4
	PmlI	CACgtg	2	2	
45	XcmI	CCANNNNNnnnntgg	2	2	
	BcgI	cgannnnnntgc	3	3	
	BclI	Tgatca	3	3	
	BglI	GCCNNNNnggc	3	3	
	BsaBI	GATNNnnatc	3	3	
50	BsrGI	Tgtaca	3	3	
	SnaBI	TACgta	3	3	
	Sse8387I	CCTGCAgg	3	3	
	ApaLI	Gtgcac	4	4	LC Signal/FR1
	BspHI	Tcatga	4	4	
55	BssSI	Ctcgtg	4	4	
	PsiI	TTAata	4	5	

10045674-102501

	SphI	GCATGc	4	4	
	AhdI	GACNNNngtc	5	5	
	BspEI	Tccgga	5	5	HC FR1
5	MscI	TGGcca	5	5	
	SacI	GAGCTc	5	5	
	ScaI	AGTact	5	5	
	SexAI	Accwgt	5	6	
	SspI	AATatt	5	5	
	TliI	Ctcgag	5	5	
10	XhoI	Ctcgag	5	5	
	BbsI	GAAGAC	7	8	
	BstAPI	GCANNNNntgc	7	8	
	BstZ17I	GTAtac	7	7	
	EcoRV	GATatc	7	7	
15	EcoRI	Gaattc	8	8	
	BlpI	GCtnagc	9	9	
	Bsu36I	CCtnagg	9	9	
	DraIII	CACNNNgtg	9	9	
	EspI	GCtnagc	9	9	
20	StuI	AGGcct	9	13	
	XbaI	Tctaga	9	9	HC FR3
	Bsp120I	Gggccc	10	11	CH1
	ApaI	GGGCCc	10	11	CH1
	PspOoMI	Gggccc	10	11	
25	BciVI	GTATCCNNNNNN	11	11	
	SalI	Gtcgac	11	12	
	DrdI	GACNNNngtc	12	12	
	KasI	Ggcgcc	12	12	
	XmaI	Cccggg	12	14	
30	BglII	Agatct	14	14	
	HincII	GTYrac	16	18	
	BamHI	Ggatcc	17	17	
	PflMI	CCANNNNntgg	17	18	
	BsmBI	Nnnnnngagacg	18	21	
35	BstXI	CCANNNNntgg	18	19	HC FR2
	XmnI	GAANNnttc	18	18	
	SacII	CCGCgg	19	19	
	PstI	CTGCAG	20	24	
	PvuII	CAGctg	20	22	
40	AvaI	Cycgrg	21	24	
	EagI	Cggccg	21	22	
	AatII	GACGTc	22	22	
	BspMI	ACCTGC	27	33	
	AccI	GTmkac	30	43	
45	StyI	Ccwwgg	36	49	
	AlwNI	CAGNNNctg	38	44	
	BsaI	GGTCTCnnnn	38	44	
	PpuMI	RGgwccy	43	46	
	BsgI	GTGCAG	44	54	
50	BseRI	NNnnnnnnnnctcctc	48	60	
	EciI	nnnnnnnnntccgcc	52	57	
	BstEII	Ggtnacc	54	61	HC Fr4, 47/79 have one
	EcoO109I	RGgnccy	54	86	
	BpmI	ctccag	60	121	
55	AvaII	Ggwcc	71	140	

10045674 " 105501


```

!
! 1293 act tcc tc
!
! .... stop of IX, IX and VIII overlap by four bases
5 1301 ATG aaa aag tct tta gtc ctc aaa gcc tct gta gcc gtt gct acc ctc
! Start signal sequence of viii.
!
! 1349 gtt ccg atg ctg tct ttc gct gct gag ggt gac gat ccc gca aaa gcg
! mature VIII ---->
10 1397 gcc ttt aac tcc ctg caa gcc tca gcg acc gaa tat atc ggt tat gcg
1445 tgg gcg atg gtt gtt gtc att
1466 gtc ggc gca act atc ggt atc aag ctg ttt aag
1499 aaa ttc acc tcg aaa gca ! 1515
! ..... -35 ..
15 1517 agc tga taaaccgat acaattaaag gctccttttg
! ..... -10 ...
!
1552 gagccttttt ttttGGAGAt ttt ! S.D. underlined
20
! <----- III signal sequence ----->
! M K K L L F A I P L V
1575 caac GTG aaa aaa tta tta ttc gca att cct tta gtt ! 1611
!
25 V P F Y S H S A Q
1612 gtt cct ttc tat tct cac aGT gcA Cag tCT
! ApaLI...
!
1642 GTC GTG ACG CAG CCG CCC TCA GTG TCT GGG GCC CCA GGG CAG
30 AGG GTC ACC ATC TCC TGC ACT GGG AGC AGC TCC AAC ATC GGG GCA
! BstEII...
1729 GGT TAT GAT GTA CAC TGG TAC CAG CAG CTT CCA GGA ACA GCC CCC AAA
1777 CTC CTC ATC TAT GGT AAC AGC AAT CGG CCC TCA GGG GTC CCT GAC CGA
1825 TTC TCT GGC TCC AAG TCT GGC ACC TCA GCC TCC CTG GCC ATC ACT
35 1870 GGG CTC CAG GCT GAG GAT GAG GCT GAT TAT
1900 TAC TGC CAG TCC TAT GAC AGC AGC CTG AGT
1930 GGC CTT TAT GTC TTC GGA ACT GGG ACC AAG GTC ACC GTC
! BstEII...
1969 CTA GGT CAG CCC AAG GCC AAC CCC ACT GTC ACT
40 2002 CTG TTC CCG CCC TCC TCT GAG GAG CTC CAA GCC AAC AAG GCC ACA CTA
2050 GTG TGT CTG ATC AGT GAC TTC TAC CCG GGA GCT GTG ACA GTG GCC TGG
2098 AAG GCA GAT AGC AGC CCC GTC AAG GCG GGA GTG GAG ACC ACC ACA CCC
2146 TCC AAA CAA AGC AAC AAC AAG TAC GCG GCC AGC AGC TAT CTG AGC CTG
2194 ACG CCT GAG CAG TGG AAG TCC CAC AGA AGC TAC AGC TGC CAG GTC ACG
45 2242 CAT GAA GGG AGC ACC GTG GAG AAG ACA GTG GCC CCT ACA GAA TGT TCA
2290 TAA TAA ACCG CCTCCACCGG GCGGCCCAAT TCTATTTC AA GGAGACAGTC ATA
! AscI.....
!
! PelB signal----->
50 M K Y L L P T A A A G L L L L
2343 ATG AAA TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TTA TTA CTC
!
! 16 17 18 19 20 21 22
! A A Q P A M A
55 2388 gcG GCC cag ccG GCC atg gcc
! SfiI.....
! NgoMI... (1/2)
! NcoI.....

```

10045674 "100501


```

!
!   L   D   R   Y   A   N   Y   E   G   C   L   W   N   A   T   G   V
3261 tta gat cgt tac gct aac tat gag ggt tgt ctg tgG AAT GCT aca ggc gtt
!                                     BsmI_____
5
!   V   V   C   T   G   D   E   T   Q   C   Y   G   T   W   V   P   I
3312 gta gtt tgt act ggt GAC GAA ACT CAG TGT TAC GGT ACA TGG GTT cct att
!
!   G   L   A   I   P   E   N
10 3363 ggg ctt gct atc cct gaa aat
!
! L1 linker -----
!   E   G   G   G   S   E   G   G   G   S
15 3384 gag ggt ggt ggc tct gag ggt ggc ggt tct
!
!   E   G   G   G   S   E   G   G   G   T
3414 gag ggt ggc ggt tct gag ggt ggc ggt act
!
! Domain 2 -----
20 3444 aaa cct cct gag tac ggt gat aca cct att ccg ggc tat act tat atc aac
3495 cct ctc gac ggc act tat ccg cct ggt act gag caa aac ccc gct aat cct
3546 aat cct tct ctt GAG GAG tct cag cct ctt aat act ttc atg ttt cag aat
!                                     BseRI_____
25 3597 aat agg ttc cga aat agg cag ggg gca tta act gtt tat acg ggc act
3645 gtt act caa ggc act gac ccc gtt aaa act tat tac cag tac act cct
3693 gta tca tca aaa gcc atg tat gac gct tac tgg aac ggt aaa ttc AGA
!                                     AlwNI
3741 GAC TGc gct ttc cat tct ggc ttt aat gaa gat cca ttc gtt tgt gaa
!                                     AlwNI
30 3789 tat caa ggc caa tcg tct gac ctg cct caa cct cct gtc aat gct
!
3834 ggc ggc ggc tct
! start L2 -----
35 3846 ggt ggt ggt tct
3858 ggt ggc ggc tct
3870 gag ggt ggt ggc tct gag ggt ggc ggt tct
3900 gag ggt ggc ggc tct gag gga ggc ggt tcc
3930 ggt ggt ggc tct ggt ! end L2
!
! Domain 3 -----
40
!   S   G   D   F   D   Y   E   K   M   A   N   A   N   K   G   A
3945 tcc ggt gat ttt gat tat gaa aag atg gca aac gct aat aag ggg gct
!
!   M   T   E   N   A   D   E   N   A   L   Q   S   D   A   K   G
45 3993 atg acc gaa aat gcc gat gaa aac gcg cta cag tct gac gct aaa ggc
!
!   K   L   D   S   V   A   T   D   Y   G   A   A   I   D   G   F
4041 aaa ctt gat tct gtc gct act gat tac ggt gct gct atc gat ggt ttc
!
!   I   G   D   V   S   G   L   A   N   G   N   G   A   T   G   D
50 4089 att ggt gac gtt tcc ggc ctt gct aat ggt aat ggt gct act ggt gat
!
!   F   A   G   S   N   S   Q   M   A   Q   V   G   D   G   D   N
55 4137 ttt gct ggc tct aat tcc caa atg gct caa gtc ggt gac ggt gat aat
!
!   S   P   L   M   N   N   F   R   Q   Y   L   P   S   L   P   Q
4185 tca cct tta atg aat aat ttc cgt caa tat tta cct tcc ctc cct caa
!

```

10045674 "100501

```

!       S   V   E   C   R   P   F   V   F   S   A   G   K   P   Y   E
4233 tcg gtt gaa tgt cgc cct ttt gtc ttt agc gct ggt aaa cca tat gaa
!
!       F   S   I   D   C   D   K   I   N   L   F   R
5 4281 ttt tct att gat tgt gac aaa ata aac tta ttc cgt
!                                     End Domain 3
!
!       G   V   F   A   F   L   L   Y   V   A   T   F   M   Y   V   F140
10 4317 ggt gtc ttt gcg ttt ctt tta tat gtt gcc acc ttt atg tat gta ttt
!       start transmembrane segment
!
!       S   T   F   A   N   I   L
4365 tct acg ttt gct aac ata ctg
!
15 !       R   N   K   E   S
4386 cgt aat aag gag tct TAA ! stop of iii
!       Intracellular anchor.
!
!       M1 P2 V L L5 G I P L L10 L R F L G15
20 4404 tc ATG cca gtt ctt ttg ggt att ccg tta tta ttg cgt ttc ctc ggt
!       Start VI
!
4451 ttc ctt ctg gta act ttg ttc ggc tat ctg ctt act ttt ctt aaa aag
4499 ggc ttc ggt aag ata gct att gct att tca ttg ttt ctt gct ctt att
25 4547 att ggg ctt aac tca att ctt gtg ggt tat ctc tct gat att agc gct
4595 caa tta ccc tct gac ttt gtt cag ggt gtt cag tta att ctc ccg tct
4643 aat gcg ctt ccc tgt ttt tat gtt att ctc tct gta aag gct gct att
4691 ttc att ttt gac gtt aaa caa aaa atc gtt tct tat ttg gat tgg gat
!
30 !       M1 A2 V3 F5 L10 G13
4739 aaa TAA t ATG gct gtt tat ttt gta act ggc aaa tta ggc tct gga
!       end VI Start gene I
!
!       14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
35 !       K T L V S V G K I Q D K I V A
4785 aag acg ctc gtt agc gtt ggt aag att cag gat aaa att gta gct
!
!       29 30 31 32 33 34 35 36 37 38 39 40 41 42 43
40 !       G C K I A T N L D L R L Q N L
4830 ggg tgc aaa ata gca act aat ctt gat tta agg ctt caa aac ctc
!
!       44 45 46 47 48 49 50 51 52 53 54 55 56 57 58
45 !       P Q V G R F A K T P R V L R I
4875 ccg caa gtc ggg agg ttc gct aaa acg cct cgc gtt ctt aga ata
!
!       59 60 61 62 63 64 65 66 67 68 69 70 71 72 73
!       P D K P S I S D L L A I G R G
4920 ccg gat aag cct tct ata tct gat ttg ctt gct att ggg cgc ggt
!
50 !       74 75 76 77 78 79 80 81 82 83 84 85 86 87 88
4965 aat gat tcc tac gat gaa aat aaa aac ggc ttg ctt gtt ctc gat
!
!       89 90 91 92 93 94 95 96 97 98 99 100 101 102 103
55 !       E C G T W F N T R S W N D K E
5010 gag tgc ggt act tgg ttt aat acc cgt tct tgg aat gat aag gaa
!
!       104 105 106 107 108 109 110 111 112 113 114 115 116 117 118

```

10045674-1005001

	!		R	Q	P	I	I	D	W	F	L	H	A	R	K	L	G
	!	5055	aga	cag	ccg	att	att	gat	tgg	ttt	cta	cat	gct	cgt	aaa	tta	gga
5	!		119	120	121	122	123	124	125	126	127	128	129	130	131	132	133
	!		W	D	I	I	F	L	V	Q	D	L	S	I	V	D	K
	!	5100	tgg	gat	att	att	ttt	ctt	gtt	cag	gac	tta	tct	att	gtt	gat	aaa
10	!		134	135	136	137	138	139	140	141	142	143	144	145	146	147	148
	!		Q	A	R	S	A	L	A	E	H	V	V	Y	C	R	R
	!	5145	cag	gcg	cgt	tct	gca	tta	gct	gaa	cat	gtt	gtt	tat	tgt	cgt	cgt
15	!		149	150	151	152	153	154	155	156	157	158	159	160	161	162	163
	!		L	D	R	I	T	L	P	F	V	G	T	L	Y	S	L
	!	5190	ctg	gac	aga	att	act	tta	cct	ttt	gtc	ggt	act	tta	tat	tct	ctt
20	!		164	165	166	167	168	169	170	171	172	173	174	175	176	177	178
	!		I	T	G	S	K	M	P	L	P	K	L	H	V	G	V
	!	5235	att	act	ggc	tcg	aaa	atg	cct	ctg	cct	aaa	tta	cat	gtt	ggc	gtt
25	!		179	180	181	182	183	184	185	186	187	188	189	190	191	192	193
	!		V	K	Y	G	D	S	Q	L	S	P	T	V	E	R	W
	!	5280	gtt	aaa	tat	ggc	gat	tct	caa	tta	agc	cct	act	gtt	gag	cgt	tgg
30	!		194	195	196	197	198	199	200	201	202	203	204	205	206	207	208
	!		L	Y	T	G	K	N	L	Y	N	A	Y	D	T	K	Q
	!	5325	ctt	tat	act	ggt	aag	aat	ttg	tat	aac	gca	tat	gat	act	aaa	cag
35	!		209	210	211	212	213	214	215	216	217	218	219	220	221	222	223
	!		A	F	S	S	N	Y	D	S	G	V	Y	S	Y	L	T
	!	5370	gct	ttt	tct	agt	aat	tat	gat	tcc	ggt	gtt	tat	tct	tat	tta	acg
40	!		224	225	226	227	228	229	230	231	232	233	234	235	236	237	238
	!		P	Y	L	S	H	G	R	Y	F	K	P	L	N	L	G
	!	5415	cct	tat	tta	tca	cac	ggt	cgg	tat	ttc	aaa	cca	tta	aat	tta	ggt
45	!		239	240	241	242	243	244	245	246	247	248	249	250	251	252	253
	!		Q	K	M	K	L	T	K	I	Y	L	K	K	F	S	R
	!	5460	cag	aag	atg	aaa	tta	act	aaa	ata	tat	ttg	aaa	aag	ttt	tct	cgc
50	!		254	255	256	257	258	259	260	261	262	263	264	265	266	267	268
	!		V	L	C	L	A	I	G	F	A	S	A	F	T	Y	S
	!	5505	gtt	ctt	tgt	ctt	gcg	att	gga	ttt	gca	tca	gca	ttt	aca	tat	agt
55	!		269	270	271	272	273	274	275	276	277	278	279	280	281	282	283
	!		Y	I	T	Q	P	K	P	E	V	K	K	V	V	S	Q
	!	5550	tat	ata	acc	caa	cct	aag	ccg	gag	gtt	aaa	aag	gta	gtc	tct	cag
60	!		284	285	286	287	288	289	290	291	292	293	294	295	296	297	298
	!		T	Y	D	F	D	K	F	T	I	D	S	S	Q	R	L
	!	5595	acc	tat	gat	ttt	gat	aaa	ttc	act	att	gac	tct	tct	cag	cgt	ctt
65	!		299	300	301	302	303	304	305	306	307	308	309	310	311	312	313
	!		N	L	S	Y	R	Y	V	F	K	D	S	K	G	K	L
	!	5640	aat	cta	agc	tat	cgc	tat	gtt	ttc	aag	gat	tct	aag	gga	aaa	TTA
	!																PacI
70	!		314	315	316	317	318	319	320	321	322	323	324	325	326	327	328
	!		I	N	S	D	D	L	Q	K	Q	G	Y	S	L	T	Y

10045674 102561

```

5685 ATT AAt agc gac gat tta cag aag caa ggt tat tca ctc aca tat
!      PacI
!
!      329 330 331 332 333 334 335 336 337 338 339 340 341 342 343
5      !      i  I  D  L  C  T  V  S  I  K  K  G  N  S  N  E
!      iv                                     M1  K
5730   att gat tta tgt act gtt tcc att aaa aaa ggt aat tca aAT Gaa
!                                           Start IV
!
10      !      344 345 346 347 348 349
!      i      I  V  K  C  N  .End of I
!      iv     L3 L  N5 V  I7 N  F  V10
5775   att gtt aaa tgt aat TAA T TTT GTT
!      IV continued.....
15      5800 ttc ttg atg ttt gtt tca tca tct tct ttt gct cag gta att gaa atg
5848   aat aat tcg cct ctg cgc gat ttt gta act tgg tat tca aag caa tca
5896   ggc gaa tcc gtt att gtt tct ccc gat gta aaa ggt act gtt act gta
5944   tat tca tct gac gtt aaa cct gaa aat cta cgc aat ttc ttt att tct
5992   gtt tta cgt gct aat aat ttt gat atg gtt ggt tca att cct tcc ata
20      6040 att cag aag tat aat cca aac aat cag gat tat att gat gaa ttg cca
6088   tca tct gat aat cag gaa tat gat gat aat tcc gct cct tct ggt ggt
6136   ttc ttt gtt ccg caa aat gat aat gtt act caa act ttt aaa att aat
6184   aac gtt cgg gca aag gat tta ata cga gtt gtc gaa ttg ttt gta aag
6232   tct aat act tct aaa tcc tca aat gta tta tct att gac ggc tct aat
25      6280 cta tta gtt gtt TCT gca cct aaa gat att tta gat aac ctt cct caa
!      ApaLI removed
6328   ttc ctt tct act gtt gat ttg cca act gac cag ata ttg att gag ggt
6376   ttg ata ttt gag gtt cag caa ggt gat gct tta gat ttt tca ttt gct
6424   gct ggc tct cag cgt ggc act gtt gca ggc ggt gtt aat act gac cgc
30      6472 ctc acc tct gtt tta tct tct gct ggt ggt tcg ttc ggt att ttt aat
6520   ggc gat gtt tta ggg cta tca gtt cgc gca tta aag act aat agc cat
6568   tca aaa ata ttg tct gtg cca cgt att ctt acg ctt tca ggt cag aag
6616   ggt tct atc tct gtT GGC CAg aat gtc cct ttt att act ggt cgt gtg
!      MscI
35      6664 act ggt gaa tct gcc aat gta aat aat cca ttt cag acg att gag cgt
6712   caa aat gta ggt att tcc atg agc gtt ttt cct gtt gca atg gct ggc
6760   ggt aat att gtt ctg gat att acc agc aag gcc gat agt ttg agt tct
6808   tct act cag gca agt gat gtt att act aat caa aga agt att gct aca
6856   acg gtt aat ttg cgt gat gga cag act ctt tta ctc ggt ggc ctc act
40      6904 gat tat aaa aac act tct caa gat tct ggc gta ccg ttc ctg tct aaa
6952   atc cct tta atc ggc ctc ctg ttt agc tcc cgc tct gat tcc aac gag
7000   gaa agc acg tta tac gtg ctc gtc aaa gca acc ata gta cgc gcc ctg
7048   TAG cggcgcat
!      End IV
45      7060 aagcgcggcg ggtgtggtgg ttacgcgcag cgtgaccgct acacttgcca gcgccttagc
7120   gccgcctcct ttcgctttct tcccttcctt tctcgccacg ttcGCCGGCt ttccccgtca
!      NgoMI
7180   agctctaaat cgggggctcc ctttaggggtt ccgatttagt gctttacggc acctcgaccc
7240   caaaaaactt gatttggtg atgggtCAGC TAGTGggcca tcgcctgat agacggtttt
50      !      DraIII
7300   tcgccctttG ACGTTGGAGT Ccaggttctt taatagtgga ctcttggtcc aaactggaac
!      DrdI
7360   aacactcaac cctatctcgg gctattcttt tgatttataa gggattttgc cgatttcgga
7420   accaccatca aacaggattt tcgcctgctg gggcaaacca gcgtggaccg cttgctgcaa
55      7480 ctctctcagg gccaggcggg gaagggaat CAGCTGttgc cCGTCTCact ggtgaaaaga
!      PvuII.      BsmBI.
7540   aaaaccaccc tGGATCC AAGCTT
!      BamHI      HindIII (1/2)

```

10045674.03501

Table
LOCUS
ORIGIN

CIRCULAR

5	1	AATGCTACTA	CTATTAGTAG	AATTGATGCC	ACCTTTTCAG	CTCGCGCCCC	AAATGAAAAA
	61	ATAGCTAAAC	AGGTTATTGA	CCATTTGCGA	AATGTATCTA	ATGGTCAAAC	TAAATCTACT
	121	CGTTTCGCAGA	ATTGGGAATC	AACTGTTACA	TGGAATGAAA	CTTCCAGACA	CCGTACTTTA
	181	GTTGCATATT	TAAAACATGT	TGAGCTACAG	CACCAATATG	AGCAATTAAG	CTCTAAGCCA
	241	TCCGCAAAAA	TGACACTCTA	TCAAAAGGAG	CAATTAAGTC	TACTCTCTAA	TCCTGACCTG
10	361	TCTTTCTGGGC	TTCTCTCTAA	TCTTTTGTAT	GCAATCCGCT	TGTCTTCTGA	TCTATAAGT
	421	CAGGGTAAAG	ACCTGATTTT	TGATTTATGG	TCATTCTCGT	TTTCTGAACT	GTTTAAAGCA
	481	TTTGAGGGGG	ATTCAATGAA	TATTTATGAC	GATTCCGCAG	TATTGGACGC	TATCCAGTCT
	541	AAACATTTTA	CTATTACCCC	CTCTGGCAAA	ACTTCTTTTG	CAAAAGCCTC	TCGTATTTTT
	601	GGTTTTTATC	GTCGTCTGGT	AAACGAGGGT	TATGATAGTG	TTGCTCTTAC	TATGCCTCTG
15	661	AATTCCTTTT	GGCGTTATGT	ATCTGCATTA	CTTGAATGTG	GTATTCTTAA	ATCTCAACTG
	721	ATGAATCTTT	CTACCTGTAA	TAAATGTTGT	CCGTTAGTTC	GTTTATTAA	CGTAGATTTT
	781	TCTTCCCAAC	GTCCTGACTG	GTATAATGAG	CCAGTTCCTA	AAATCGCATA	AGGTAATTCA
	841	CAATGATTAA	AGTTGAAATT	AAACCATCTC	AAGCCCAATT	TACTACTCGT	TCTGGTGTTC
	901	CTCGTCAGGG	CAAGCCTTAT	TCACTGAATG	AGCAGCTTTG	TTACGTTGAT	TTGGGTAATG
20	961	AATATCCGGT	TCTTGTCAAG	ATTACTCTTG	ATGAAGGTCA	GCCAGCCTAT	GCGCCTGGTC
	1021	TGTACACCGT	TCATCTGTCC	TCTTTCAAAG	TTGGTCAGTT	CGGTTCCCTT	ATGATTGACC
	1081	GTCTCGCGCT	CGTTCGGCT	AAGTAAACATG	GAGCAGGTGC	CGGATTTCGA	CACAATTTAT
	1141	CAGGCGATGA	TACAAATCTC	CGTTGTACTT	TGTTTCGCGC	TTGGTATAAT	CGCTGGGGGT
	1201	CAAAGATGAG	TGTTTTAGTG	TATTCCTTCG	CCTCTTTCGT	TTTAGGTTGG	TGCCCTTCGTA
25	1261	GTGGCATTAC	GTATTTTACC	CGTTTAAATG	AAACTTCCTC	ATGAAAAAGT	CTTTAGTCCT
	1321	CAAAGCCTCT	GTAGCCGTTG	CTACCCTCGT	TCCGATGCTG	TCTTTCGCTG	CTGAGGGTGA
	1381	CGATCCCGCA	AAAGCGGCCCT	TTAATCCCTT	GCAAGCCTCA	GGCACCAGAT	ATATCGGTTA
	1441	TGCGTGGGCG	ATGGTTGTTG	CTATTGTGCG	CGCAACTATC	CGCATACAAGC	TGTTTAAAGAA
	1501	ATTCACCTCG	AAAGCAAGCT	GATAAACCGA	TACAATTAAA	GGCTCCTTTT	GGAGCCTTTT
30	1561	TTTTTGAGAG	TTTTCAACGT	GAAAAAATTA	TTATTGCGAA	TTCCTTTAGT	TGTTCTTTTC
	1621	TATTCCTACA	GTGCACAGTC	TGTCGTGACG	CAGCCGCCCT	CAGTGTCTGG	GGCCCCAGGG
	1681	CAGAGGGTCA	CCATCTCCTG	CACCTGGGAGC	AGCTCCAACA	TCGGGGCAGG	TTATGATGTA
	1741	CACCTGGTACC	AGCAGCTTCC	AGGAACAGCC	CCCAAACCTC	TCATCTATGG	TAACAGCAAT
	1801	CGGCCCTCAG	GGGTCCCTGA	CCGATTCTCT	GGCTCCAAGT	CTGGCACCTC	AGCCTCCCTG
35	1861	GCCATCACTG	GGCTCCAGGC	TGAGGATGAG	GCTGATTATT	ACTGCCAGTC	CTATGACAGC
	1921	AGCCTGAGTG	GCCTTTATGT	CTTCGGAACT	GGGACCAAGG	TCACCGTCCT	AGGTCAGCCC
	1981	AAGGCCAACC	CCACTGTCAC	TCTGTTCCCG	CCCTCCTCTG	AGGAGCTCCA	AGCCAACAAG
	2041	GCCACACTAG	TGTGTCTGAT	CAGTGACTTC	TACCCGGGAG	CTGTGACAGT	GGCCTGGAAG
	2101	GCAGATAGCA	GCCCCGTCAA	GGCGGGAGTG	GAGACACCA	CACCTTCCAA	ACAAAGCAAC
40	2161	AACAAGTAGC	CGGCCAGCAG	CTATCTGAGC	CTGACGCCTG	AGCAGTGGAA	TCCCCACAGA
	2221	AGCTACAGCT	GCCAGGTCAC	GCATGAAGGG	AGCACCGTGG	AGAAGACAGT	GGCCCCTACA
	2281	GAATGTTTAT	AATAAACCGC	CTCCACCGGG	CGCGCCAATT	CTATTTCAAG	GAGACAGTCA
	2341	TAATGAAATA	CCTATTGCCT	ACGGCAGCCG	CTGGATTGTT	ATTACTCGCG	GCCCAGCCGG
	2401	CCATGGCCGA	AGTTCAATTG	TTAGAGTCTG	GTGGCGGTCT	TGTTACAGCT	GGTGGTTCTT
45	2461	TACGTCTTTC	TTGCGCTGCT	TCCGGATTCA	CTTTCTCTTC	TGACGCTATG	CTTTGGGTTT
	2521	GCCAAGCTCC	TGGTAAAGGT	TTGGAGTGGG	TTTCTGCTAT	CTCTGGTTCT	GGTGGCAGTA
	2581	CTTACTATGC	TGACTCCGTT	AAAGGTCGCT	TCACTATCTC	TAGAGACAAC	TCTAAGAATA
	2641	CTCTCTACTT	GCAGATGAAC	AGCTTAAGGG	CTGAGGACAC	TGCAGTCTAC	TATTGCGCTA
	2701	AAGACTATGA	AGGTACTGGT	TATGCTTTCG	ACATATGGGG	TCAAGGTACT	ATGGTCACCG
50	2761	TCTCTAGTGC	CTCCACCAAG	GGCCCATCGG	TCTTCCCCCT	GGCACCCCTC	TCCAAGAGCA
	2821	CCTCTGGGGG	CACACGGGCC	CTGGGCTGCC	TGGTCAAGGA	CTACTTCCCC	GAACCCGGTA
	2881	CGGTGTCGTG	GAACTCAGGC	CGCCTGACCA	CGGCGCTCCA	CACCTTCCCG	GCTGTCCTAC
	2941	AGTCTAGCGG	ACTCTACTCC	CTCAGCAGCG	TAGTGACCGT	GCCCTCTTCT	AGCTTGGGCA
	3001	CCCAGACCTA	CATCTGCAAC	GTGAATCACA	AGCCCAGCAA	CACCAAGGTG	GACAAGAAAG
55	3061	TTGAGCCCAA	ATCTTGTGCG	GCCGCTCATC	ACCACCATCA	TCACTCTGCT	GAACAAAAAC
	3121	TCATCTCAGA	AGAGGACTGT	AATGGTGCCG	CAGATATCAA	CGATGATCGT	ATGGCTGGCG
	3181	CCGCTGAAAC	TGTTGAAAGT	TGTTTAGCAA	AACCCCATAC	AGAAAATTCA	TTTACTAAACG
	3241	TCTGGAAAGA	CGACAAAAC	TTAGATCGTT	ACGCTAACTA	TGAGGGTTGT	CTGTGGAATG

3301	CTACAGGCGT	TGTAGTTTGT	ACTGGTGACG	AAACTCAGTG	TTACGGTACA	TGGGTTTCCTA
3361	TTGGGCTTGC	TATCCCTGAA	AATGAGGGTG	GTGGCTCTGA	GGGTGGCGGT	TCTGAGGGTG
3421	GCGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT	ATTCGGGGCT
3481	ATACTTATAT	CAACCCCTC	GACGGCACTT	ATCCGCCTGG	TACTGAGCAA	AACCCCGCTA
5 3541	ATCCTAATCC	TTCTCTTGAG	GAGTCTCAGC	CTCTTAATAC	TTTCATGTTT	CAGAATAATA
3601	GGTTCCGAAA	TAGGCAGGGG	GCATTAAC TG	TTTATACGGG	CACGTGTACT	CAAGGCACTG
3661	ACCCCGTTAA	AACTTATTAC	CAGTACACTC	CTGTATCATC	AAAAGCCATG	TATGACGCTT
3721	ACTGGAACGG	TAAATTCAGA	GACTGCGCTT	TCCATTCTGG	CTTTAATGAA	GATCCATTCTG
3781	TTTGTGAATA	TCAAGGCCAA	TCGTCTGACC	TGCCCTCAACC	TCCTGTCAAT	GCTGGCGGCG
10 3841	GCTCTGGTGG	TGGTCTGGT	GGCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT	GGCGGTTCTG
3901	AGGGTGGCGG	CTCTGAGGGA	GGCGGTTCCG	GTGGTGGCTC	TGGTTCCGGT	GATTTTGATT
3961	ATGAAAAGAT	GGCAAACGCT	AATAAGGGGG	CTATGACCGA	AAATGCCGAT	GAAAACGCGC
4021	TACAGTCTGA	CGCTAAAGGC	AAACTTGATT	CTGTCGCTAC	TGATTACGGT	GCTGCTATCG
4081	ATGGTTTCAT	TGGTGACGTT	TCCGGCCTTG	CTAATGGTAA	TGGTGCTACT	GGTGATTTTG
15 4141	CTGGCTCTAA	TTCCCAAATG	GCTCAAGTCG	GTGACGGTGA	TAATTCACCT	TTAATGAATA
4201	ATTTCCGTCA	ATATTTACCT	TCCCTCCCTC	AATCGGTTGA	ATGTCGCCCT	TTTGCTTTTA
4261	GCGCTGGTAA	ACCATATGAA	TTTTCTATTG	ATTGTGACAA	AATAAACTTA	TTCCGTGGTG
4321	TCTTTGCGTT	TCTTTTATAT	TTTGCCACCT	TTATGTATGT	ATTTTCTACG	TTTGCTAACA
4381	TACTGCGTAA	TAAGGAGTCT	TAATCATGCC	AGTTCTTTTG	GGTATTCCGT	TATTATTGCG
20 4441	TTTCCTCGGT	TTCTTCTGG	TAAC TTGTT	CGGCTATCTG	CTTACTTTTC	TTAAAAAGGG
4501	CTTCGGTAAG	ATAGCTATTG	CTATTTCAAT	GTTCCTTGCT	CTTATTATTG	GGCTTAACTC
4561	AATTCTTG TG	GGTTATCTCT	CTGATATTAG	CGCTCAATTA	CCCTCTGACT	TTGTTCAAGG
4621	TGTTCAAGTA	ATTCCTCCGT	CTAATGCGCT	TCCCTGTTTT	TATGTTATTCT	TCTCTGTAAA
4681	GGCTGCTATT	TTTATTTTTG	ACGTAAACA	AAAAATCGTT	TCTTATTTGG	ATTGGGATAA
25 4741	ATAATATGGC	TGTTTATTTT	GTAAC TGGA	AATTAGGCTC	TGGAAAGACG	CTCGTTAGCG
4801	TTGGTAAGAT	TCAGGATAAA	ATTGTAGCTG	GGTGCAAAAT	AGCAACTAAT	CTTGATTTAA
4861	GGCTTCAAAA	CCTCCCGCAA	GTCCGGAGGT	TCGCTAAAAC	GCCTCGCGTT	CTTAGAATAC
4921	CGGATAAGCC	TTCTATATCT	GATTTGCTTG	CTATTGGGCG	CGGTAATGAT	TCCTACGATG
4981	AAAATAAAAA	CGGCTTGCTT	GTTCCTCATG	AGTGCGGTAC	TTGGTTTAA	ACCGGTTCTT
30 5041	GGAATGATAA	GGAAAGACAG	CCGATTATTG	ATTGGTTTCT	ACATGCTCGT	AAATTAGGAT
5101	GGGATATTAT	TTTTCTTGTT	CAGGACTTAT	CTATTGTTGA	TAAACAGGCG	CGTTCTGCAT
5161	TAGCTGAACA	TGTTGTTTAT	TGTCGTCGTC	TGGACAGAAT	TACTTTACCT	TTTGTCGGTA
5221	CTTTATATTC	TCTTATTACT	GGCTCGAAAA	TGCCTCTGCC	TAAATTACAT	GTTGGCGTTG
5281	TTAAATATGG	CGATTCTCAA	TTAAGCCCTA	CTGTTGAGCG	TTGGCTTTAT	ACTGGTAAGA
35 5341	ATTTGTATAA	CGCATATGAT	ACTAAACAGG	CTTTTCTAG	TAATTATGAT	TCCGGTGT TT
5401	ATTCTTATTT	AACGCCTTAT	TTATCACACG	GTCGGTATTT	CAAACCATTA	AATTTAGGTC
5461	AGAAGATGAA	ATTAAC TAAA	ATATATTTGA	AAAAGTTTTT	TCGCGTTCTT	TGCTTTGCGA
5521	TTGGATTTGC	ATCAGCATTT	ACATATAGTT	ATATAACCCA	ACCTAAGCCG	GAGGTTAAAA
5581	AGGTAGTCTC	TCAGACCTAT	GATTTTGATA	AATTCAC TAT	TGACTCTTCT	CAGCGTCTTA
40 5641	ATCTAAGCTA	TCGCTATGTT	TTCAAGGATT	CTAAGGGAAA	ATTAATTAAT	AGCGACGATT
5701	TACAGAAGCA	AGGTTATTCA	CTCACATATA	TTGATTTATG	TACTGTTTCC	ATTAATAAAG
5761	GTAATTCAAA	TGAAATTGTT	AAATGTAATT	AATTTTGTTT	TCTTGATGTT	TGTTTCATCA
5821	TCTTCTTTTG	CTCAGGTAAT	TGAAATGAAT	AATTCGCCCTC	TGCGCGATTT	TGTAAC TTGG
5881	TATTC AAAGC	AATCAGGCGA	ATCCGTTATT	GTTTCTCCCG	ATGTAAAAGG	TACTGTTACT
45 5941	GTATATT CAT	CTGACGT TAA	ACCTGAAAAT	CTACGCAATT	TCTTTATTTT	TGTTTTACGT
6001	GCTAATAATT	TTGATATGGT	TGGTTCAATT	CCTTCCATAA	TTTCAAGATA	TAATCCAAAC
6061	AATCAGGATT	ATATTGATGA	ATTGCCATCA	TCTGATAATC	AGGAATATGA	TGATAATTCC
6121	GCTCCTTCTG	GTGGTTTCTT	TGTTCCGCAA	AATGATAATG	TTACTCAAAC	TTTTAAATTT
6181	AATAACGTTT	GGGCAAAGGA	TTTAATACGA	GTTGTGCAAT	TGTTTG TAAA	GTCTAATACT
50 6241	TCTAAATCCT	CAAATGTATT	ATCTATTGAC	GGCTCTAATC	TATTAGTTGT	TTCTGCACCT
6301	AAAGATATTT	TAGATAACCT	TCCTCAATTC	CTTTCTACTG	TTGATTTGCC	AACTGACCAG
6361	ATATTGATTG	AGGTTTGTAT	ATTTGAGGTT	CAGCAAGGTG	ATGCTTTAGA	TTTTTCAATT
6421	GCTGCTGGCT	CTCAGCGTGG	CACTGTTGCA	GGCGGTGTTA	ATACTGACCG	CCTCACCTCT
6481	GTTTTATCTT	CTGCTGGTGG	TTCGTTCCGG	ATTTTAAATG	GCGATGTTTT	AGGGCTATCA
55 6541	GTTTCGCGCAT	TAAAGACTAA	TAGCCATTCA	AAAATATTGT	CTGTGCCACG	TATCTTTACG
6601	CTTTCAGGTC	AGAAGGGTTC	TATCTCTGTT	GGCCAGAATG	TCCCTTTTAT	TACTGGTCTG
6661	GTGACTGGTG	AATCTGCCAA	TGTAAATAAT	CCATTTTCAGA	CGATTGAGCG	TCAAAATGTA
6721	GGTATTTCCA	TGAGCGTTTT	TCCTGTTGCA	ATGGCTGGCG	GTAATATTGT	TCTGATATT

10045674 " 102501

6781	ACCAGCAAGG	CCGATAGTTT	GAGTTCTTCT	ACTCAGGCAA	GTGATGTTAT	TACTAATCAA
6841	AGAAGTATTG	CTACAACGGT	TAATTTGCGT	GATGGACAGA	CTCTTTTACT	CGGTGGCCTC
6901	ACTGATTATA	AAAACACTTC	TCAAGATTCT	GGCGTACCGT	TCCTGTCTAA	AATCCCTTTA
6961	ATCGGCCTCC	TGTTTAGCTC	CCGCTCTGAT	TCCAACGAGG	AAAGCACGTT	ATACGTGCTC
5 7021	GTCAAAGCAA	CCATAGTACG	CGCCCTGTAG	CGGCGCATTA	AGCGCGGCGG	GTGTGGTGGT
7081	TACGCGCAGC	GTGACCGCTA	CACTTGCCAG	CGCCCTAGCG	CCCGCTCCTT	TCGCTTTCTT
7141	CCCTTCCTTT	CTCGCCACGT	TCGCCGGCTT	TCCCCGTCAA	GCTCTAAATC	GGGGGCTCCC
7201	TTTAGGGTTC	CGATTTAGTG	CTTTACGGCA	CCTCGACCCC	AAAAAACTTG	ATTTGGGTGA
7261	TGGTTCACGT	AGTGGGCCAT	CGCCCTGATA	GACGGTTTTT	CGCCCTTTGA	CGTTGGAGTC
10 7321	CACGTTCTTT	AATAGTGGAC	TCCTGTTCCT	AACTGGAACA	ACACTCAACC	CTATCTCGGG
7381	CTATTCTTTT	GATTTATAAG	GGATTTTGCC	GATTTTCGGA	CCACCATCAA	ACAGGATTTT
7441	CGCCTGCTGG	GGCAAACCGC	CGTGGACCGC	TTGCTGCAAC	TCTCTCAGGG	CCAGGCGGTG
7501	AAGGGCAATC	AGCTGTTGCC	CGTCTCACTG	GTGAAAAGAA	AAACCACCTT	GGATCCAAGC
7561	TTGCAGGTGG	CACTTTTCGG	GGAAATGTGC	GCGGAACCCC	TATTTGTTTA	TTTTTCTAAA
15 7621	TACATTCAAA	TATGTATCCG	CTCATGAGAC	AATAACCTTG	ATAAATGCTT	CAATAATATT
7681	GAAAAAGGAA	GAGTATGAGT	ATTCAACATT	TCCGTGTGCG	CCTTATTTCC	TTTTTTGCGG
7741	CATTTTGCCT	TCCTGTTTTT	GCTCACCCAG	AAACGCTGGT	GAAAGTAAAA	GATGCTGAAG
7801	ATCAGTTGGG	CGCACGAGTG	GGTTACATCG	AACTGGATCT	CAACAGCGGT	AAGATCCTTG
7861	AGAGTTTTCG	CCCCGAAGAA	CGTTTTCCAA	TGATGAGCAC	TTTTTAAAGT	CTGTATGTCT
20 7921	ATACACTATT	ATCCCGTATT	GACGCCGGGC	AAGAGCAACT	CGGTGCGCCG	GCGCGGTATT
7981	CTCAGAATGA	CTTGTTGAG	TACTCACCAG	TCACAGAAAA	GCATCTTACG	GATGGCATGA
8041	CAGTAAGAGA	ATTATGCACT	GCTGCCATAA	CCATGAGTGA	TAACACTGCG	GCCAACTTAC
8101	TTCTGACAA	GATCGGAGGA	CCGAAGGAGC	TAACCGCTTT	TTTGACAAC	ATGGGGGATC
8161	ATGTAACCTG	CCTTGATCGT	TGGGAACCGG	AGCTGAATGA	AGCCATACCA	AACGACGAGC
25 8221	GTGACACCAC	GATGCCTGTA	GCAATGCCAA	CAACGTTGCG	CAAACCTATTA	ACTGGCGAAC
8281	TACTTACTCT	AGCTTCCCGG	CAACAATTAA	TAGACTGGAT	GGAGGCGGAT	AAAGTTGCAG
8341	GACCACTTCT	GCGCTCGGCC	CTTCCGGCTG	GCTGGTTTAT	TGCTGATAAA	TCGTGAGCCG
8401	GTGAGCGTGG	GTCTCGCGGT	ATCATTGCAG	CACTGGGGCC	AGATGGTAAG	CCCTCCCGTA
8461	TCGTAGTTAT	CTACACGACG	GGGAGTCAGG	CAACTATGGA	TGAACGAAAT	AGACAGATCG
30 8521	CTGAGATAGG	TGCCTCACTG	ATTAAGCATT	GGTAACGTGC	AGACCAAGTT	TACTCATATA
8581	TACTTTAGAT	TGATTTAAAA	CTTCATTTTT	AATTTAAAAG	GATCTAGGTG	AAGATCCTTT
8641	TTGATAATCT	CATGACCAAA	ATCCCTTAAC	GTGAGTTTTT	GTTCCACTGT	ACGTAAGACC
8701	CCCAAGCTTG	TCGACTGAAT	GGCGAATGGC	GCTTTGCCTG	GTTTCCGGCA	CCAGAAGCGG
8761	TGCCGGAAAG	CTGGCTGGAG	TGCGATCTTC	CTGAGGCCGA	TACTGTGCTC	GTCCCTCAA
35 8821	ACTGGCAGAT	GCACGGTTAC	GATGCGCCCA	TCTACACCAA	CGTAACCTAT	CCCATTACGG
8881	TCAATCCGCC	GTTTGTTCCT	ACGGAGAATC	CGACGGGTTG	TTACTCGCTC	ACATTTAATG
8941	TTGATGAAAG	CTGGCTACAG	GAAGGCCAGA	CGCGAATTAT	TTTTGATGGC	GTTTCTATTG
9001	GTAAAAAAT	GAGCTGATTT	AACAAAAATT	TAACGCGAAT	TTTAACAAAA	TATTAACGTT
9061	TACAATTTAA	ATATTTGCTT	ATACAATCTT	CCTGTTTTTG	GGGCTTTTCT	GATTATCAAC
40 9121	CGGGGTACAT	ATGATTGACA	TGCTAGTTTT	ACGATTACCG	TTCATCGATT	CTCTGTTTTG
9181	CTCCAGACTC	TCAGGCAATG	ACCTGATAGC	CTTTGTAGAT	CTCTCAAAAA	TAGCTACCTT
9241	CTCCGGCATG	AATTTATCAG	CTAGAACGGT	TGAATATCAT	ATTGATGGTG	ATTTGACTGT
9301	CTCCGGCCTT	TCTACCCCTT	TTGAATCTTT	ACCTACACAT	TACTCAGGCA	TTGCATTTAA
9361	AATATATGAG	GGTTCTAAAA	ATTTTTATCC	TTGCGTTGAA	ATAAAGGCTT	CTCCGCAAAA
45 9421	AGTATTACAG	GGTCATAATG	TTTTTGGTAC	AACCGATTTA	GCTTTATGCT	CTGAGGCTTT
9481	ATTGCTTAAT	TTTGCTAATT	CTTTGCCTTG	CCTGTATGAT	TTATTGGATG	TT

10045674 100504

Table 22: Primers used in RACE amplification:

Heavy chain	
HuClμ-FOR (1st PCR)	5'-TGG AAG AGG CAC GTT CTT TTC TTT-3'
HuClμ-Nested (2nd PCR)	5' CTT TTC TTT GTT GCC GTT GGG GTG-3'
Kappa light chain	
HuClκFor (1st PCR)	5'-ACA CTC TCC CCT GTT GAA GCT CTT-3'
HuClκForAscI(2nd PCR)	5'-ACC GCC TCC ACC GGG CGC GGC TTA TTA ACA CTC TCC CCT GTT GAA GCT CTT-3'
Lambda light chain	
HuClambdaFor (1st PCR)	5'-TGA ACA TTC TGT AGG GGC CAC TG-3'
HuCL2-FOR	5'-AGA GCA TTC TGC AGG GGC CAC TG-3'
HuCL7-FOR	
HuClambdaForAscI (2nd PCR)	
HuCL2-FOR-ASC	5'-ACC GCC TCC ACC GGG CGC GCC TTA TTA TGA ACA TTC TGT AGG GGC CAC TG-3'
HuCL7-FOR-ASC	5'-ACC GCC TCC ACC GGG CGC GCC TTA TTA AGA GCA TTC TGC AGG GGC CAC TG-3'
GeneRacer 5' Primers provided with the kit (Invitrogen)	
5'A 1st PCR	5'CGACTGGAGCAGGAGGACACTGA 3'
20 5'NA 2nd PCR	5'GGACACTGACATGGACTGAAGGAGTA-3'

Table 23: ONs used in Capture of kappa light chains using CJ method and *BsmAI*

All ONs are written 5' to 3'.

REdapters (6)	
ON_20SK15O12	888AggATggAgAcTgggTc
ON_20SK15L12	888AAgATggAgAcTgggTc
ON_20SK15A17	888AgAgTggAgAcTgAgTc
ON_20SK15A27	888TggcTggAgAcTgcgTc
ON_20SK15A11	888TggcTggAgAcTgcgTc
ON_20SK15B3	888AggTcTggAgAcTgggTc
Bridges (6)	
kapbr11O12	888AggATggAgAcTgggTcATcTggATgTcTTgTgcAcTgTgAcAgAgg
kapbr11L12	888AAgATggAgAcTgggTcATcTggATgTcTTgTgcAcTgTgAcAgAgg
kapbr11A17	888AgAgTggAgAcTgggTcATcTggATgTcTTgTgcAcTgTgAcAgAgg
kapbr11A27	888TggcTggAgAcTgggTcATcTggATgTcTTgTgcAcTgTgAcAgAgg
kapbr11A11	888TggcTggAgAcTgggTcATcTggATgTcTTgTgcAcTgTgAcAgAgg
kapbr11B3	888AgTcTggAgAcTgggTcATcTggATgTcTTgTgcAcTgTgAcAgAgg
Extender (5' biotinylated)	
kapext1bio	ccTcTgTcAcAgTgcAcAAGAcATccAgATgAcccAgTcTcc
Primers	
kapPCRtl	ccTcTgTcAcAgTgcAcAAGAc
kapfor	5'-aca ctc tcc cct gtt gaa gct ctt-3'

Table 24: PCR program for amplification of kappa DNA

	95°C	5 minutes
	95°C	15 seconds
	65°C	30 seconds
5	72°C	1 minute
	72°C	7 minutes
	4°C	hold

Reagents (100 ul reaction):

10	Template	50 ng
	10x turbo PCR buffer	1x
	turbo Pfu	4U
	dNTPs	200 µM each
	kaPCRu1	300 nM
	kapfor	300 nM

Table 25: h3401-h2 captured Via CJ with BsmAI

! 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
! S A Q D I Q M T Q S P A T L S
aGT GCA Caa gac atc cag atg acc cag tct cca gcc acc ctg tct
5 ! ApaLI... a gcc acc ! L25,L6,L20,L2,L16,A11
! Extender.....Bridge...

! 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
! V S P G E R A T L S C R A S Q
10 ! gtg tct cca ggg gaa agg gcc acc ctc tcc tgc agg gcc agt cag

! 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
! S V S N N L A W Y Q Q K P G Q
! agt gtt agt aac aac tta gcc tgg tac cag cag aaa cct ggc cag
15

! 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
! V P R L L I Y G A S T R A T D
! gtt ccc agg ctc ctc atc tat ggt gca tcc acc agg gcc act gat
20

! 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75
! I P A R F S G S G S G T D F T
! atc cca gcc agg ttc agt ggc agt ggg tct ggg aca gac ttc act
25

! 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
! L T I S R L E P E D F A V Y Y
! ctc acc atc agc aga ctg gag cct gaa gat ttt gca gtg tat tac
30

! 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105
! C Q R Y G S S P G W T F G Q G
! tgt cag cgg tat ggt agc tca ccg ggg tgg acg ttc ggc caa ggg
35

! 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
! T K V E I K R T V A A P S V F
! acc aag gtg gaa atc aaa cga act gtg gct gca cca tct gtc ttc
40

! 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
! I F P P S D E Q L K S G T A S
! atc ttc ccg cca tct gat gag cag ttg aaa tct gga act gcc tct
45

! 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150
! V V C L L N N F Y P R E A K V
! gtt gtg tgc ctg ctg aat aac ttc tat ccc aga gag gcc aaa gta
50

! 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165
! Q W K V D N A L Q S G N S Q E
! cag tgg aag gtg gat aac gcc ctc caa tgc ggt aac tcc cag gag
55

! 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180
! S V T E Q D S K D S T Y S L S
! agt gtc aca gag cag gac agc aag gac agc acc tac agc ctc agc
185

! 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195

70045674 "102501

! S T L T L S K A D Y E K H K V

agc acc ctg acg ctg agc aaa gca gac tac gag aaa cac aaa gtc

! 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210

5 ! Y A C E V T H Q G L S S P V T

tac gcc tgc gaa gtc acc cat cag ggc ctg agc tgc cct gtc aca

! 211 212 213 214 215 216 217 218 219 220 221 222 223

! K S F N K G E C K G E F A

10 aag agc ttc aac aaa gga gag tgt aag ggc gaa ttc gc.....

$\frac{1}{x}$ $\frac{1}{x^2}$ $\frac{1}{x^3}$ $\frac{1}{x^4}$ $\frac{1}{x^5}$ $\frac{1}{x^6}$ $\frac{1}{x^7}$ $\frac{1}{x^8}$ $\frac{1}{x^9}$ $\frac{1}{x^{10}}$ $\frac{1}{x^{11}}$ $\frac{1}{x^{12}}$ $\frac{1}{x^{13}}$ $\frac{1}{x^{14}}$ $\frac{1}{x^{15}}$ $\frac{1}{x^{16}}$ $\frac{1}{x^{17}}$ $\frac{1}{x^{18}}$ $\frac{1}{x^{19}}$ $\frac{1}{x^{20}}$ $\frac{1}{x^{21}}$ $\frac{1}{x^{22}}$ $\frac{1}{x^{23}}$ $\frac{1}{x^{24}}$ $\frac{1}{x^{25}}$ $\frac{1}{x^{26}}$ $\frac{1}{x^{27}}$ $\frac{1}{x^{28}}$ $\frac{1}{x^{29}}$ $\frac{1}{x^{30}}$ $\frac{1}{x^{31}}$ $\frac{1}{x^{32}}$ $\frac{1}{x^{33}}$ $\frac{1}{x^{34}}$ $\frac{1}{x^{35}}$ $\frac{1}{x^{36}}$ $\frac{1}{x^{37}}$ $\frac{1}{x^{38}}$ $\frac{1}{x^{39}}$ $\frac{1}{x^{40}}$ $\frac{1}{x^{41}}$ $\frac{1}{x^{42}}$ $\frac{1}{x^{43}}$ $\frac{1}{x^{44}}$ $\frac{1}{x^{45}}$ $\frac{1}{x^{46}}$ $\frac{1}{x^{47}}$ $\frac{1}{x^{48}}$ $\frac{1}{x^{49}}$ $\frac{1}{x^{50}}$ $\frac{1}{x^{51}}$ $\frac{1}{x^{52}}$ $\frac{1}{x^{53}}$ $\frac{1}{x^{54}}$ $\frac{1}{x^{55}}$ $\frac{1}{x^{56}}$ $\frac{1}{x^{57}}$ $\frac{1}{x^{58}}$ $\frac{1}{x^{59}}$ $\frac{1}{x^{60}}$ $\frac{1}{x^{61}}$ $\frac{1}{x^{62}}$ $\frac{1}{x^{63}}$ $\frac{1}{x^{64}}$ $\frac{1}{x^{65}}$ $\frac{1}{x^{66}}$ $\frac{1}{x^{67}}$ $\frac{1}{x^{68}}$ $\frac{1}{x^{69}}$ $\frac{1}{x^{70}}$ $\frac{1}{x^{71}}$ $\frac{1}{x^{72}}$ $\frac{1}{x^{73}}$ $\frac{1}{x^{74}}$ $\frac{1}{x^{75}}$ $\frac{1}{x^{76}}$ $\frac{1}{x^{77}}$ $\frac{1}{x^{78}}$ $\frac{1}{x^{79}}$ $\frac{1}{x^{80}}$ $\frac{1}{x^{81}}$ $\frac{1}{x^{82}}$ $\frac{1}{x^{83}}$ $\frac{1}{x^{84}}$ $\frac{1}{x^{85}}$ $\frac{1}{x^{86}}$ $\frac{1}{x^{87}}$ $\frac{1}{x^{88}}$ $\frac{1}{x^{89}}$ $\frac{1}{x^{90}}$ $\frac{1}{x^{91}}$ $\frac{1}{x^{92}}$ $\frac{1}{x^{93}}$ $\frac{1}{x^{94}}$ $\frac{1}{x^{95}}$ $\frac{1}{x^{96}}$ $\frac{1}{x^{97}}$ $\frac{1}{x^{98}}$ $\frac{1}{x^{99}}$ $\frac{1}{x^{100}}$

```

! 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
! S A Q D I Q M T Q S P A T L S
aGT GCA Caa gac atc cag atg acc cag tct cct gcc acc ctg tct
! ApaLI...Extender.....a gcc acc ! L25,L6,L20,L2,L16,A11
!                               A GCC ACC CTG TCT ! L2

```

! 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
15 ! N L L S N L A W Y Q Q K P G Q
aat ctt ctc agc aac tta gcc tgg tac cag cag aaa cct ggc cag

! 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75
! I P A R F S G S G S G T E F T
atc cca gcc agg ttc agt ggc agt ggg tct ggg aca gag ttc act

! 76 77 78 79 80. 81 82 83 84 85 86 87 88 89 90
! L T I S S L Q S E D F A V Y F
ctc acc atc agc agc ctg cag tct gaa gat ttt gca gtg tat ttc

30 ! 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105
! C Q Q Y G T S P P T F G G G T
tgt cag cag tat ggt acc tca ccg ccc act ttc ggc gga ggg acc

35 ! K V E I K R T V A A P S V F I
aag gtg gag atc aaa cga act gtg gct gca cca tct gtc ttc atc

40 ! 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
! F P P S D E Q L K S G T A S V
ttc ccg cca tct gat gag cag ttg aaa tct gga act gcc tct gtt

! 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150
! V C P L N N F Y P R E A K V Q
gtg tgc ccg ctg aat aac ttc tat ccc aga gag gcc aaa gta cag

! 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165
! W K V D N A L Q S G N S Q E S
tgg aag gtg gat aac gcc ctc caa tcg ggt aac tcc cag gag agt

50 ! 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180
! V T E Q D N K D S T Y S L S S
gtc aca gag cag gac aac aag gac agc acc tac agc ctc agc agc


```

17 18 19 20 21 22
A Q P A M A
5'-ctg tct gaa cG GCC cag ccG GCC atg gcc 29
3'-gac aga ctt gc cgg gtc cgg cgg tac cgg
Scab.....SfiI.....
NcoI....
FR1(DP47/V3-23)-----
23 24 25 26 27 28 29 30
E V Q L L E S G
gaa|gtt|CAA|TTG|tta|gag|tct|ggg| 53
ctt|caa|gtt|aac|aat|ctc|aga|cca|
|MfeI |
-----FR1-----
31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
G G L V Q P G G S L R L S C A
|ggc|ggg|ctt|gtt|cag|cct|ggg|ggg|tct|tta|cgt|ctt|tct|tgc|gct| 98
|ccg|cca|gaa|caa|gtc|gga|cca|cca|aga|aat|gca|gaa|aga|acg|cga|
Sites to be varied--> *** *** ***
---FR1----->|...CDR1.....|---FR2---
46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
A S G F T F S S Y A M S W V R
|gct|TCC|GGA|ttc|act|ttc|tct|TCG|TAC|Gct|atg|tct|tgg|gtt|cgC| 143
|cga|agg|cct|aag|tga|aag|aga|agc|atg|cga|tac|aga|acc|caa|gcg|
|BspEI | |BsiWI| |BstXI.
Sites to be varies--> *** *** ***
---FR2----->|...CDR2.....
61 62 63 64 65 66 67 68 69 70 71 72 73 74 75
Q A P G K G L E W V S A I S G
|CAa|gct|ccT|GGt|aaa|ggg|ttg|gag|tgg|gtt|tct|gct|atc|tct|ggg| 188
|gtt|cga|gga|cca|ttt|cca|aac|ctc|acc|caa|aga|cga|tag|aga|cca|
...BstXI |
*** ***
....CDR2.....|---FR3---
76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
S G G S T Y Y A D S V K G R F
|tct|ggg|ggc|agt|act|tac|tat|gct|gac|tcc|gtt|aaa|ggg|cgc|ttc| 233
|aga|cca|ccg|tca|tga|atg|ata|cga|ctg|agg|caa|ttt|cca|gcg|aag|
-----FR3-----
91 92 93 94 95 96 97 98 99 100 101 102 103 104 105
T I S R D N S K N T L Y L Q M
|act|atc|TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg| 278
|tga|tag|aga|tct|ctg|ttg|aga|ttc|tta|tga|gag|atg|aac|gtc|tac|
|XbaI |
---FR3----->|
106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
N S L R A E D T A V Y C A K
|aac|agC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|tgc|gct|aaa| 323
|ttg|tcg|aat|tcc|cga|ctc|ctg|tga|cgt|cag|atg|ata|acg|cga|ttt|

```

```

!      |AflII|      |PstI|
!
!      .....CDR3.....|---FR4-----
!      121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
5      !      D Y E G T G Y A F D I W G Q G
!      |gac|tat|gaa|ggg|act|ggg|tat|gct|ttc|gaC|ATA|TGg|ggg|caa|ggg| 368
!      |ctg|ata|ctt|cca|tga|cca|ata|cga|aag|ctg|tat|acc|cca|gtt|cca|
!      |NdeI|
!
!      -----FR4----->|
10     !      136 137 138 139 140 141 142
!      !      T M V T V S S
!      |act|atG|GTC|ACC|gtc|tct|agt- 389
!      |tga|tac|cag|tgg|cag|aga|tca-
15     !      |BstEII|
!
!      143 144 145 146 147 148 149 150 151 152
!      !      A S T K G P S V F P
!      gcc tcc acc aaG GGC CcA tgc GTC TTC ccc-3' 419
20     !      cgg agg tgg ttc ccg ggt agc cag aag ggg-5'
!      Bsp120I. BbsI...(2/2)
!      ApaI....
!
!      (SFPRMET) 5'-ctg tct gaa cG GCC cag ccG-3'
!      (TOPFR1A) 5'-ctg tct gaa cG GCC cag ccG GCC atg gcc-
25     !      gaa|gtt|CAA|TTG|tta|gag|tct|ggg|-
!      |ggc|ggg|ctt|gtt|cag|cct|ggg|ggg|tct|tta-3'
!      (BOTFR1B) 3'-caa|gtc|gga|cca|cca|aga|aat|gca|gaa|aga|acg|cga|-
!      |cga|agg|cct|aag|tga|aag-5' ! bottom strand
!      (BOTFR2) 3'-acc|caa|gag|-
30     !      |gtt|cga|gga|cca|ttt|cca|aac|ctc|acc|caa|aga|-5' ! bottom strand
!      (BOTFR3) 3'- a|cga|ctg|agg|caa|ttt|cca|gag|aag|-
!      |tga|tag|aga|tct|ctg|ttg|aga|ttc|tta|tga|gag|atg|aac|gtc|tac|-
!      |ttg|tcg|aat|tcc|cga|ctc|ctg|tga-5'
!      (F06) 5'-gC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|tgc|gct|aaa|-
35     !      |gac|tat|gaa|ggg|act|ggg|tat|gct|ttc|gaC|ATA|TGg|ggg|c-3'
!      (BOTFR4) 3'-cga|aag|ctg|tat|acc|cca|gtt|cca|-
!      |tga|tac|cag|tgg|cag|aga|tca-
!      cgg agg tgg ttc ccg ggt agc cag aag ggg-5' ! bottom strand
!      (BOTPRCPRIM) 3'-gg ttc ccg ggt agc cag aag ggg-5'
40     !
!      CDR1 diversity
!
!      (ON-vgC1) 5'-|gct|TCC|GGA|ttc|act|ttc|tct|<1>|TAC|<1>|atg|<1>|-
!      CDR1.....6859
45     !      |tgg|gtt|cgC|CAa|gct|ccT|GG-3'
!
!      |<1> stands for an equimolar mix of {ADEF GHIKLMNPQRSTVWY}; no C
!      (this is not a sequence)
!
!      CDR2 diversity
!
!      (ON-vgC2) 5'-ggg|ttg|gag|tgg|gtt|tct|<2>|atc|<2>|<3>|-
!      CDR2.....
!      |tct|ggg|ggc|<1>|act|<1>|tat|gct|gac|tcc|gtt|aaa|gg-3'
55     !      CDR2.....
!      |<1> is an equimolar mixture of {ADEF GHIKLMNPQRSTVWY}; no C
!      |<2> is an equimolar mixture of {YRWVGS}; no ACDEF GHIKLMNPQT

```

10045674 "1005674

! <3> is an equimolar mixture of {PS}; no ACDEFGHIKLMNQRTVWY

10045674.102501

Table 28: Stuffer used in VH

1	TCGCGAGCTT CAGATCTGTT TGCCTTTTGG TGGGTGGTG CAGATCGCGT TACGGAGATC
61	GACCGACTGC TTGAGCAAAA GCCACGCTTA ACTGCTGATC AGGCATGGGA TGTATTGCG
121	CAAAACCAAGTC GTCAGGATCT TAACCTGAGG CTTTTTTTAC CTACTCTGCA AGCAGCGACA
181	TCTGGTTTGA CACAGAGCGA TCCGCGTCGT CAGTTGGTAG AAACATTAAAC ACGTTGGGAT
241	GGCATCAATT TGCTTAATGA TGATGGTAAA ACCTGGCAGC AGCCAGGCTC TGCCATCCTG
301	AACGTTTGGC TGACCAAGTAT GTTGAAGCGT ACCGTAGTGG CTGCCGTACC TATGCCATTT
361	GATAAGTGGT ACAGCGCCAG TGGCTACGAA ACAACCCAGG ACGGCCCAAC TGGTTCGCTG
421	AATATAAGTG TTGGAGCAAA AATTTTGTAT GAGGCGGTGC AGGAGACAA ATCACCATC
481	CCACAGGCGG TTGATCTGTT TGCTGGGAAA CCACAGCAGG AGGTGTGTT GGCTGCGCTG
541	GAAGATAACCT GGGAGACTCT TTCCAAACGC TATGGCAATA ATGTAGTAA CTGGAACAACA
601	CCTGCAATGG CCTTAACGTT CCGGGCAAAT AATTTCTTTG GTGTACCGCA GGCCGCAAGC
661	GAAGAAACGC GTCATCAGGC GGAGTATCAA AACCGTGGA CAGAAAACGA TATGATTGTT
721	TTCTCACCAA CGACAAGCGA TCGTCTGTG CTGCTCTGG ATGTGTCGC ACCCGTCAG
781	AGTGGGTTTA TTGCTCCCGA TGGAACAGTT GATAAGCACT ATGAAGATCA GCTGAAAATG
841	TACGAAAATT TTGGCCGTAA GTCGCTCTGG TTAACGAAGC AGGATGTGGA GGCGCATAAG
901	GAGTCGCTCA GA

Table 29: DNA sequence of pCESS

! pCES5 6680 bases = pCes4 with stuffers in CDR1-2 and CDR3 2000.12.13

! Ngene = 6680

! Useful REs (cut MAnoLI fewer than 3 times) 2000.06.05

! Non-cutters

!Acc65I Ggtacc AfeI AGCgct AvrII Cctagg
!BsaBI GATNnnatc BsiWI Cgtacc BsmFI Nnnnnnnnnnnnnngtccc

10

!BstGI Tgtaca	BstAPI GCANNNNttgc	BstBI TTcgaa
!BstZ171GTAtac	BtrI CACgtg	Ecl136I GAGctc
!EcoRV GATatc	FseI GGCCGGcc	KpnI GGTACc

15

IPpuMI RGVwcy
ISaII CCGGg
ISgf GCGATgc
ISphI GCATGc
ISwal ATTTaat
PshAI GACNNmgtc SacI GAGCTc
SbfI CCTGCagg SexAI Accwgtt
SnaBI TACgta SphI Actagt
SseC387I CCTGCagg StuI AGGcct
XmaI Ccgggg

20

! cutters

! Enzymes that cut more than 3 times.

!AlwNI CAGNNNctg 5

!Bs9I ct9cac 4

!BsrFI Rccggy

!Earl CTCCTCNnnn 4

!FauI nNNNNNGCGG 10

30

! Enzymes that cut from 1 to 3 times.

!EcoO109I RGgncy 3 7 2636 4208

!BssSI Ctctg!g

1703	1	Cacgag
------	---	--------

!BspHI Tcatga	3	43	148	1156
---------------	---	----	-----	------

•

	!AatII GACGTc	1	65
	!BciVI GTATCCNNNNNN	2	140 1667
	!Eco57I CTGAAG	1	301
5	!-" ctcag	2	1349
	!AvaI Cycgrg	3	319 2347 6137
	!BsiHKA! GWGCWc	3	401 2321 4245
	!HgiAI GWGCWc	3	401 2321 4245
	!BclI gcannnnntcg	1	461
	!ScaI AGTact	1	505
10	!PvuI CGATcg	3	616 3598 5926
	!FspI TGCgca	2	763 5946
	!BglI GCCNNNNNnggc	3	864 2771 5952
	!BpmI CTGGAG	1	898
	!-" ctcag	1	4413
15	!BsaI GGTC:TCNnnn	1	916
	!AhdI GACNNNngtc	1	983
	!EamI 105I GACNNNngtc	1	983
	!DrdI GACNNNNNngtc	3	1768 6197 6579
	!SapI gaagagc	1	1998
20	!PvuII CAGctg	3	2054 3689 5896
	!PflMI CCANNNNNntgg	3	2233 3943 3991
	!HindIII Aagctt	1	2235
	!ApaLI Gtgcac	1	2321
	!BspMI Nnnnnnnngcaggt	1	2328
25	!-" ACCTGCNNNNn	2	3460
	!PstI CTGCAG	1	2335
	!AclI GTmkac	2	2341 2611
	!HincII GTYrac	2	2341 3730
	!SalI Gtcgac	1	2341
30	!TliI Ctcag	1	2347
	!XhoI Ctcag	1	2347
	!BbsI gtcttc	2	2383 4219
	!BplI GCtnagc	1	2580
	!EspI GCtnagc	1	2580
35	!SgrAI CRccgyg	1	2648
	!AclI Accggt	2	2649 4302

5 !AclI GGcgcc 1 2689
 !BssHII Gcgcc 1 2690
 !SfiI GGCCNNNNngcc 1 2770
 !NaeI GCCggc 2 2776 6349
 !NgoMIV Gcgcc 2 2776 6349
 !BtgI Ccrygg 3 2781 3553 5712
 !DsaI Ccrygg 3 2781 3553 5712
 !NcoI Ccatgg 1 2781
 !StyI Ccwvgg 3 2781 4205 4472
 !MfeI Caatg 1 2795
 !BspEI Tccgga 1 2861
 !BglII Agatct 1 2872
 !BclI Tgatca 1 2956
 !Bsu36I CCtnagg 3 3004 4143 4373
 15 !XcmI CCANNNNNnnntgg 1 3215
 !MluI Acgct 1 3527
 !HpaI GTTaac 1 3730
 !XbaI Tctaga 1 3767
 !
 20 !AflII Cttaag 1 3811
 !BsmI NGcattc 1 3821
 !"- GAATGCN 1 4695
 !RsrII CGgwccg 1 3827
 !NheI Gctagc 1 4166
 25 !BstEII Ggtnac 1 4182
 !BsmBI CGTCTCnmmn 2 4188 6625
 !"- Nmmnnagacg 1 6673
 !ApaI GGCCc 1 4209
 !BanII GRGCYc 3 4209 4492 6319
 30 !Bsp120I Gggccc 1 4209
 !PspOMI Gggccc 1 4209
 !BseRI NNnnnnnnctctc 1 4226
 !"- GAGGAGNNNNNNNNN 1 4957
 !EcoNI CCTNNnnnagg 1 4278
 35 !PflFI GACNngtc 1 4308
 !Thl111I GACNngtc 1 4308

```

!KasI Ggcc 2 4327 5967
!BstXl CCANNNNNntgg 1 4415
!NotI GCggcgc 1 4507
5 !EagI Cggcgc 1 4508
!BamHI Ggatcc 1 5169
!BspDI ATcgat 1 5476
!NdeI CAtag 1 5672
!EcoRI Gaattc 1 5806
10 !PstI TTAaa 1 6118
!DraIII CACNNNGtg 1 6243
!BsaAI YACgr 1 6246
!
! 1 gacgaaggg cTCGTGata cgcctattt tataggtaa tgcataata ataatggtt
! BssSI.(1/2)
15 ! 61 ctaGACGTC aggtggcact ttccgggaa atg'gcgcgg aaccctatt tgttatttt
! AatII.
! 121 tctaaataca ttcaaatatG TATCCgctca tgagacaata accctgataa atgcttcaat
! BclVI.(1 of 2)
! 181 aatatigaaa aaggagagt
20 ! Base # 201 to 1061 = ApR gene from pUC119 with some RE sites removed
!
! 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
! M S I Q H F R V A L I P F F A
25 ! 201 atg agt att caa cat ttc cgt gtc gcc ctt att ccc ttt ttt gcg
!
! 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
! A F C L P V F A H P E T L V K
! 246 gca ttt 'gc ctt cct gtt ttt gct cac cca gaa acg ctg gtg aaa
!
30 ! 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
! V K D A E D Q L G A R V G Y I
! 291 gta aaa gat gct gaa gat cag tgg ggt gcc cga gta ggt tac atc
!
! 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
! E L D L N S G K I L E S F R P
35 ! 336 gaa ctg gat ctc aac agc ggt aag atc ctt gag agt ttt cgc ccc

```

```

5 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75
   E E R F P M M S T F K V L L C
381 gaa gaa cgt ttt cca atg atg agc act ttt aaa gtt ctg cta tgt
   76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
   G A V L S R I D A G Q E Q L G
426 ggc ggc gta tta tcc cgt att gac gcc ggg caa gaG CAa ctc ggT
   Bgl.....
10 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105
   R R I H Y S Q N D L V E Y S P
   CGc cgc ata cac tat tct cag aat gac ttg gtt gAG TAC Tca cca
471 ...Bgl.....
   Seal....
15 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
   V T E K H L T D G M T V R E L
516 gtc aca gaa aag cat ctt acg gat ggc atg aca gta aga gaa tta
   121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
   C S A A I T M S D N T A A N L
561 tgc agt gct gcc ata acc atg gat aac act gcg gcc aac tta
   136 137 138 139 140 141 142 143 144 145 146 147 148 149 150
   L L T T I G G P K E L T A F L
606 ctt ctg aca aCGATC Gga gga ccg aag gag cta acc gct ttt ttg
   PvuI.... (1/2)
   151 152 153 154 155 156 157 158 159 160 161 162 163 164 165
   H N M G D H V T R L D R W E P
651 cac aac atg ggg gat cat gta act cgc ctt cgt tgg gaa ccg
   166 167 168 169 170 171 172 173 174 175 176 177 178 179 180
   E L N E A I P N D E R D T T M
696 gag ctg aat gaa gcc ata cca aac gac gag cgt gac acc acg atg

```

181 182 183 184 185 186 187 188 189 190 191 192 193 194 195
P V A M A T T L R K L L T G E
741 cct gta GCA ATG gca aca aeg tTG CGC Aaa cta tta act ggc gaa
BsrDI...(1/2) Fspl.... (1/2)
5
196 197 198 199 200 201 202 203 204 205 206 207 208 209 210
L L T L A S R Q Q L I D W M E
786 cta ctt act cta gct toc cgg caa caa tta ata gac tgg atg gag
211 212 213 214 215 216 217 218 219 220 221 222 223 224 225
A D K V A G P L L R S A L P A
831 gcg gat aaa gtt gca gga cca cti cig cgc tgc gcc ctt ccg gct
226 227 228 229 230 231 232 233 234 235 236 237 238 239 240
G W F I A D K S G A G E R G S
15 876 ggc tgg tt att gct gat aaa tCT GGA Gcc ggt gag cgt gGG TCT
Bpml...(1/2) Bsal....
241 242 243 244 245 246 247 248 249 250 251 252 253 254 255
R G I I A A L G P D G K P S R
20 921 Cgc ggt atC ATT GCa gca ctg ggg cca gat ggt aag ccc tcc cgt
Bsal..... BsrDI...(2/2)
256 257 258 259 260 261 262 263 264 265 266 267 268 269 270
I V V I Y T T G S Q A T M D E
25 966 atc gta gtt atc tac acG ACg ggg aGT Cag gca act atg gat gaa
AhdI.....
271 272 273 274 275 276 277 278 279 280 281 282 283 284 285
R N R Q I A E I G A S L I K H
30 1011 cga aut aga cag atc gct gag ata ggt gcc tca ctg att aag cat
286 287
W
35 1056 tgg taa
1062 cgtcagac caagttact

1081 catalact tagattgat taaacctic attttaatt taaaggatc taggtgaaga
 1141 tctttttga taatcicag accaaaacc cttaacgtga gttttgttc cactgagcgt
 1201 cagacccegt agaaaagatc aaagatctt cttagatcc ttttttctg cegtaact
 1261 gctgttga acaaaaaaaa ccacgctac cagcgttgt tgtttccg gataagagc
 1321 taccactt tttccgaag gtaacttgt tccagagagc gcagatacca aalactgtcc
 1381 tttagtga ggcgtgtta ggcaccact tcaagaact tgtgacaccc cctataacc
 1441 tgccttgt aatcctgtta ccagtggtc ctgccagtg ccataagtcg tgcctaccg
 1501 ggttgact aagacgatag ttaccgata aggcgcagc gtcggcgtga acggggggt
 1561 cgtgataca gccagcttg gagcgaacga cctacacga acgagatac ctacagcgtg
 1621 agcattgaga aagcgccacg ctccgaag ggagaagc ggacagGTAT CCggttaagc
 ! BclVI.. (2 of 2)
 1681 gcagggtcgg aacaggagag cgCACGAGgg agctccagg eggaaacgcc tggatcttt
 ! BssSI (2/2)
 1741 atagtcctgt cagggttcgc cactctgac ttgagcgcg atttttga tgcctgtcag
 1801 gggggcggag cctatgaaa aacccagca acgggctt ttacgggtc ctgaccttt
 1861 gctggcctt tctcACATG Tctttctg cgtatccc tgaattctg gataacgta
 ! PciI...
 1921 ttacgcctt tgaftgagct galaccgtc gcgcagcgc aacgacggag cgcagcgagt
 1981 cagttagcga ggaagcgGAA GAGCgcca taccgaaacc gccctcccc gcgcgttggc
 ! Sapl....
 2041 cgattcatta atGCAGCTGg cagacaggt ttccgactg gaaagcgggc agtgagcgca
 ! PvuII (1/3)
 2101 acgcaatTAA TGTgagttag ctactcatt aggcacccca ggcTTTACAc ttatgcttc
 ! ..35... Plac
 2161 cggctcgat gttgtgtga attgtgagc gataacaatt tcacaCAGGA AACAGCTATG
 ! M13Rev_seq_primer
 2221 ACcatgatta cgCCAAGCTT TGAgcctt ttgttgaga tttaaac
 ! PflMI.....
 ! Hind3.
 30 ! signal::linker::CLight
 !
 ! 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
 ! fM K L L F A I P L V V P F Y
 2269 gtg aaa aaa tta tta ttc gca att cct tta gtt gtt cct ttc tat
 35 !
 ! Linker..... End of FR4

```

! 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
! S H S A Q V Q L Q V D L E I K
! 2314 tct cac aGT GCA Cag gtc caa CTG CAG GTC GAC CTC GAG atc aaa
! ApalI..... PstI... XhoI...
! 5 BspMI...
! SalI...
! AclI...(1/2)
! HincII(1/2)
!
! 10 Vlight domains could be cloned in as ApalI-XhoI fragments.
! VL-CL(kappa) segments can be cloned in as ApalI-AscI fragments. <-----
!
! Ckappa-----
! 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
! R G T V A A P S V F I F P P S
! 2359 cgt gga act gfg gct gca cca tct GTC TTC atc ttc ccg cca tct
! BbsI...(1/2)
!
! 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
! D E Q L K S G T A S V V C L L
! 2404 gat gag cag ttg aaa tct gga act gcc tct gtt gfg tgc cfg cfg
!
! 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75
! N N F Y P R E A K V Q W K V D
! 2449 aat aac ttc tat ccc aga gag gcc aaa gla cag tgg aag gfg gat
!
! 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
! N A L Q S G N S Q E S V T E Q
! 2494 aac gcc ctc caa tgg ggt aac tcc cag gag agt gtc aca gag cag
!
! 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105
! D S K D S T Y S L S S T L T L
! 2539 gac agc aag gac agc acc tac agc ctc agc acc ctc acc ctc acG CTG
! Espl...
!
! 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120

```

- 228 -

```

!   S K A D Y E K H K V Y A C E V
2584 AGC aaa gag tac tac gag aaa cac aaa GTC TAC gcc tgc gaa gtc
!   ...Espl....
!           Accl...(2/2)
5   ! 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
!   T H Q G L S S P V T K S F N R
2629 acc cat cag ggc ctc agt tcA CCG GTg aca aag agc ttc aac agg
!           AgeI...(1/2)
10  ! 136 137 138 139 140
!   G E C . .
2674 gga gag tgt taa taa GG CGCGCCaatt
!           Ascl.....
!           BssHII.
15  ! 2701 ctatttcaag gagacagtc a ta
!
!   PeIB::3-23(stuffed)::CH1::III fusion gene
20  ! 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
!   M K Y L L P T A A A G L L L L
2723 atg aaa tac cta ttg cct acg gca gcc gct gga ttg tta tta ctc
!
!
25  !
!   16 17 18 19 20 21 22
!   A A Q P A M A
2768 gcG GCC cag ccG GCC atg gcc
!   SfiI.....
30  !   NgoMIV.(1/2)
!   NcoI....
!
!   FRI(DP47/V3-23)-----
35  ! 23 24 25 26 27 28 29 30
!   E V Q L L E S G
!   gaa|gtt|CAA|TTG|tta|gag|tct|gg|
2789

```

```

!      | MfeI |
!      -----FR1-----
!      31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
5      G G L V Q P G S L R L S C A
!      2813 |ggc|gg|ctt|gt|cag|cc|lgg|lgt|ct|ta|lgt|ct|ct|lgt|gct|
!      -----FR1-----
!      46 47 48
10     A S G
!      2858 |gct|TCC|GGA|
!      | BspEI |
!
!      Stuffer for CDR1, FR2, and CDR2----->
15     There are no stop codons in this stuffer.
!      gcttcAGATC Tgtttgcct
!      BglII..
!      2867
!      2887 ttgtgggt ggtgcagatc gcgttacgga gatcgaccga ctgcttgagc aaaaagccagc
20     2947 cttaacgtcT GATCAggcat gggatgttat tggccaaacc agtcgtcagg atctaacct
!      Bcl...
!      3007 gaggctttt ttacctactc tgcacgcagc gacatctggt ttgacacaga ggcattccgcg
!      3067 tctgcagtgt gtagaaacat taacacgttg ggaaggcatc aatttgctta atgatgatgg
!      3127 taaaaccctg cagcagccag gctctgccat cctgaacgtt 'ggcgtgacca gta'gtgaa
!      3187 gcgtaccgtta gggcgcgcg tactatgCC Attgataag TGGtiacagcg ccagtgaggc
25     | XcmI.....
!      3247 cgaacaacc caggccggcc caactggttc gc'gaatata aglgtggag caaaaatttt
!      3307 glataggcg gtgcaggagg acaaatcacc aatcccacag gcggtgalc lgttgcgg
!      3367 gaaaccacag caggaggttg lgttggcgc gctggaagat acctgggaga ctcttccaa
!      3427 acgtatggc aataatgtga gtaactggaa aacacctgca atggccitaa cgttcgggc
30     3487 aaahaattic ttgggtlac cgcaggccgc agcgggaagaa ACGCGTcatc agcggaggla
!      | MluI..
!      3547 tcaaaacgtt ggaacagaaa acgataatgat tgttttctca ccaagacaa ggcattgcc
!      3607 tgtgcttgcg tgggatgagg tcgcaccggg tcagagtggg ttattgctc ccgatggaac
!      3667 agtgaataag cactatgaag atcagctgaa aatgtacgaa aattttggc gtaangtgc
35     | PvuII.
!      3727 ctgGTTAACg aagcaggatg tggaggcgca taaggagtcg

```



```

!      K S T S G G T A A L G C L V K
4243  aag agc acc tct ggg ggc aca gcg gcc ctg ggc tgc ctg gtc aag
!
!      166 167 168 169 170 171 172 173 174 175 176 177 178 179 180
5      D Y F P E P V T V S W N S G A
!      4288  gac tac ttc ccc gaa cgg g'g acg g'g tgg aac tca ggc gcc
!
!      181 182 183 184 185 186 187 188 189 190 191 192 193 194 195
!      L T S G V H T F P A V L Q S S
10     4333  ctg acc agc ggc gtc cac acc ttc cgg gct cta cag tcc tca
!
!      196 197 198 199 200 201 202 203 204 205 206 207 208 209 210
!      G L Y S L S S V V T V P S S S
!      4378  gga ctc tac tcc ctc agc agc gta g'g acc g'g ccc tcc agc agc
15     !
!      211 212 213 214 215 216 217 218 219 220 221 222 223 224 225
!      L G T Q T Y I C N V N H K P S
!      4423  t'g ggc acc cag acc tac atc tgc aac g'g aat cac aag ccc agc
!
!      226 227 228 229 230 231 232 233 234 235 236 237 238
20     !      N T K V D K K V E P K S C
!      4468  aac a'c aag g'g gac aaG AAA GTT GAG CCC AAA TCT TGT
!      ON-TQHCforw.....
!
!      Poly His linker
!      139 140 141 142 143 144 145 146 147 148 149 150
!      A A A H H H H H G A A
!      4507  GCG GCC GCa cat cat cat cac ggg gcc gca
!      Notl.....
!      Eagl....
30     !
!      151 152 153 154 155 156 157 158 159 160 161 162 163 164 165
!      E Q K L I S E D L N G A A
!      4543  gaa caa aaa ctc atc tca gaa gag gat ctg aat ggg gcc gca tag
35     !
!      Mature III----->...

```

5 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180
 T V E S C L A K P H T E N S F
 4588 act gtt gaa agt tgt tta gca aaa cct cat aca gaa aat tca ttt
 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195
 T N V W K D D K T L D R Y A N
 4633 act aac gtc tgg aaa gac gac aaa act tta gat cgt tac gct aac
 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210
 Y E G C L W N A T G V V C T
 4678 tat gag ggc tgt ctg tgg AAT GCt aca ggc gtt gtg gtt tgt act
 BsmI....
 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225
 G D E T Q C Y G T W V P I G L
 4723 ggt gac gaa act cag tgt tac ggt aca tgg gtt cct att ggg ctt
 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240
 A I P E N E G G S E G G S
 4768 gct atc cct gaa aat gag ggt ggt ggc tct gag ggt ggc ggt tct
 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255
 E G G S E G G T K P P E Y
 4813 gag ggt ggc tct gag ggt ggc ggt act aaa cct cct gag tac
 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270
 G D T P I P G Y T Y I N P L D
 4858 ggt gat aca cct att cgg ggc tat act atc aac cct ctc gac
 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285
 G T Y P P G T E Q N P A N P N
 4903 ggc act tat cgg cct ggt act gag caa aac ccc gct aat cct aat

! 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300
 ! P S L E S Q P L N T F M F Q
 4948 cct tct GAG GAG tct cag cct ctt aat act ttc atg ttt cag
 ! BseRI..(2/2)
 5 !
 ! 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315
 ! N N R F R N R Q G A L T V Y T
 4993 aat aat agg ttc cga aat agg cag ggt gca tta act gtt tat acg
 !
 10 ! 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330
 ! G T V T Q G T D P V K T Y Y Q
 5038 ggc act gtt act caa ggc act gac ccc gtt aaa act tat tac cag
 !
 15 ! 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345
 ! Y T P V S S K A M Y D A Y W N
 5083 lac act cct gta tca aaa gcc alg tat gac gct tac tgg aac
 !
 20 ! 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360
 ! G K F R D C A F H S G F N E D
 5128 ggt aaa ttc aga gac tgc gct ttc cat tct ggc ttt aat gaG GAT
 ! BamHI..
 ! 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375
 ! P F V C E Y Q G Q S S D L P Q
 5173 CcA ttc gtt tgt gaa tat caa ggc caa tgc tct gAC CTG Cct caa
 ! BamHI..
 ! BspMI...(2/2)
 ! 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390
 ! P P V N A G G S G G S G G
 5218 cct cct gtc aat gct ggc ggc tct ggt ggt tct ggt ggc
 !
 ! 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405
 ! G S E G G S E G G S E G G
 5263 ggc tct gag ggt ggc tct gag ggt ggc tct gag ggt ggc
 !
 35 ! 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420


```

!   G S E G G S G G S G S G D
5308 ggc tct gag ggt ggc tcc ggt ggc ggc tcc ggt ggt gat
!
!   421 422 423 424 425 426 427 428 429 430 431 432 433 434 435
!   F D Y E K M A N A N K G A M T
5353 ttt gat tat gaa aaa atg gca aac gct aat aag ggg gct atg acc
!
!   436 437 438 439 440 441 442 443 444 445 446 447 448 449 450
!   E N A D E N A L Q S D A K G K
5398 gaa aat gcc gat gaa aac gcg cia cag tct gac gct aaa ggc aaa
!
!   451 452 453 454 455 456 457 458 459 460 461 462 463 464 465
!   L D S V A T D Y G A A I D G F
5443 ctt gat tct gtc gct act gat tac ggt gct gct ATC GAT ggt ttc
!   BspDI.
!
!   466 467 468 469 470 471 472 473 474 475 476 477 478 479 480
!   I G D V S G L A N G N G A T G
5488 att ggt gac gtt tcc ggc ctt gct aat ggt aat ggt gct act ggt
!
!   481 482 483 484 485 486 487 488 489 490 491 492 493 494 495
!   D F A G S N S Q M A Q V G D G
5533 gat ttt gct ggc tct aat tcc caa atg gct caa gtc ggt gac ggt
!
!   496 497 498 499 500 501 502 503 504 505 506 507 508 509 510
!   D N S P L M N N F R Q Y L P S
5578 gat aat tca cct tta atg aat aat ttc cgt caa tat tta cct tct
!
!   511 512 513 514 515 516 517 518 519 520 521 522 523 524 525
!   L P Q S V E C R P Y V F G A G
5623 tlg cct cag tgg gtt gaa tgt cgc cct tat gtc ttt ggc gct ggt
!
!   526 527 528 529 530 531 532 533 534 535 536 537 538 539 540
!   K P Y E F S I D C D K I N L F
5668 aaa cCA TAT Gaa ttt att tgt gac aaa ata aac tta ttc
!   NdeI...

```

541 542 543 544 545 546 547 548 549 550 551 552 553 554 555
R G V F A F L L Y V A T F M Y
5713 cgt ggt gtc ttt ggc ttt ctt tta tat gtc acc ttt atg tat
556 557 558 559 560 561 562 563 564 565 566 567 568 569 570
V F S T F A N I L R N K E S
5758 gta ttt teg acg ttt gct aac ala clg cgt aat aag gag tct taa
5803 taa GAATTC
EcoRI
5812 actggcgt cgttttaca cgtcgtgact gggaataccc tgggttacc caactaatc
5871 gcttgacgc acatccccc ttgccagct gggttaatag cgaagaggcc cgcacCGATC
PvuII
5931 Gcccttccca acagTGGCG Agcctgaatg ggaatGGCG CCtgatcgg tatttctcc
...PvuII... (3/3) FspI... (2/2) KspI... (2/2)
5991 ttacgcatt gtgcgttatt tcacacgca tataaatgt aaacgttaatt atttgttaa
6051 aaatcggtt aaatttgtt taatcagct catttttaa ccaataggcc gaaatcggca
6111 aaatccTTA TAAataana gaatagccg agatagcgtt ggtgtgtt ccagtttgga
PstI
6171 acaagatcc actataaag aacgtggact ccaacgtcaa agggcgaaaa accgtctac
6231 agggcgatgg ccCAcIacGT Gaaccatcac ccaaatcaag tttttgggg tggagggcc
DraIII...
6291 gtaagcact aaatcgaac cctaaaggga gcccgcgatt tagagcttga cgggggaaaGC
NgoMIV..
6351 CGGCGaacgt ggcgagaaaag gaagggaaga aagcgaaaag agcgggcgct agggcgctgg
..NgoMIV (2/2)
6411 caagtgtagc agtcaagctg cgcgttaacca ccaacccgc cgcgctaat gcgcgctac
6471 agggcgctga ctatgttgc ttgacgggt gcagctcag tacaatcgc tctgatgcc
6531 catagtaag ccaagcccca caccgccca caccgccga cggcgcttgc
6591 tgcctcggc atcccttac agacaagctg tgaccgtc cggcgagctc atgtgtcaga
6651 ggttttacc gtcattaccg aaacgcgga

All sequences are 5' to 3'.

5

10

15

20

25

30

35

40

g A T A g
19 20 21 22 23

Table 31: Bridge/Extender Oligonucleotides

	ON_Lam1aB7(rc)GTGCTGACTCAGCCACCCTC.	20
	ON_Lam2aB7(rc)GCCCTGACTCAGCTGCCTC.	20
5	ON_Lam31B7(rc)GAGCTGACTCAGG.ACCCTGC	20
	ON_Lam3rB7(rc)GAGCTGACTCAGCCACCCTC.	20
	ON_LamHf1cBrg(rc)	CCTCGACAGCGAAGTGCACAGAGCGTCTTGACTCAGCC.....	38
	ON_LamHf1cExt	CCTCGACAGCGAAGTGCACAGAGCGTCTTG.....	30
	ON_LamHf2b2Brg(rc)	CCTCGACAGCGAAGTGCACAGAGCGCTTTGACTCAGCC.....	38
10	ON_LamHf2b2Ext	CCTCGACAGCGAAGTGCACAGAGCGCTTTG.....	30
	ON_LamHf2dBrg(rc)	CCTCGACAGCTAAGTGCACAGAGCGCTTTGACTCAGCC.....	38
	ON_LamHf2dExt	CCTCGACAGCGAAGTGCACAGAGCGCTTTG.....	30
	ON_LamHf31Brg(rc)	CCTCGACAGCGAAGTGCACAGAGCGAATTGACTCAGCC.....	38
	ON_LamHf31Ext	CCTCGACAGCGAAGTGCACAGAGCGAATTG.....	30
15	ON_LamHf3rBrg(rc)	CCTCGACAGCGAAGTGCACAGTACGAATTGACTCAGCC.....	38
	ON_LamHf3rExt	CCTCGACAGCGAAGTGCACAGTACGAATTG.....	30
	ON_lamPlePCR	CCTCGACAGCGAAGTGCACAG.....	21
	Consensus		

1005674 "1005674

Table 32: Oligonucleotides used to make SSDNA locally double-stranded

Adapters (8)	
5	H43HF3.1-02#1 5'-cc gtg tat tac tgt gcg aga g-3'
	H43.77.97.1-03#2 5'-ct gtg tat tac tgt gcg aga g-3'
	H43.77.97.323#22 5'-cc gta tat tac tgt gcg aaa g-3'
	H43.77.97.330#23 5'-ct gtg tat tac tgt gcg aaa g-3'
	H43.77.97.439#44 5'-ct gtg tat tac tgt gcg aga c-3'
10	H43.77.97.551#48 5'-cc atg tat tac tgt gcg aga c-3'

10045674.102501

Table 33: Bridge/extender pairs

Bridges (2)

H43.XABr1

5 5'ggtagtagtgATCTAGtgacaactctaagaatactctctacttgcagatgaacagC
TTtAGggctgaggacaCTGCAGtctactattgtgcgaga-3'

H43.XABr2

10 5'ggtagtagtgATCTAGtgacaactctaagaatactctctacttgcagatgaacagC
TTtAGggctgaggacaCTGCAGtctactattgtgcgaaa-3'

Extender

H43.XAExt

15 5'ATAgTAgAcTgcAgTgTccTcAgcccTTAAgcTgTTcATcTgcAAgTAgAgAgTA
TTcTTAgAgTTgTcTcTAgATcAcTAcAcc-3'

10045674.102501

Table 34: PCR primers

Primers

H43.XAPCR2	gactgggTgTAgTgATcTAg
5 Hucmnest	cttttctttgttgccgttggggtg

100456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100

Table 35: PCR program for amplification of heavy chain CDR3 DNA

5	95 degrees C	5 minutes	
	95 degrees C	20 seconds	
	60 degrees C	30 seconds	repeat 20x
	72 degrees C	1 minute	
10	72 degrees C	7 minutes	
	4 degrees C	hold	

Reagents (100 ul reaction):

	Template	5ul ligation mix
15	10x PCR buffer	1x
	Taq	5U
	dNTPs	200 uM each
	MgCl ₂	2mM
	H43.XAPCR2-biotin	400 nM
20	Hucmnest	200 nM

1005674-1005674

! Table 36: Annotated sequence of CJR DY3F7 (CJR-A05) 10251 bases

! Non-cutters					
5	!BclI Tgatca	BsiWI Cgtacg	BssSI Cacgag		
	!BstZ17I GTAtac	BtrI CACgtg	EcoRV GATatc		
	!FseI GGCCGGcc	HpaI GTTaaC	MluI Acgcgt		
	!PmeI GTTTaaac	PmlI CACgtg	PpuMI RGgwccy		
	!RsrII CGgwccg	SapI GCTCTTC	SexAI AccwggT		
10	!SgfI GCGATcgC	SgrAI CRccggyg	SphI GCATGc		
	!StuI AGGcct	XmaI Cccggg			
! cutters					
15	! Enzymes that cut from 1 to 4 times and other features				
	!End of genes II and X				
			829		
	!Start gene V				
			843		
	!BsrGI Tgtaca	1	1021		
20	!BspMI Nnnnnnnnnngcaggt	3	1104	5997	9183
	!-"- ACCTGCNNNNn	1	2281		
	!End of gene V				
			1106		
	!Start gene VII				
			1108		
	!BsaBI GATNNnnatc	2	1149	3967	
25	!Start gene IX		1208		
	!End gene VII				
			1211		
	!SnaBI TACgta	2	1268	7133	
	!BspHI Tcatga	3	1299	6085	7093
	!Start gene VIII				
			1301		
30	!End gene IX		1304		
	!End gene VIII				
			1522		
	!Start gene III				
			1578		
	!EagI Cggccg	2	1630	8905	
	!XbaI Tctaga	2	1643	8436	
35	!KasI Ggcgcc	4	1650	8724	9039 9120
	!BsmI GAATGCN	2	1769	9065	
	!BseRI GAGGAGNNNNNNNNNN	2	2031	8516	
	!-"- NNNnnnnnnnctcctc	2	7603	8623	
	!AlwNI CAGNNNctg	3	2210	8072	8182
40	!BspDI ATcgat	2	2520	9883	
	!NdeI CATatg	3	2716	3796	9847
	!End gene III				
			2846		
	!Start gene VI				
			2848		
	!AfeI AGCgct	1	3032		
45	!End gene VI		3187		
	!Start gene I				
			3189		
	!EarI CTCTTCNnnn	2	4067	9274	
	!-"- Nnnnngaagag	2	6126	8953	
	!PacI TTAATtaa	1	4125		
50	!Start gene IV		4213		
	!End gene I				
			4235		
	!BsmFI Nnnnnnnnnnnnnngtccc	2	5068	9515	
	!MscI TGGcca	3	5073	7597	9160
	!PsiI TTAtaa	2	5349	5837	
55	!End gene IV		5493		
	!Start ori				
			5494		
	!NgoMIV Gccggc	3	5606	8213	9315
	!BanII GRGCYc	4	5636	8080	8606 8889
	!DraIII CACNNNgtg	1	5709		
60	!DrdI GACNNNNngtc	1	5752		
	!AvaI Cycgrg	2	5818	7240	
	!PvuII CAGctg	1	5953		

10045674.1025001

	!BsmBI CGTCTCNnnnn	3	5964	8585	9271
	!End ori region		5993		
	!BamHI Ggatcc	1	5994		
5	!HindIII Aagctt	3	6000	7147	7384
	!BciVI GTATCCNNNNNN	1	6077		
	!Start bla		6138		
	!Eco57I CTGAAG	2	6238	7716	
	!SpeI Actagt	1	6257		
10	!BcgI gcannnnnnntcg	1	6398		
	!ScaI AGTact	1	6442		
	!PvuI CGATcg	1	6553		
	!FspI TGCgca	1	6700		
	!BglI GCCNNNNnggc	3	6801	8208	8976
	!BsaI GGTCTCNnnnn	1	6853		
15	!AhdI GACNNNngtc	1	6920		
	!Eam1105I GACNNNngtc	1	6920		
	!End bla		6998		
	!AccI GTmkac	2	7153	8048	
	!HincII GTYrac	1	7153		
20	!SalI Gtcgac	1	7153		
	!XhoI Ctcgag	1	7240		
	!Start PlacZ region		7246		
	!End PlacZ region		7381		
	!PflMI CCANNNNntgg	1	7382		
25	!RBS1		7405		
	!start M13-iii signal seq for LC		7418		
	!ApaLI Gtgcac	1	7470		
	!end M13-iii signal seq		7471		
	!Start light chain kappa L20:JK1		7472		
30	!PflFI GACNngtc	3	7489	8705	9099
	!SbfI CCTGCAGg	1	7542		
	!PstI CTGCAG	1	7543		
	!KpnI GGTACc	1	7581		
	!XcmI CCANNNNNnnnnntgg	2	7585	9215	
35	!NsiI ATGCAt	2	7626	9503	
	!BsgI ctgcac	1	7809		
	!BbsI gtcttc	2	7820	8616	
	!BlpI GCtnagc	1	8017		
	!EspI GCtnagc	1	8017		
40	!EcoO109I RGnccy	2	8073	8605	
	!Ecl136I GAGctc	1	8080		
	!SacI GAGCTc	1	8080		
	!End light chain		8122		
	!AscI GGcgcgcc	1	8126		
45	!BssHII Gcgcg	1	8127		
	!RBS2		8147		
	!SfiI GGCCNNNNnggcc	1	8207		
	!NcoI Ccatgg	1	8218		
	!Start 3-23, FR1		8226		
50	!MfeI Caattg	1	8232		
	!BspEI Tccgga	1	8298		
	!Start CDR1		8316		
	!Statt FR2		8331		
	!BstXI CCANNNNNntgg	2	8339	8812	
55	!EcoNI CCTNNnnnagg	2	8346	8675	
	!Start FR3		8373		
	!XbaI Tctaga	2	8436	1643	
	!AflII Cttaag	1	8480		
	!Start CDR3		8520		
60	!AatII GACGTc	1	8556		
	!Start FR4		8562		
	!PshAI GACNNngtc	2	8573	9231	

	!BstEII Ggtnacc	1	8579	
	!Start CH1		8595	
	!ApaI GGGCCc	1	8606	
	!Bspl20I Gggccc	1	8606	
5	!PspOMI Gggccc	1	8606	
	!AgeI Accggt	1	8699	
	!Bsu36I CCtnagg	2	8770	9509
	!End of CH1		8903	
	!NotI GCggccgc	1	8904	
10	!Start His6 tag		8913	
	!Start cMyc tag		8931	
	!Amber codon		8982	
	!NheI Gctagc	1	8985	
	!Start M13 III Domain 3		8997	
15	!NruI TCGcga	1	9106	
	!BstBI TTcgaa	1	9197	
	!EcoRI Gaattc	1	9200	
	!XcmI CCANNNNNnnnntgg	1	9215	
	!BstAPI GCANNNNntgc	1	9337	
20	!SacII CCGCgg	1	9365	
	!End IIistump anchor		9455	
	!AvrII Cctagg	1	9462	
	!trp terminator		9470	
	!SwaI ATTTaaat	1	9784	
25	!Start gene II		9850	
	!BglIII Agatct	1	9936	

	--			
30	1 aat gct act act att agt aga att gat gcc acc ttt tca gct cgc			
	gcc			
	! gene ii continued			
	49 cca aat gaa aat ata gct aaa cag gtt att gac cat ttg cga aat			
	gta			
	97 tct aat ggt caa act aaa tct act cgt tcg cag aat tgg gaa tca			
35	act			
	145 gtt aTa tgg aat gaa act tcc aga cac cgt act tta gtt gca tat			
	tta			
	193 aaa cat gtt gag cta cag caT TaT att cag caa tta agc tct aag			
	cca			
40	241 tcc gca aaa atg acc tct tat caa aag gag caa tta aag gta ctc			
	tct			
	289 aat cct gac ctg ttg gag ttt gct tcc ggt ctg gtt cgc ttt gaa			
	gct			
	337 cga att aaa acg cga tat ttg aag tct ttc ggg ctt cct ctt aat			
45	ctt			
	385 ttt gat gca atc cgc ttt gct tct gac tat aat agt cag ggt aaa			
	gac			
	433 ctg att ttt gat tta tgg tca ttc tcg ttt tct gaa ctg ttt aaa			
	gca			
50	481 ttt gag ggg gat tca ATG aat att tat gac gat tcc gca gta ttg			
	gac			
	! Start gene x, ii continues			
	529 gct atc cag tct aaa cat ttt act att acc ccc tct ggc aaa act			
	tct			
55	577 ttt gca aaa gcc tct cgc tat ttt ggt ttt tat cgt cgt ctg gta			
	aac			
	625 gag ggt tat gat agt gtt gct ctt act atg cct cgt aat tcc ttt			
	tgg			
	673 cgt tat gta tct gca tta gtt gaa tgt ggt att cct aaa tct caa			
60	ctg			
	721 atg aat ctt tct acc tgt aat aat gtt gtt ccg tta gtt cgt ttt			
	att			

```

769 aac gta gat ttt tct tcc caa cgt cct gac tgg tat aat gag cca
ggt
817 ctt aaa atc gca TAA
! End X & II
5 832 ggtaattca ca
!
! M1 E5 Q10 T15
843 ATG att aaa gtt gaa att aaa cca tct caa gcc caa ttt act act
cgt
10 ! Start gene V
!
! S17 S20 P25 E30
891 tct ggt gtt tct cgt cag ggc aag cct tat tca ctg aat gag cag
ctt
15 !
! V35 E40 V45
939 tgt tac gtt gat ttg ggt aat gaa tat ccg gtt ctt gtc aag att
act
!
20 ! D50 A55 L60
987 ctt gat gaa ggt cag cca gcc tat gcg cct ggt ctG TAC Acc gtt
cat
!
! BsrGI...
25 ! L65 V70 S75
R80
1035 ctg tcc tct ttc aaa gtt ggt cag ttc ggt tcc ctt atg att gag
cgt
!
! P85 K87 end of V
30 ! 1083 ctg cgc ctc gtt ccg gct aag TAA C
!
! 1108 ATG gag cag gtc gcg gat ttc gac aca att tat cag gcg atg
! Start gene VII
!
35 ! 1150 ata caa atc tcc gtt gta ctt tgt ttc gcg ctt ggt ata atc
!
! VII and IX overlap.
! ..... S2 V3 L4 V5 S10
40 ! 1192 gct ggg ggt caa agA TGA gt gtt tta gtg tat tct ttT gcc tct ttc
ggt
!
! End VII
! |start IX
! L13 W15 G20 T25
45 E29
1242 tta ggt tgg tgc ctt cgt agt ggc att acg tat ttt acc cgt tta
atg gaa
!
! 1293 act tcc tc
!
50 ! .... stop of IX, IX and VIII overlap by four bases
1301 ATG aaa aag tct tta gtc ctc aaa gcc tct gta gcc gtt gct acc
ctc
! Start signal sequence of viii.
!
55 ! 1349 gtt ccg atg ctg tct ttc gct gct gag ggt gac gat ccc gca aaa
gcg
!
! mature VIII --->
1397 gcc ttt aac tcc ctg caa gcc tca gcg acc gaa tat atc ggt tat
gcg
60 ! 1445 tgg gcg atg gtt gtt gtc att
1466 gtc ggc gca act atc ggt atc aag ctg ttt aag
!
```

```

! bases 1499-1539 are probable promoter for iii
1499 aaa ttc acc tcg aaa gca ! 1515
! ..... -35 ..
!
5 1517 agc tga taaaccgat acaattaaag gctccttttg
! ..... -10 ...
!
1552 gagccttttt ttt GGAGAt ttt ! S.D. uppercase, there may be 9 Ts
!
10 ! <----- III signal sequence ----->
!
! M K K L L F A I P L V V P F
1574 caac GTG aaa aaa tta tta ttc gca att cct tta gtt gtt cct ttc !
1620
15 ! Y S G A A E S H L D G A
1620 tat tct ggc gCG GCC Gaa tca caT CTA GAc ggc gcc
! EagI.... XbaI....
!
20 ! Domain 1 -----
!
! A E T V E S C L A
1656 gct gaa act gtt gaa agt tgt tta gca
!
25 ! K S H T E I S F T N V W K D D K
T
1683 aaA Tcc cat aca gaa aat tca ttt aCT AAC GTC TGG AAA GAC GAC
AAA ACT
!
30 ! L D R Y A N Y E G S L W N A T G
V
1734 tta gat cgt tac gct aac tat gag ggC tgt ctg tgG AAT GcT aca
ggc gtt
! BsmI....
35 ! V V C T G D E T Q C Y G T W V P
I
1785 gta gtt tgt act ggt GAC GAA ACT CAG TGT TAC GGT ACA TGG GTT
cct att
40 !
! G L A I P E N
1836 ggg ctt gct atc cct gaa aat
!
! L1 linker -----
45 ! E G G G S E G G G S
1857 gag ggt ggt ggc tct gag ggt ggc ggt tct
!
! E G G G S E G G G T
1887 gag ggt ggc ggt tct gag ggt ggc ggt act
50 !
! Domain 2 -----
1917 aaa cct cct gag tac ggt gat aca cct att ccg ggc tat act tat
atc aac
1968 cct ctc gac ggc act tat ccg cct ggt act gag caa aac ccc gct
55 aat cct
2019 aat cct tct ctt GAG GAG tct cag cct ctt aat act ttc atg ttt
cag aat
! BseRI..
2070 aat agg ttc cga aat agg cag ggg gca tta act gtt tat acg ggc
60 act
2118 gtt act caa ggc act gac ccc gtt aaa act tat tac cag tac act
cct

```

100456741005004

```

2166 gta tca tca aaa gcc atg tat gac gct tac tgg aac ggt aaa ttC
AGA
!
AlwNI
5 2214 GAC TGc gct ttc cat tct ggc ttt aat gaG gat TTa ttT gtt tgt
gaa
! AlwNI
2262 tat caa ggc caa tcg tct gac ctg cct caa cct cct gtc aat gct
!
10 2307 ggc ggc ggc tct
! start L2 -----
-----
2319 ggt ggt ggt tct
2331 ggt ggc ggc tct
15 2343 gag ggt ggt ggc tct gag gga ggc ggt tcc
2373 ggt ggt ggc tct ggt ! end L2
!
! Many published sequences of M13-derived phage have a longer linker
! than shown here by repeats of the EGGGS motif two more times.
20 !
! Domain 3 -----
-----
! S G D F D Y E K M A N A N K G A
2388 tcc ggt gat ttt gat tat gaa aag atg gca aac gct aat aag ggg
25 gct
!
! M T E N A D E N A L Q S D A K G
2436 atg acc gaa aat gcc gat gaa aac gcg cta cag tct gac gct aaa
30 ggc
!
! K L D S V A T D Y G A A M D G F
2484 aaa ctt gat tct gtc gct act gat tac ggt gct gct atc gat ggt
ttc
!
! I G D V S G L A N G N G A T G D
35 2532 att ggt gac gtt tcc ggc ctt gct aat ggt aat ggt gct act ggt
gat
!
! F A G S N S Q M A Q V G D G D N
40 2580 ttt gct ggc tct aat tcc caa atg gct caa gtc ggt gac ggt gat
aat
!
! S P L M N N F R Q Y L P S L P Q
45 2628 tca cct tta atg aat aat ttc cgt caa tat tta cct tcc ctc cct
caa
!
! S V E C R P F V F G A G K P Y E
2676 tcg gtt gaa tgt cgc cct ttt gtc ttt Ggc gct ggt aaa cca tat
50 gaa
!
! F S I D C D K I N L F R
2724 ttt tct att gat tgt gac aaa ata aac tta ttc cgt
! End Domain 3
!
! G V F A F L L Y V A T F M Y V
55 F140
2760 ggt gtc ttt gcg ttt ctt tta tat gtt gcc acc ttt atg tat gta
ttt
! start transmembrane segment
60 !
! S T F A N I L
2808 tct acg ttt gct aac ata ctg

```

10045674.100500.1

```

!
!       R   N   K   E   S
2829 cgt aat aag gag tct TAA ! stop of iii
!       Intracellular anchor.
5  !
!       M1  P2  V   L  L5   G   I   P   L  L10  L   R   F   L
G15
2847 tc ATG cca gtt ctt ttg ggt att ccg tta tta ttg cgt ttc ctc
ggt
10 !       Start VI
!
2894 ttc ctt ctg gta act ttg ttc ggc tat ctg ctt act ttt ctt aaa
aag
2942 ggc ttc ggt aag ata gct att gct att tca ttg ttt ctt gct ctt
15 att
2990 att ggg ctt aac tca att ctt gtg ggt tat ctc tct gat att agc
gct
3038 caa tta ccc tct gac ttt gtt cag ggt gtt cag tta att ctc ccg
tct
20 3086 aat gcg ctt ccc tgt ttt tat gtt att ctc tct gta aag gct gct
att
3134 ttc att ttt gac gtt aaa caa aaa atc gtt tct tat ttg gat tgg
gat
25 !
!       M1  A2  V3       F5                      L10          G13
3182 aaa TAA t ATG gct gtt tat ttt gta act ggc aaa tta ggc tct gga
!       end VI      Start gene I
!
!       K   T   L   V   S   V   G   K   I   Q   D   K   I   V   A
30 3228 aag acg ctc gtt agc gtt ggt aag att cag gat aaa att gta gct
!
!       G   C   K   I   A   T   N   L   D   L   R   L   Q   N   L
3273 ggg tgc aaa ata gca act aat ctt gat tta agg ctt caa aac ctc
!
!       P   Q   V   G   R   F   A   K   T   P   R   V   L   R   I
35 3318 ccg caa gtc ggg agg ttc gct aaa acg cct cgc gtt ctt aga ata
!
!       P   D   K   P   S   I   S   D   L   L   A   I   G   R   G
40 3363 ccg gat aag cct tct ata tct gat ttg ctt gct att ggg cgc ggt
!
!       N   D   S   Y   D   E   N   K   N   G   L   L   V   L   D
3408 aat gat tcc tac gat gaa aat aaa aac ggc ttg ctt gtt ctc gat
!
!       E   C   G   T   W   F   N   T   R   S   W   N   D   K   E
45 3453 gag tgc ggt act tgg ttt aat acc cgt tct tgg aat gat aag gaa
!
!       R   Q   P   I   I   D   W   F   L   H   A   R   K   L   G
3498 aga cag ccg att att gat tgg ttt cta cat gct cgt aaa tta gga
!
!       W   D   I   I   F   L   V   Q   D   L   S   I   V   D   K
50 3543 tgg gat att att ttt ctt gtt cag gac tta tct att gtt gat aaa
!
!       Q   A   R   S   A   L   A   E   H   V   V   Y   C   R   R
3588 cag gcg cgt tct gca tta gct gaa cat gtt gtt tat tgt cgt cgt
55 !
!       L   D   R   I   T   L   P   F   V   G   T   L   Y   S   L
3633 ctg gac aga att act tta cct ttt gtc ggt act tta tat tct ctt
!
!       I   T   G   S   K   M   P   L   P   K   L   H   V   G   V
60 3678 att act ggc tcg aaa atg cct ctg cct aaa tta cat gtt ggc gtt
!
!       V   K   Y   G   D   S   Q   L   S   P   T   V   E   R   W

```

10045674-100501

```

3723 gtt aaa tat ggc gat tct caa tta agc cct act gtt gag cgt tgg
!
!   L   Y   T   G   K   N   L   Y   N   A   Y   D   T   K   Q
3768 ctt tat act ggt aag aat ttg tat aac gca tat gat act aaa cag
5
!
!   A   F   S   S   N   Y   D   S   G   V   Y   S   Y   L   T
3813 gct ttt tct agt aat tat gat tcc ggt gtt tat tct tat tta acg
!
!   P   Y   L   S   H   G   R   Y   F   K   P   L   N   L   G
10
3858 cct tat tta tca cac ggt cgg tat ttc aaa cca tta aat tta ggt
!
!   Q   K   M   K   L   T   K   I   Y   L   K   K   F   S   R
3903 cag aag atg aaa tta act aaa ata tat ttg aaa aag ttt tct cgc
!
!   V   L   C   L   A   I   G   F   A   S   A   F   T   Y   S
15
3948 gtt ctt tgt ctt gcg att gga ttt gca tca gca ttt aca tat agt
!
!   Y   I   T   Q   P   K   P   E   V   K   K   V   V   S   Q
20
3993 tat ata acc caa cct aag ccg gag gtt aaa aag gta gtc tct cag
!
!   T   Y   D   F   D   K   F   T   I   D   S   S   Q   R   L
4038 acc tat gat ttt gat aaa ttc act att gac tct tct cag cgt ctt
!
!   N   L   S   Y   R   Y   V   F   K   D   S   K   G   K   L
25
4083 aat cta agc tat cgc tat gtt ttc aag gat tct aag gga aaa TTA
PacI
!
!   I   N   S   D   D   L   Q   K   Q   G   Y   S   L   T   Y
4128 ATT AAt agc gac gat tta cag aag caa ggt tat tca ctc aca tat
30
PacI
!
!   i   I   D   L   C   T   V   S   I   K   K   G   N   S   N   E
!   iv                                     M1 K
4173 att gat tta tgt act gtt tcc att aaa aaa ggt aat tca aAT Gaa
35
Start
IV
!
!   i   I   V   K   C   N   .End of I
!   iv   L3 L N5' V I7 N F V10
40
4218 att gtt aaa tgt aat TAA T TTT GTT
! IV continued.....
4243 ttc ttg atg ttt gtt tca tca tct tct ttt gct cag gta att gaa
atg
4291 aat aat tcg cct ctg cgc gat ttt gta act tgg tat tca aag caa
45
tca
4339 ggc gaa tcc gtt att gtt tct ccc gat gta aaa ggt act gtt act
gta
4387 tat tca tct gac gtt aaa cct gaa aat cta cgc aat ttc ttt att
tct
50
4435 gtt tta cgt gcA aat aat ttt gat atg gtA ggt tct aAC cct tcc
atT
4483 att cag aag tat aat cca aac aat cag gat tat att gat gaa ttg
cca
4531 tca tct gat aat cag gaa tat gat gat aat tcc gct cct tct ggt
55
ggt
4579 ttc ttt gtt ccg caa aat gat aat gtt act caa act ttt aaa att
aat
4627 aac gtt cgg gca aag gat tta ata cga gtt gtc gaa ttg ttt gta
aag
60
4675 tct aat act tct aaa tcc tca aat gta tta tct att gac ggc tct
aat
4723 cta tta gtt gtt agt gcT cct aaa gat att tta gat aac ctt cct

```

10045674.102501


```

!                                     RBS.?...
!       Start bla gene
6138 ATG agt att caa cat ttc cgt gtc gcc ctt att ccc ttt ttt gcg
gca ttt
5   6189 tgc ctt cct gtt ttt gct cac cca gaa acg ctg gtg aaa gta aaa
gat gct
6240 gaa gat cag ttg ggC gcA CTA GTg ggt tac atc gaa ctg gat ctc
aac agc
!                                     SpeI....
10  !                                     ApaLI & BssSI Removed
6291 ggt aag atc ctt gag agt ttt cgc ccc gaa gaa cgt ttt cca atg
atg agc
6342 act ttt aaa gtt ctg cta tgt GGC GcG Gta tta tcc cgt att gac
gcc ggg
15  6393 caa gaG CAA CTC GGT CGc cgC ATA cAC tat tct cag aat gac ttg
gtt gAG
!                                     BcgI.....
ScaI
6444 TAC Tca cca gtc aca gaa aag cat ctt acg gat ggc atg aca gta
20  aga gaa
!                                     ScaI.
6495 tta tgc agt gct gcc ata acc atg agt gat aac act gcg gcc aac
tta ctt
6546 ctg aca aCG ATC Gga gga ccg aag gag cta acc gct ttt ttg cac
25  aac atg
!                                     PvuI....
6597 ggg gat cat gta act cgc ctt gat cgt tgg gaa ccg gag ctg aat
gaa gcc
6648 ata cca aac gac gag cgt gac acc acg atg cct gta gca atg Gca
30  aca acg
6699 tTG CGC Aaa cta tta act ggc gaa cta ctt act cta gct tcc cgg
caa caa
!                                     FspI....
6750 tta ata gac tgg atg gag gcg gat aaa gtt gca gga cca ctt ctg
35  cgc tcg
6801 GCC ctt ccG GcT ggc tgg ttt att gct gat aaa tct gga gcc ggt
gag cgt
!                                     BglI.....
40  6852 gGG TCT Cgc ggt atc att gca gca ctg ggg cca gat ggt aag ccc
tcc cgt
!                                     BsaI....
6903 atc gta gtt atc tac acG ACg ggg aGT Cag gca act atg gat gaa
cga aat
45  !                                     AhdI.....
6954 aga cag atc gct gag ata ggt gcc tca ctg att aag cat tgg TAA
ctgt
!
7003 cagaccaagt ttactcatat atactttaga ttgatttaaa acttcatttt stop
50  taatttaaaa
7063 ggatctaggt gaagatcctt ttgataatc tcatgaccaa aatcccttaa
cgtgagtttt
7123 cgttccactg tacgtaagac cccc
7147 AAGCTT GTCGAC tgaa tggcgaatgg cgctttgcct
55  !                                     HindIII SalI..
!                                     (2/2) HincII
7183 ggtttccggc accagaagcg gtgccgaaa gctggctgga gtgcgatctt
!
! Start of Fab-display cassette, the Fab DSR-A05, selected for
60  ! binding to a protein antigen.
!
7233 CCTGAcG CTCGAG

```

10045674.102501

xBsu36I XhoI..

PlacZ promoter is in the following block

```

5 7246          cgcaacgc aattaatgtg agttagctca
7274 ctcattaggc accccaggtt ttacacttta tgcttccggc tcgtatgttg
7324 tgtggaattg tgagcggata acaatttcac acaggaaaca gctatgacca
7374 tgattacgCC AagcttTGGa gccttttttt tggagatttt caac

10      PflMI.....
      Hind3. (there are 3)
! Gene iii signal sequence:
!       1  2  3  4  5  6  7  8  9 10 11 12 13 14 15
!       M  K  K  L  L  F  A  I  P  L  V  V  P  F  Y
7418  gtg aaa aaa tta tta ttc gca att cct tta gtt gtt cct ttc tat

15      16 17 18          Start light chain (L20:JK1)
!       S  H  S  A  Q  D  I  Q  M  T  Q  S  P  A
7463  tct cac aGT GCA Caa gac atc cag atg acc cag tct cca gcc

20      ApaLI...
      Sequence supplied by extender.....

!       T  L  S  L
7505  acc ctg tct ttg

25      S  P  G  E  R  A  T  L  S  C  R  A  S  Q  G
7517  tct cca ggg gaa aga gcc acc ctc tcc tgc agg gcc agt cag Ggt

!       V  S  S  Y  L  A  W  Y  Q  Q  K  P  G  Q  A
7562  gtt agc agc tac tta gcc tgg tac cag cag aaa cct ggc cag gct

30      P  R  L  L  I  Y  D  A  S  S  R  A  T  G  I
7607  ccc agg ctc ctc atc tat gAt gca tcc aAc agg gcc act ggc atc

!       P  A  R  F  S  G  S  G  P  G  T  D  F  T  L
7652  cca gCc agg ttc agt ggc agt ggg Cct ggg aca gac ttc act ctc

!       T  I  S  S  L  E  P  E  D  F  A  V  Y  Y  C
7697  acc atc agc agC ctA gag cct gaa gat ttt gca gtT tat tac tgt

40      Q  Q  R  S  W  H  P  W  T  F  G  Q  G  T  R
7742  cag cag CGt aAc tgg cat ccg tgg ACG TTC GGC CAA GGG ACC AAG

!       V  E  I  K  R  T  V  A  A  P  S  V  F  I  F
7787  gtg gaa atc aaa cga act gtg gCT GCA Cca tct gtc ttc atc ttc

45      BsgI....

!       P  P  S  D  E  Q  L  K  S  G  T  A  S  V  V
7832  ccg cca tct gat gag cag ttg aaa tct gga act gcc tct gtt gtg

50      C  L  L  N  N  F  Y  P  R  E  A  K  V  Q  W
7877  tgc ctg ctg aat aac ttc tat ccc aga gag gcc aaa gta cag tgg

!       K  V  D  N  A  L  Q  S  G  N  S  Q  E  S  V
7922  aag gtg gat aac gcc ctc caa tcg ggt aac tcc cag gag agt gtc

55      T  E  R  D  S  K  D  S  T  Y  S  L  S  S  T
7967  aca gag cgg gac agc aag gac agc acc tac agc ctc agc agc acc

!       L  T  L  S  K  A  D  Y  E  K  H  K  V  Y  A
8012  ctg acG CTG AGC aaa gca gac tac gag aaa cac aaa gtc tac gcc

60      EspI.....

```

10045674.102301

```

!      C   E   V   T   H   Q   G   L   S   S   P   V   T   K   S
8057   tgc gaa gtc acc cat cag ggc ctG AGC TCg ccc gtc aca aag agc
!                                     SacI....
5
!      F   N   R   G   E   C   .   .
8102   ttc aac agg gga gag tgt taa taa
!
8126   GGCGCG CCAattctat ttcaaGGAGA cagtcata
!       AscI..... RBS2.
10
!      PelB signal sequence----->(22 codons)----->
!      1   2   3   4   5   6   7   8   9  10  11  12  13  14  15
!      M   K   Y   L   L   P   T   A   A   A   G   L   L   L   L
8160   atg aaa tac cta ttg cct acg gca gcc gct gga ttg tta tta ctc
15
!      ...PelB signal-----> Start VH, FR1----->
!      16  17  18  19  20  21  22  23  24  25  26  27  28  29  30
!      A   A   Q   P   A   M   A   E   V   Q   L   L   E   S   G
8205   gcG GCC cag ccG GCC atg gcc gaa gtt CAA TTG tta gag tct ggt
20
!      SfiI..... MfeI...
!      NcoI....
!
!      31  32  33  34  35  36  37  38  39  40  41  42  43  44  45
!      G   G   L   V   Q   P   G   G   S   L   R   L   S   C   A
25   8250   ggc ggt ctt gtt cag cct ggt ggt tct tta cgt ctt tct tgc gct
!
!      ...FR1-----> CDR1-----> FR2-----
!
!      46  47  48  49  50  51  52  53  54  55  56  57  58  59  60
!      A   S   G   F   T   F   S   T   Y   E   M   R   W   V   R
30   8295   gct TCC GGA ttc act ttc tct act tac gag atg cgt tgg gtt cgC
!      BspEI..
!      BstXI...
35
!      FR2-----> CDR2 -----
!
!      61  62  63  64  65  66  67  68  69  70  71  72  73  74  75
!      Q   A   P   G   K   G   L   E   W   V   S   Y   I   A   P
8340   CAa gct ccT GGt aaa ggt ttg gag tgg gtt tct tat atc gct cct
40
!      BstXI.....
!
!      ...CDR2-----> FR3-----
!
!      76  77  78  79  80  81  82  83  84  85  86  87  88  89  90
!      S   G   G   D   T   A   Y   A   D   S   V   K   G   R   F
45   8385   tct ggt ggc gat act gct tat gct gac tcc gtt aaa ggt cgc ttc
!
!      91  92  93  94  95  96  97  98  99 100 101 102 103 104 105
!      T   I   S   R   D   N   S   K   N   T   L   Y   L   Q   M
50   8430   act atc TCT AGA gac aac tct aag aat act ctc tac ttg cag atg
!      XbaI...
!      Supplied by extender-----
!
!      -----FR3----->
55
!      106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
!      N   S   L   R   A   E   D   T   A   V   Y   Y   C   A   R
8475   aac agC TTA AGg gct gag gac act gca gtc tac tat tgt gcg agg
!      AflIII...
!      from extender----->
60

```

10045674-102504

```

! CDR3----->
FR4-->
! 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
! R L D G Y I S Y Y Y G M D V W
5 8520 agg ctc gat ggc tat att tcc tac tac tac ggt atg GAC GTC tgg
! AatII..
!
! 136 137 138 139 140 141 142 143 144 145
! G Q G T T V T V S S
10 8565 ggc caa ggg acc acG GTC ACC gtc tca agc
! BstEII...
!
! CH1 of IgG1----->
! A S T K G P S V F P L A P S S
15 8595 gcc tcc acc aag ggc cca tcg gtc ttc ccc ctg gca ccc tcc
! tcc
!
! K S T S G G T A A L G C L V K
20 8640 aag agc acc tct ggg ggc aca gcg gcc ctg ggc tgc ctg gtc
!
! D Y F P E P V T V S W N S G A
25 8685 gac tac ttc ccc gaa ccg gtg acg gtg tcg tgg aac tca ggc
! gcc
!
! L T S G V H T F P A V L Q S S
27 8730 ctg acc agc ggc gtc cac acc ttc ccg gct gtc cta cag tCC
! TCA
!
! Bsu36I....
30 8775 G L Y S L S S V V T V P S S S
! GgA ctc tac tcc ctc agc agc gta gtg acc gtg ccc tcc agc
! agc
! Bsu36I....
35 8820 L G T Q T Y I C N V N H K P S
! ttg ggc acc cag acc tac atc tgc aac gtg aat cac aag ccc
! agc
!
! N T K V D K K V E P K S C A A
40 8865 aac acc aag gtg gac aag aaa gtt gag ccc aaa tct tgt GCG
! GCC
!
! NotI.....
45 8910 A H H H H H H G A A E Q K L I
! GCa cat cat cat cac cat cac ggg gcc gca gaa caa aaa ctc
! atc
! ..NotI.... H6 tag..... Myc-
50 Tag.....
!
! S E E D L N G A A q A S S A
55 8955 tca gaa gag gat ctg aat ggg gcc gca tag GCT AGC tct gct
! Myc-Tag..... NheI...
! Amber
!
! III'stump
!
60 ! Domain 3 of III -----
! -----
!

```

10045674.102504

```

!       S   G   D   F   D   Y   E   K   M   A   N   A   N   K   G   A
8997 agt ggc gac ttc gac tac gag aaa atg gct aat gcc aac aaa GGC
GCC
!       tcc  t   t   t   t   t   a   g           a   c   t   t   g   g
5  t !W.T.
!
KasI...(2/4)
!
!       M   T   E   N   A   D   E   N   A   L   Q   S   D   A   K   G
10  9045 atG ACT GAG AAC GCT GAC GAG aat gct ttg caa agc gat gcc aag
ggt
!       c   a   t   c   t   a   c   g   c   a   g   tct   c   t   a
c !W.T.
!
15  !       K   L   D   S   V   A   T   D   Y   G   A   A   I   D   G   F
9093 aag tta gac agc gTC GCG Acc gac tat GGC GCC gcc ATC GAc ggc
ttt
!       a   c   t   t   tct           t   t   t   c   t   t   t           t   t
c !W.T.
20  !
!       NruI....           KasI...(3/4)
!
!       I   G   D   V   S   G   L   A   N   G   N   G   A   T   G   D
9141 atc ggc gat gtc agt ggt tTG GCC Aac ggc aac gga gcc acc gga
gac
25  !       t   t   c   t   tcc   c   ct   t   t   t   t   t   t   t   t
t !W.T.
!
!       MscI...(3/3)
!
!       F   A   G   S   N   S   Q   M   A   Q   V   G   D   G   D   N
30  9189 ttc GCA GGT tcG AAT TCt cag atg gcC CAG GTT GGA GAT GGg gac
aac
!       t   t   c   t           c   a           t   a   c   t   c   t   t
t !W.T.
!
!       BspMI.. (2/2)           XcmI.....
35  !       EcoRI...
!
!       S   P   L   M   N   N   F   R   Q   Y   L   P   S   L   P   Q
9237 agt ccg ctt atg aac aac ttt aga cag tac ctt ccg tct ctt ccg
cag
40  !       tca  t t a           t   t   c   ct   a   t t a   t   c   c   t
a !W.T.
!
!       S   V   E   C   R   P   F   V   F   S   A   G   K   P   Y   E
9285 agt gtc gag tgc cgt cca ttc gtt ttc tct gcc ggc aag cct tac
gag
45  !       tcg  t   a   t   c   t   t   c   t   agc   t   t   a   a   t
a !W.T.
!
!       F   S   I   D   C   D   K   I   N   L   F   R
50  9333 ttc aGC Atc gac TGC gat aag atc aat ctt ttC CGC
!       t   tct   t   t   t   c   a   a   c   t a   c   t   !W.T.
!       BstAPI.....           SacII...
!       End Domain 3
!
55  !       G   V   F   A   F   L   L   Y   V   A   T   F   M   Y   V   F
9369 GGC gtt ttc gct ttc ttg cta tac gtc gct act ttc atg tac gtt
ttc
!       t   c   t   g   t   ct t a   t   t   c   c   t           t   a
t !W.T.
60  !       start transmembrane segment
!
!       S   T   F   A   N   I   L           R   N   K   E   S

```

10045674-102504

```

    9417 aGC ACT TTC GCC AAT ATT TTA   Cgc aac aaa gaa agc
    !      tct  g   t   t   c   a c g   t   t   g   g tct !W.T.
    !                                     Intracellular anchor.
    !
5   !
    9453          tag tga tct CCT AGG
    !                               AvrII..
    !
    9468 aag ccc gcc taa tga gcg ggc ttt ttt ttt ct  ggt
10  !      | Trp terminator |
    !
    ! End Fab cassette
    !
    9503  ATGCAT CCTGAGG  ccgat actgtcgtcg tcccctcaaa ctggcagatg
15  !      NsiI.. Bsu36I.(3/3)
    9551 cacggttacg atgcgccccat ctacaccaac gtgacctatc ccattacggt
    caatccgcgcg
    9611 tttgttccca cggagaatcc gacgggttgt tactcgctca catttaatgt
    tgatgaaagc
20  ! 9671 tggctacagg aaggccagac gcgaattatt tttgatggcg ttcctattgg
    ttaaaaaatg
    9731 agctgattta acaaaaattt aaTgcgaatt ttaacaaaat attaacgttt
    acaATTTAAA
    !
25  ! SwaI...
    9791 Tatttgctta tacaatcttc ctgttttttg ggcttttctg attatcaacc
    GGGGTAcac
    9850 ATG att gac atg cta gtt tta cga tta ccg ttc atc gat tct ctt
    gtt tgc
30  !      Start gene II
    9901 tcc aga ctc tca ggc aat gac ctg ata gcc ttt gtA GAT CTc tca
    aaa ata
    !
    9952 gct acc ctc tcc ggc atT aat tta tca gct aga acg gtt gaa tat
35  ! cat att
    10003 gat ggt gat ttg act gtc tcc ggc ctt tct cac cct ttt gaa tct
    tta cct
    10054 aca cat tac tca ggc att gca ttt aaa ata tat gag ggt tct aaa
    aat ttt
40  ! 10105 tat cct tgc gtt gaa ata aag gct tct ccc gca aaa gta tta cag
    ggt cat
    10156 aat gtt ttt ggt aca acc gat tta gct tta tgc tct gag gct tta
    ttg ctt
    10207 aat ttt gct aat tct ttg cct tgc ctg tat gat tta ttg gat gtt !
45  ! gene II continues
    !----- End of Table -----
    -

```

10045674 100501

[illegible]

		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
5	1579	fm	K	K	L	L	F	A	I	P	L	V	V	P	F	Y
		gtg	aaa	aaa	tta	tta	ttc	gca	att	cct	tta	ggt	ggt	cct	ttc	tat
		Signal sequence.....														
10	1624	S	H	S	A	E	T	V	E	S	C	L	A	K	P	H
		tct	cac	tcc	gct	gaa	act	ggt	gaa	agt	tgt	tta	gca	aaa	ccc	cat
		Signal sequence> Domain 1-----														
15	1669	T	E	N	S	F	T	N	V	W	K	D	D	K	T	L
		aca	gaa	aat	tca	ttt	act	aac	gtc	tgg	aaa	gac	gac	aaa	act	tta
		Domain 1-----														
20	1714	D	R	Y	A	N	Y	E	G	C	L	W	N	A	T	G
		gat	cgt	tac	gct	aac	tat	gag	ggg	tgt	ctg	tgG	AAT	GCt	aca	ggc
		BsmI....														
		Domain 1-----														
25	1759	V	V	V	C	T	G	D	E	T	Q	C	Y	G	T	W
		ggt	gta	ggt	tgt	act	ggg	gac	gaa	act	cag	tgt	tac	ggg	aca	tgg
		Domain 1-----														
30	1804	V	P	I	G	L	A	I	P	E	N	E	G	G	G	S
		ggt	cct	att	ggg	ctt	gct	atc	cct	gaa	aat	gag	ggg	ggg	ggc	tct
		Domain 1-----> Linker 1-----														
35	1849	E	G	G	G	S	E	G	G	G	S	E	G	G	G	T
		gag	ggg	ggc	ggg	tct	gag	ggg	ggc	ggg	tct	gag	ggg	ggc	ggg	act
		Linker 1----->														
40	1894	K	P	P	E	Y	G	D	T	P	I	P	G	Y	T	Y
		aaa	cct	cct	gag	tac	ggg	gat	aca	cct	att	ccg	ggc	tat	act	tat
		Domain 2-----														
45	1939	I	N	P	L	D	G	T	Y	P	P	G	T	E	Q	N
		atc	aac	cct	ctc	gac	ggc	act	taT	CCG	CCt	ggg	act	gag	caa	aac
		EciI....														
		Domain 2-----														
50	1984	P	A	N	P	N	P	S	L	E	E	S	Q	P	L	N
		ccc	gct	aat	cct	aat	cct	tct	ctt	GAG	GAG	tct	cag	cct	ctt	aat
		BseRI..														
		Domain 2-----														
55	2029	T	F	M	F	Q	N	N	R	F	R	N	R	Q	G	A
		act	ttc	atg	ttt	cag	aat	aat	agg	ttc	cga	aat	agg	cag	ggg	gca
		Domain 2-----														
60		L	T	V	Y	T	G	T	V	T	Q	G	T	D	P	V


```

2074 tta act gtt tat acg ggc act gtt act caa ggc act gac ccc gtt
! Domain 2-----
!
!
5 !      181 182 183 184 185 186 187 188 189 190 191 192 193 194 195
!      K   T   Y   Y   Q   Y   T   P   V   S   S   K   A   M   Y
2119 aaa act tat tac cag tac act cct gta tca tca aaa gcc atg tat
! Domain 2-----
!
!
10 !      196 197 198 199 200 201 202 203 204 205 206 207 208 209 210
!      D   A   Y   W   N   G   K   F   R   D   C   A   F   H   S
2164 gac gct tac tgg aac ggt aaa ttC AGa gaC TGc gct ttc cat tct
!                               AlwNI.....
! Domain 2-----
!
!
15 !      211 212 213 214 215 216 217 218 219 220 221 222 223 224 225
!      G   F   N   E   D   P   F   V   C   E   Y   Q   G   Q   S
2209 ggc ttt aat gaG GAT CCA ttc gtt tgt gaa tat caa ggc caa tcg
!                               BamHI...
! Domain 2-----
!
20 !      226 227 228 229 230 231 232 233 234 235 236 237 238 239 240
!      S   D   L   P   Q   P   P   V   N   A   G   G   G   S   G
2254 tct gac ctg cct caa cct cct gtc aat gct ggc ggc ggc tct ggt
! Domain 2-----> Linker 2-----
!
25 !      241 242 243 244 245 246 247 248 249 250 251 252 253 254 255
!      G   G   S   G   G   G   S   E   G   G   G   S   E   G   G
2299 ggt ggt tct ggt ggc ggc tct gag ggt ggt ggc tct gag ggt ggc
! Linker 2-----
!
30 !      256 257 258 259 260 261 262 263 264 265 266 267 268 269 270
!      G   S   E   G   G   G   S   E   G   G   G   S   G   G   G
2344 ggt tct gag ggt ggc ggc tct gag gga ggc ggt tcc ggt ggt ggc
! Linker 2-----
!
35 !      271 272 273 274 275 276 277 278 279 280 281 282 283 284 285
!      S   G   S   G   D   F   D   Y   E   K   M   A   N   A   N
2389 tct ggt tcc ggt gat ttt gat tat gaa aag atg gca aac gct aat
! Linker 2> Domain 3-----
!
40 !      286 287 288 289 290 291 292 293 294 295 296 297 298 299 300
!      K   G   A   M   T   E   N   A   D   E   N   A   L   Q   S
2434 aag ggg gct atg acc gaa aat gcc gat gaa aac gcg cta cag tct
! Domain 3-----
!
45 !      301 302 303 304 305 306 307 308 309 310 311 312 313 314 315
!      D   A   K   G   K   L   D   S   V   A   T   D   Y   G   A
2479 gac gct aaa ggc aaa ctt gat tct gtc gct act gat tac ggt gct
! Domain 3-----
!
50 !      316 317 318 319 320 321 322 323 324 325 326 327 328 329 330
!      A   I   D   G   F   I   G   D   V   S   G   L   A   N   G
2524 gct atc gat ggt ttc att ggt gac gtt tcc ggc ctt gct aat ggt
! Domain 3-----
!
55 !      331 332 333 334 335 336 337 338 339 340 341 342 343 344 345
!      N   G   A   T   G   D   F   A   G   S   N   S   Q   M   A
2569 aat ggt gct act ggt gat ttt gct ggc tct aat tcc caa atg gct
! Domain 3-----
!
60 !

```

T0045074.102500.1

THE **NEW** **AMERICAN** **DICTIONARY** **OF** **THE** **ENGLISH** **LANGUAGE**

Table 38: Whole mature III anchor M13-III
derived anchor with recoded DNA

```

!
!      1   2   3
5  !      A   A   A
!      1   GCG gcc gca
!      NotI.....
!
!      4   5   6   7   8   9  10  11  12  13  14  15  16  17
10 !      H   H   H   H   H   H   G   A   A   E   Q   K   L   I
!      10   cat cat cat cac cat cac ggg gcc gca gaa caa aaa ctc atc
!
!      18  19  20  21  22  23  24  25  26  27  28  29
!      S   E   E   D   L   N   G   A   A   .   A   S
15 !      52   tca gaa gag gat ctg aat ggg gcc gca Tag GCT AGC
!
!                                     NheI...
!
!      30  31  32  33  34  35  36   37  38  39
!      D   I   N   D   D   R   M   A   S   T
20 !      88   GAT ATC aac gat gat cgt atg gct tct act
! (ON_G37bot) [RC] 5'-c aac gat gat cgt atg gcG CAT Gct gcc gag aca
! g-3'
!
!      EcoRV..
!      Enterokinase cleavage site.
25 !
!      Start mature III (recoded) Domain 1 ---->
!      40  41  42  43
!      A   E   T   V
!      118   |gcC|gaG|acA|gtC|
30 !      t   a   t   t ! W.T.
!
!      44  45  46  47  48  49  50  51  52  53  54  55  56  57  58
!      E   S   C   L   A   K   P   H   T   E   N   S   F   T   N
!      130 |gaa|TCC|tgC|CTG|GCC|AaG|ccT|caC|acT|gaG|aat|AGT|ttC|aCA|Aat|
35 !      agt   t t a   a   a   c   t   a   a   tca   t   t   c
! W.T.
!
!      MscI....
!
!      59  60  61  62  63  64  65  66  67  68  69  70  71  72  73
!      V   W   K   D   D   K   T   L   D   R   Y   A   N   Y   E
!      175 |gtg|TGG|aaG|gaT|gaT|aaG|acC|CtT|gAT|CGA|TaT|gcC|aat|taC|gaA|
!      c       a   c   c   a   t t a       t   c   t   c   t   g !
! W.T.
!
!      BspDI...
45 !
!      74  75  76  77  78  79  80  81  82  83  84  85  86  87  88
!      G   C   L   W   N   A   T   G   V   V   V   C   T   G   D
!      220 |ggC|tgC|TtA|tgG|aat|gcC|ACC|GGC|GtC|gtT|gtC|TGC|ACG|ggC|gaT|
!      t   t c g       t   a       t   a   t   t   t   t   c !
50 ! W.T.
!
!      SgrAI.....      BspI....
!
!      89  90  91  92  93  94  95  96  97  98  99  100 101 102 103
!      E   T   Q   C   Y   G   T   W   V   P   I   G   L   A   I
55 !      265 |gaG|acA|caA|tgC|taT|ggC|ACG|TGg|gtG|ccG|atA|gGC|TTA|GCC|atA|
!      a   t   g   t   c   t   a       t   t   t   g c t   t   c !
! W.T.
!
!      PmlI.....      BlpI.....
!

```

10045674 102504

```

!      Domain 1-----> Linker 1-----> Domain 2----->
!      104 105 106 107 108 109 110 111 112 113 114 115 116 117 118
!      P   E   N   E   G   G   G   S   E   G   G   G   S   E   G
5  310 |ccG|gaG|aaC|gaA|ggC|ggC|ggT|AGC|gaA|ggC|ggT|ggC|AGC|gaA|ggC|
!      t   a   t   g   t   t   c tct   g   t   c   t tct   g   t !
W.T.
!
!      Linker 1-----> Domain 2----->
!      119 120 121 122 123 124 125 126 127 128 129 130 131 132 133
!      G   G   S   E   G   G   G   T   K   P   P   E   Y   G   D
10 355 |ggT|GGA|TCC|gaA|ggA|ggT|ggA|acC|aaG|ccG|ccG|gaA|taT|ggC|gaC|
!      c   t   t   g   t   c   t   t   a   t   t   g   c   t   t !
W.T.
!      BamHI.. (2/2)
!
!      134 135 136 137 138 139 140 141 142 143 144 145 146 147 148
!      T   P   I   P   G   Y   T   Y   I   N   P   L   D   G   T
!      400 |acT|ccG|atA|CCT|GGT|taC|acC|taC|atT|aaT|ccG|TtA|gaT|ggA|acC|
!      a   t   t   g   c   t   t   t   c   c   t c c   c   c   t !
20 W.T.
!      SexAI....
!
!      149 150 151 152 153 154 155 156 157 158 159 160 161 162 163
!      Y   P   P   G   T   E   Q   N   P   A   N   P   N   P   S
25 445 |taC|ccT|ccG|ggC|acC|gaA|caG|aaT|ccT|gcC|aaC|ccG|aaC|ccA|AGC|
!      T   G   t   t   t   g   a   c   c   t   t   t   t   t tct !
W.T.
!      HindIII...
!
!      164 165 166 167 168 169 170 171 172 173 174 175 176 177 178
!      L   E   E   S   Q   P   L   N   T   F   M   F   Q   N   N
!      490 |TTA|gaA|gaA|AGC|caA|ccG|TtA|aaC|acC|ttT|atg|ttC|caA|aaC|aaC|
!      c t   G   G tct   g   t c t   t   t   c           t   g   t   t !
35 W.T.
!      HindIII.
!
!      179 180 181 182 183 184 185 186 187 188 189 190 191 192 193
!      R   F   R   N   R   Q   G   A   L   T   V   Y   T   G   T
40 535 |CgT|ttT|AgG|aaC|CgT|caA|gGT|GCT|CtT|acC|gTG|TAC|AcT|ggA|acC|
!      a g   c c a   t a g   g   g   a t a   t   t   t   g   c   t !
W.T.
!      HgiAI...      BsrGI...
!
!      194 195 196 197 198 199 200 201 202 203 204 205 206 207 208
!      V   T   Q   G   T   D   P   V   K   T   Y   Y   Q   Y   T
50 580 |gtC|acC|caG|GGT|ACC|gaT|ccT|gtC|aaG|acC|taC|taT|caA|taT|acC|
!      t   t   a   c   t   c   c   t   a   t   t   c   g   c   t !
W.T.
!      KpnI...
!
!      209 210 211 212 213 214 215 216 217 218 219 220 221 222 223
!      P   V   S   S   K   A   M   Y   D   A   Y   W   N   G   K
55 625 |ccG|gtC|TCG|AGT|aaG|gcT|atg|taC|gaT|gcC|taT|tgg|aaT|ggC|aaG|
!      t   a   a tca   a   c           t   c   t   c           c   t   a !
W.T.
!      BsaI....
!      XhoI....
!
!      224 225 226 227 228 229 230 231 232 233 234 235 236 237 238
!      F   R   D   C   A   F   H   S   G   F   N   E   D   P   F
60 670 |ttT|CgT|gaT|tgT|gcC|ttT|caC|AGC|ggT|ttC|aaC|gaa|gac|CCT|ttT|

```

```

!           C A a   C   c   t   c   t t c t   c   t   t   G   T   a   c !
W.T.
!
!           239 240 241 242 243 244 245 246 247 248 249 250 251 252 253
5 !           V   C   E   Y   Q   G   Q   S   S   D   L   P   Q   P   P
!       715 |gtC|tgC|gaG|taC|caG|ggT|caG|AGT|AGC|gaT|TtA|ccG|caG|ccA|CCG|
!           t   t   a   t   a   c   a t c g t c t   c c g   t . a   t   t !
W.T.
! DrdI.....
10 AgeI.....
!
!   Domain 2----->   Linker 2----->
!           254 255 256 257 258 259 260 261 262 263 264 265 266 267 268
!           V   N   A   G   G   G   S   G   G   G   S   G   G   G   S
15 !       760 |GTT|AAC|gcG|ggT|ggT|ggT|AGC|ggC|ggA|ggC|AGC|ggC|ggT|ggT|AGC|
!           c   t   t   c   c   c t c t   t   t   t t c t   t   c   c t c t
! W.T.
! AgeI.....
!           HpaI...
20 !           HincII.
!
!           Linker 2----->
Domain 3-->
!           269 270 271 272 273 274 275 276 277 278 279 280 281 282 283
25 !           E   G   G   G   S   E   G   G   G   S   G   G   G   S   G
!       805 |gaA|ggC|ggA|ggT|AGC|gaA|ggA|ggT|ggC|AGC|ggA|ggC|ggT|AGC|ggC|
!           g   t   t   c t c t   g   t   c   t t c t   g   t   c t c t   t
! W.T.
!
!           -----Domain 3----->
!           284 285 286 287 288 289 290 291 292 293 294 295 296 297 298
!           S   G   D   F   D   Y   E   K   M   A   N   A   N'   K   G
!       850 |AGT|ggC|gac|ttc|gac|tac|gag|aaa|atg|gct|aat|gcc|aac|aaa|GGC|
!           t c c   t   t   t   t   t   a   g           a   c   t   t   g   g !
35 W.T.
!
!           KasI....
!
!           299 300 301 302 303 304 305 306 307 308 309 310 311 312 313
40 !           A   M   T   E   N   A   D   E   N   A   L   Q   S   D   A
!       895 |GCC|atg|act|gag|aac|gct|gac|gaG|AAT|GCA|ctg|caa|agt|gat|gCC|
!           t           c   a   t   c   t   a   c   g   a   g t c t   c   t !
W.T.
! KasI....
45 StyI....
!           BsmI....
!
!           314 315 316 317 318 319 320 321 322 323 324 325 326 327 328
!           K   G   K   L   D   S   V   A   T   D   Y   G   A   A   I
!       940 |AAG|GGt|aag|tta|gac|agc|gTC|GCc|Aca|gac|tat|ggT|GCT|gcc|atc|
50 !           a   c   a c t   t t c t           t   t   t   c           t   !
W.T.
! StyI.....
!           PflFI.....
!
!           329 330 331 332 333 334 335 336 337 338 339 340 341 342 343
55 !           D   G   F   I   G   D   V   S   G   L   A   N   G   N   G
!       985 |gac|ggc|ttt|atc|ggc|gat|gtc|agt|ggT|ctg|gct|aac|ggc|aac|gga|
!           t   t   c   t   t   c   t t c c   c c t           t   t   t   t !
W.T.
!

```

10045674-1005604

```

!       344 345 346 347 348 349 350 351 352 353
!       A   T   G   D   F   A   G   S   N   S
1030 |gcc|acc|gga|gac|ttc|GCA|GGT|tcG|AAT|TCt|
!       t   t   t   t   t   t   c   t           c ! W.T.
5  !       BstBI...
!       EcoRI...
!       BspMI..
!
!       354 355 356 357 358 359 360 361 362 363
10  !       Q   M   A   Q   V   G   D   G   D   N
1060 |cag|atg|gcC|CAG|GTT|GGA|GAT|GGg|gac|aac|
!       a       t   a   c   t   c   t   t   t ! W.T.
!       XcmI.....
!
15  !       364 365 366 367 368 369 370 371 372 373 374 375 376 377 378
379
!       S   P   L   M   N   N   F   R   Q   Y   L   P   S   L   P   Q
1090 |agt|ccg|ctt|atg|aac|aac|ttt|aga|cag|tac|ctt|ccg|tct|ctt|ccg|
cag
20  !       tca   t t a           t   t   c c t   a   t t a   t   c   c   t
a ! W.T.
!
!       380 381 382 383 384 385 386 387 388 389 390 391 392 393 394
395
25  !       S   V   E   C   R   P   F   V   F   S   A   G   K   P   Y   E
1138 |agt|gtc|gag|tgc|cgt|cca|ttc|gtt|ttc|tct|gcc|ggc|aag|cct|tac|
gag
!       tcg   t   a   t   c   t   t   c   t agc   t   t   a   a   t
a ! W.T.
30  !
!       Domain 3----->
!       396 397 398 399 400 401 402 403 404 405 406 407
!       F   S   I   D   C   D   K   I   N   L   F   R
1186 |ttc|aGC|Atc|gac|TGC|gat|aag|atc|aat|ctt|ttC|CGC|
35  !       t tct   t   t   t   c   a   a   c t a           t
!       BstAPI..... SacII...
!
!       transmembrane segment----->
!       408 409 410 411 412 413 414 415 416 417 418 419 420 421 422
40  423
!       G   V   F   A   F   L   L   Y   V   A   T   F   M   Y   V   F
1222 |GGc|gtt|ttc|gct|ttc|ttg|cta|tac|gtc|gct|act|ttc|atg|tac|gtt|
ttc
!       t   c   t   g   t c t t a   t   t   c   c   t           t   a
45  t ! W.T.
!
!       424 425 426 427 428 429 430       431 432 433 434 435
!       S   T   F   A   N   I   L       R   N   K   E   S
1270 |aGC|ACT|TTC|GCC|AAT|ATT|TTA       Cgc|aac|aaa|gaa|agc|
50  !       tct   g   t   t   c   a c g           t   t   g   g tct ! W.T.
!
!       Intracellular anchor.
!
!
55  !       1306           tag tga tct CCT AGG.
!       AvrII..
!
!       1321 aag ccc gcc taa tga gcg ggc ttt ttt ttt ct ggt
!       | Trp terminator |
60  !
! End Fab cassette
!----- End of Table -----

```

10045674.102500t

•

use with *NheI*

[illegible]

Table 40: Phage titers and enrichments of selections with a DY3F31-based human Fab library

	Input (total cfu)	Output (total cfu)	Output/input ratio
5 R1-ox selected on phOx-BSA	$4,5 \times 10^{12}$	$3,4 \times 10^5$	$7,5 \times 10^{-8}$
R2-Strep selected on Strep-beads	$9,2 \times 10^{12}$	3×10^8	$3,3 \times 10^{-5}$

10045674-102504

5 Table 41: Frequency of ELISA positives in
DY3F31-based Fab libraries

	Anti-M13 HRP	9E10/RAM- HRP	Anti-CK/CL Gar-HRP
R2-ox (with IPTG induction)	18/44	10/44	10/44
R2-ox (without IPTG)	13/44	ND	ND
10 R3-strep (with IPTG)	39/44	38/44	36/44
R3-strep (without IPTG)	33/44	ND	ND

100445674 102501